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 1 
PREFACE 
 
Despite the importance of lymph vessels in both health and disease, very little is 
known about the genetic regulation of lymphangiogenesis, the formation of lymph vessels. 
The Notch signaling pathway is involved in many developmental processes. During 
angiogenesis, the formation of blood vessels, Notch regulates arterial versus venous 
differentiation of blood endothelial cells and controls the branching process of the blood 
vessel network. The molecular mechanisms determining the establishment of lymphatic 
endothelial cells, the third type of endothelial cells, and the outgrowth of an elaborate 
network of lymph vessels, are still poorly understood. Several indications suggest a role for 
Notch in all three EC types. Components of the Notch pathway are expressed in LECs and 
several Notch-related genes that are important for arterial differentiation are also required in 
lymphatic development. We therefore reasoned that Notch signaling itself might also be 
involved in lymphangiogenesis. In this study we investigated the role of the Notch signaling 
pathway in lymphangiogenesis using zebrafish embryos and tadpoles, two small animal 
models that allow high-throughput screening for lymphatic genes. By selecting chemical and 
genetic silencing strategies to avoid vascular defects, we now identified for the first time a 
dual role for Notch signaling in developmental lymphangiogenesis.  
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1 LYMPHANGIOGENESIS 
1.1 THE LYMPHATIC SYSTEM 
The lymphatic system has long remained in the shadow of the blood vascular system. 
This ‘second’ circulation system was merely looked at as a drainage network. About one 
decade ago, the lymphatic circulation gained more and more interest of scientists due to its 
importance as a key player in several diseases and its crucial role in normal functioning of 
the body of vertebrate organisms.  
 
1.1.1 Structure 
The lymphatic system is organized as an elaborate network of vessels that end blindly 
in capillaries, throughout the entire body except the central nervous system and avascular 
tissues like epidermis and cartilage. These capillaries have a unique structure that allows 
the uptake of fluids from the surrounding tissue, but prevents it from leaking out. The 
endothelial cells that make up the thin wall of the lymphatic capillaries are slightly 
overlapping and loosely connected to each other. When fluid pressure in the surrounding 
tissue is higher than in the lumen of the lymph vessel, the cells are pushed apart and open 
up like a one-way swinging door. However, when pressure inside the vessel is higher than 
outside, the cell junctions are tightly closed and fluid is prevented from leaking out. The thin-
walled capillaries are prevented from being collapsed under this pressure by the attachment 
of anchoring filaments that secure the lymphatic endothelial cells (LECs) to the surrounding 
matrix and tissue 1,2. Furthermore, under high fluid pressure the anchoring filaments are 
stretched making the gaps between the endothelial cells even larger and thus allowing 
faster uptake of fluid 3. Baluk et al 4 have made high-resolution images of the junctions of 
endothelial cells in lymphatic capillaries. They found that these cells have oak leaf-like 
shapes with overlapping flaps that lack junctions at the tip but are anchored on the sides by 
discontinuous button-like junctions that differ from the conventional, continuous zipper-like 
junctions in collecting lymphatics and blood vessels 4 (Figure 1A-C). This organization 
allows fluids to enter the capillaries via openings between the buttons, without disrupting the 
junctional integrity between the lymphatic endothelial cells (Figure 1D). 
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Figure1: Oak-leaf like lymphatic endothelial cells with button-like junctions in 
lymphatic capillaries. (A) Schematic drawing of the endothelium of an initial 
lymphatic (capillary) with discontinuous buttons and a collecting lymphatic with 
continuous zipper junctions. (B) Oak leaf shape of endothelial cells in lymphatic 
capillaries. Buttons with adherens and tight junctions are indicated in red. (C-D) 
Most PECAM-1 expression is at the tips of flaps. Neighbouring LECs have 
overlapping edges (C). Fluid is taken up through the loose flaps (D). 4 
 
 
 
After being taken up by the capillaries the lymph fluid is transported by collecting 
lymph vessels. These vessels are lined by LECs and have a thin layer of smooth muscle 
cells. Valves ensure that the lymph can only be transported in one direction. The lymph 
vessels transport the lymph to either the right lymphatic duct or the thoracic duct, the largest 
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lymph vessel in the body. These vessels eventually drain the lymph into the right and left 
subclavian veins respectively and in this way return it to the general circulation. 
Comparative phylogenetic analysis has shown that a true lymphatic system is present 
only in vertebrates 5. Primitive fish have a lymphatic-like secondary vascular system, but 
this contains blood and is considered to be part of the circulatory system. Teleost fish, like 
zebrafish and Medaka, are probably the first vertebrates with a lymphatic system that is 
anatomically distinct from the blood vasculature (6,7 and Tomonori Deguchi, personal 
communication). 
 
1.1.2 Functions in health and disease 
1.1.2.1 normal functions 
As explained above, the primary function of the lymphatic system is the reabsorption 
of interstitial fluids that have leaked out from the blood vessels. Due to the action of oncotic 
pressure, interstitial fluid leaks out from the blood vessels at the arterial side of the capillary 
bed where pressure is higher in the blood vessels than in the surrounding tissues. The 
interstitial fluid forms the immediate surrounding of the cells to which they constantly add 
and remove substances. Most of the interstitial fluid is taken up again by the venules. The 
remaining 10-20% is taken up by the lymphatics and returned to the circulation as lymph 8,9. 
Secondly, lymphatics in the gastrointestinal tract, predominantly the small intestine, 
are responsible for the uptake of lipids from the digestive tract. While most other nutrients 
are taken up directly into the blood stream and are transported through the portal vein to the 
liver, lipids are first taken up by lymphatics to be subsequently transported to the blood 
circulation. These intestinal lymphatics are called lacteals and the milky white lymph they 
transport, containing emulsified fat, is called chyle 10. 
Finally, the lymphatic network is of critical importance for the normal function of the 
immune system. Lymphatics pass through several lymphoid organs, especially lymph 
nodes where antigen presenting cells and foreign substances that were taken up from the 
interstitial fluid are removed from the lymph and lymphocytes are added 10.  
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1.1.2.2 lymphedema 
Malfunctioning of the lymphatic system causes accumulation of interstitial fluid in the 
tissues, which leads to swelling or lymphedema. This can lead to quite severe and 
disfiguring effects usually at the limbs, but also face, neck and abdomen can be affected. 
When malfunctioning is caused by damage to the lymphatics, for example after surgery or 
infection with certain parasites, it is called acquired or secondary lymphedema. Congenital 
or primary lymphedema is caused by genetic mutations and is less common 10.  
Furthermore, when lymphedema is caused by a (temporary) increase in the production of 
waste material (leading to increased osmotic pressure in the tissues) it is called dynamic 
edema. Static edema in contrast, is caused by damage to the lymphatic system and does 
not disappear by itself 11. Today, the most important treatment still is manipulation through 
massage and bandaging. So far, no surgical or genetic treatment is being applied on 
lymphedema patients 11. 
 
1.1.2.3 cancer metastasis 
Metastasis, the spread of tumor cells from the primary tumor to different parts of the 
body, is thought to be responsible directly or indirectly for more than 90% of all cancer 
deaths 12. Many tumor types, including melanoma, breast and prostate cancers first 
metastasize to their regional lymph nodes via lymph vessels, after which they are 
disseminated to other parts of the body. Therefore, the presence of metastatic tumor cells in 
the regional lymph nodes of a tumor is an indication of poor prognoses and is used for 
determination of tumor stage.  
Only recently it was shown that the lymphatic system plays an active role in cancer 
metastasis via direct interaction between tumors and lymph vessels. First of all, their 
architecture makes lymphatics more amenable to the entry of invasive tumor cells than 
blood vessels. They have loose overlapping cell-cell junctions and no or only an incomplete 
basement membrane. Furthermore, malignant tumors are often associated with an 
increased density of lymph vessels, mostly in the peritumoral region. Intratumoral 
lymphatics are rare and are considered to be nonfunctional due to mechanical compression 
13. This increased density is caused by co-option of existing lymphatics by the tumor and by 
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induction of the outgrowth of new lymph vessels. The induction of lymphangiogenesis, i.e. 
the formation of lymph vessels, by tumors is mediated by prolymphangiogenic factors and 
cytokines that can be produced by the tumor cells themselves, or by stromal cells, tumor-
associated macrophages or damaged platelets 14-16. In addition to local lymphangiogenesis, 
tumor-derived vascular endothelial growth factor (VEGF)-A and VEGF-C can also induce 
lymphangiogenesis within the tumor-draining lymph nodes, thereby promoting the flow of 
lymph to them and increasing the efficacy of transport of disseminating tumor cells to the 
lymph nodes 17,18.  On the other hand, lymphatics also communicate to tumors. LECs have 
been shown to produce the chemokine CCL-21. Tumor cells that express the cognate 
receptor CCR-7, chemotactically migrate towards these CCL-21 producing LECs, thereby 
promoting the entry of tumor cells into the lymphatics 19,20.  
 
1.1.2.4 inflammation 
Inflammation is a local or systemic reaction of the immune system caused by external 
or internal stimuli, e.g. microbial infections or malignantly transformed cancer cells, with the 
objective to remove the source of the injury, inhibit its further dissemination and eventually 
repair damaged tissue. However, when this process is not controlled and inflammation 
spreads, it loses its repairing function and may even cause damage. Blood vessels play an 
important role in the inflammatory process and inflamed tissue is characterized by 
hyperaemia and increased permeability of capillaries. Recent studies provide evidence that 
lymphatic vessels actively participate in acute and chronic inflammation as well and that 
they are not just a passive route for circulating lymphocytes. During inflammation 
lymphangiogenesis is induced, mainly to facilitate removal of the accumulated interstitial 
fluid because of increased vascular permeability induced by angiogenic and inflammatory 
stimuli. 
Proinflammatory cytokines produced by inflammatory cells induce VEGF-C 
expression in fibroblasts, stimulating lymphatic vessel growth at inflammation sites 21. Also 
macrophages that are attracted to inflammation sites can transform into VEGF-C/D 
producing cells to stimulate the growth of lymphatic vessels 15. Furthermore, macrophages 
are suggested to have a dual role in inflammation-induced lymphangiogenesis since they 
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can also contribute to lymphangiogenesis by transdifferentiating into LECs, which can 
incorporate into the lymphatic endothelium 22,23.  
Many inflammatory diseases seem to be associated with lymphatic activation and 
dysfunction. Kidney transplant rejection is often accompanied by massive lymphatic 
neoangiogenesis, induced by macrophages producing VEGF-C. These new lymph vessels 
produce CCL-21 (ligand of chemokine receptor CCR-7), which attracts CCR-7+ lymphocytes 
and dendritic cells and might actively promote the inflammatory process 24. Similar 
examples of inflammatory diseases associated with lymphatic hyperplasia are psoriasis, 
chronic airway inflammation or astma and rheumatoid arthritis 25-27. 
 
 
1.2 LYMPHATIC DEVELOPMENT IN MAMMALS 
1.2.1 History 
Despite only recent advances in the genetic basis of lymphatic development, the 
existence of the lymphatic system has been known since antiquity. Already in 400 BC 
Hippocrates (460 – 377 BC) observed vessels containing ‘white blood’ when studying the 
axillary lymph nodes but only in 1627 Gasparo Aselli (1581 – 1626) described the lacteal 
vessels as ‘milky veins’ in a ‘well-fed’ dog 28. In the early 20th century, vascular anatomists 
such as Florence Sabin (1871 – 1953) characterized the anatomy of the lymphatic system 
in more detail. By using dye injections and histological methods they found that the 
lymphatic system is an extensive network that is ramified throughout the entire body 29,30. At 
that time two competing theories were proposed about the origin of lymphatics. Based on 
her studies Florence Sabin proposed that primitive lymph sacs originate from endothelial 
cells that bud from the embryonic veins during early development 29,30. In contrast, the 
theory put forward by Huntington (1861 – 1927) and McClure (1852 – 1944) describes that 
rudimentary lymphatics first arise independently in the mesenchyme and only later establish 
connections with the venous system 31. For almost a century, this controversy has remained 
and it was only a few decades ago that new insights were gained into the genesis of the 
lymphatic system. This delay was largely due to the lack of reliable molecular markers for 
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the detection of LECs and to the lack of identified regulators of lymphangiogenesis. 
However, several markers have been recently identified that have allowed significant 
advances in the understanding of lymphatic development. These new findings have largely 
confirmed Sabin’s original theory of mammalian lymphatic development, although in birds 
and frogs recruitment of lymphangioblasts also contributes to the formation of lymphatics 32-
34. Studies in mice have provided significant evidence for the origin of the mammalian 
lymphatic system from embryonic veins 35. Of the known lymphatic-specific markers, 
several only acquire their specificity as embryonic development progresses, so 
differentiation of the lymphatic vasculature is probably a stepwise process. For example, the 
expression pattern of vascular endothelial growth factor receptor 3 (VEGFR3) during 
embryonic development has provided additional support for Sabin’s model. VEGFR3 was 
the first lymphatic-specific growth factor receptor identified 36, but is initially expressed in 
angioblasts of murine head mesenchyme, dorsal aorta, cardinal vein and allantois 36,37. At 
embryonic day 12.5 (E12.5), VEGFR3 is expressed both in developing venous and in 
presumptive lymphatic endothelia, and only later, in adult tissues, VEGFR3 is largely 
restricted to the lymphatic endothelium 36,38. These findings suggested that VEGFR3 plays a 
role in the development of both the vascular and lymphatic system. This was confirmed by 
the fact that VEGFR3 null mice are not viable and die from cardiovascular failure even 
before the emergence of the lymphatic vessels 37. More direct evidence for the venous 
origin of lymphatics came from a Cre/loxP-based lineage-tracing study using Prox1-
promoter elements, that showed that, at least in mammals, the lymphatic vasculature is 
derived from venous ECs and that hematopoietic cells do not contribute to the developing 
lymph sacs 35. Finally, the overlap of several other molecular markers between LECs and 
blood endothelial cells (BECs) demonstrates the close structural and developmental 
relationship between the blood and lymphatic systems. The current model of early 
lymphatic development describes that the expression of a limited number of additional 
genes by certain BECs induces the step-wise process of lymphatic competence, 
commitment, differentiation and maturation that ultimately leads to the formation of the 
lymphatic network (Figure 2). 
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Figure 2: Model of lymphatic development (Oliver & Srinivasan, 2010 39). For 
details: see text. 
 
 
1.2.2 Competence, commitment and differentiation of LECs 
Lymphatic development in the mouse starts at about E9-9.5 when venous endothelial 
cells become competent to respond to a lymphatic-inducing signal. Competence denotes 
the ability of cells to respond to an inducing signal 39. The molecular factor(s) that regulate 
the initial stage of lymphatic competence remain unknown. However, the expression of the 
lymphatic vessel endothelial hyaluronan receptor 1 (Lyve-1) in the cardinal veins can be 
considered as an indication that venous cells are competent 40 (Figure 2). Despite this early 
expression of Lyve-1 in lymphatic progenitor cells, Lyve-1 null mice develop a largely 
normal lymphatic vasculature, arguing against a role of Lyve-1 in establishing LEC identity 
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41,42. Specific expression of Prox1 at E9.5 in a subpopulation of these Lyve-1 positive cells is 
the first indication that lymphangiogenesis has begun. This step is called ‘lymphatic 
commitment’ which denotes that the developmental potential of these cells becomes 
restricted 39. At about E10.5 these Prox1 positive cells, which are located on one side of the 
cardinal vein, start to bud off in a polarized manner (Figure 2). After budding these cells 
start expressing higher levels of additional lymphatic endothelial markers such as 
Secondary Lymphoid Tissue (SLC) chemokine and VEGFR3. Expression of VEGFR3 in 
BECs decreases. The expression of Prox1, Lyve-1, SLC and VEGFR3 probably indicates 
that the cells are irreversibly committed to the lymphatic pathway (Figure 2). The 
commitment stage is characterized by an initial labile phase of specification (when a cell is 
able to differentiate autonomously if placed in a neutral environment) and a second stage of 
determination (when committed cells will differentiate autonomously even if placed into 
another tissue context) 39,43. 
Prox1 has been described as the key transcription factor determining lymphatic 
development. Prox1 is a homeobox transcription factor that is homologous to the 
Drosophila prospero gene. Analysis of its expression pattern suggested that it has a 
functional role in a variety of tissues, including lens, heart, liver, pancreas and the central 
nervous system 44. Later, Wigle and Oliver proved that Prox1 is a specific marker of a 
subpopulation of ECs in the cardinal vein that by budding and sprouting give rise to the 
lymphatic system 45. This finding thus fully validated Sabin’s proposal of the venous origin of 
the primary lymph sacs 29,30. Analysis of Prox1 null embryos showed that early in 
development the initial budding of the ECs that give rise to the lymphatic system appeared 
to be unaffected and is thus Prox1 independent. However, maintenance of endothelial 
budding and sprouting is Prox1 dependent as these processes were completely blocked in 
Prox1 null mice, causing the arrest of lymphatic development. Vasculogenesis and 
angiogenesis are unaffected in these mice 45. These results demonstrate that Prox1 activity 
is essential for normal lymphatic development and that vascular and lymphatic development 
are independent processes. More recently, different groups have shown that Prox1 
expression is not only necessary, but also sufficient to induce transdifferentiation of BECs to 
LECs 46,47. Adenoviral overexpression of Prox1 in BECs results in induction of LEC-specific 
gene transcription and suppresses the expression of ±40% of BEC-specific genes, thus 
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identifying Prox1 as a master switch in the lymphatic differentiation process 46,47. Once 
more, this indicates that during evolution the lymphatic vasculature originated from the 
blood vasculature by the additional expression of only a few gene products such as Prox1. 
Finally, it has also been shown that conditional downregulation of Prox1 during embryonic, 
postnatal or adult stages is sufficient to reprogram LECs into BECs 48. Therefore, Prox1 
appears to be a binary switch that suppresses BEC identity and promotes and maintains 
LEC identity. However, this interchangeability of BEC and LEC identity is remarkable and 
raises questions as to how specified endothelial cells really are, since differentiation or 
specification is considered to be irreversible. 
Defects in the transcription factor SOX18 (SRY (sex determining region Y) box 18) 
cause lymphatic dysfunction in the human syndrome hypotrichosis-lymphoedema-
telangiectasia 49. It has been shown that SOX18 is expressed in a subset of cardinal vein 
cells that later co-express Prox1 and bud off to form the primary lymph sacs (Figure 2). 
Overexpression of SOX18 in BECs induces them to express Prox1 and other LEC-specific 
markers. SOX18 null embryos fail to express Prox1 in the cardinal vein and develop edema 
due to a complete blockade of LEC differentiation from the cardinal vein 50. Further 
investigation determined that SOX18 directly controls Prox1 expression by binding to its 
promoter 50. Altogether these findings demonstrate a critical role for SOX18 in lymphatic 
development even upstream of Prox1. It is not certain whether SOX18 rather than Prox1 is 
the actual key transcription factor regulating lymphatic differentiation or whether SOX18 
expression merely makes ECs competent. In contrast to Prox1, SOX18 expression is only 
detected up to ±E14.5 50. The loss of SOX18 expression after this stage indicates that 
SOX18 is only required during the early stages of lymphatic development, perhaps solely to 
induce Prox1, which is also required for maintenance of the lymphatic identity at later 
stages 48.  
 
1.2.3 Maturation and wiring of the lymphatic network 
Once LECs have been specified from the cardinal vein, they migrate and proliferate to 
establish the initial lymph sacs and early lymphatic vessels. VEGFR3 controls both 
proliferation and migration of LECs 51. Although VEGFR3 is initially expressed in both blood 
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and lymphatic vessels, its expression becomes restricted to LECs at E12.5 36. In humans, 
mutations in the VEGFR3 gene cause Milroy Disease, a form of congenital lymphoedema 
caused by hypoplasia of the lymphatic vessels 52. The ligands for VEGFR3 are VEGF-C and 
VEGF-D 53,54. VEGF-C is expressed by vascular smooth muscle cells and mesenchymal 
cells close to the migratory destination of lymphatic progenitors 55,56. VEGF-D is produced in 
a dynamic pattern most strongly in the lung, kidney and mesenchymal cells in the skin 53. 
Further, also myeloid cells have been identified as sources of VEGF-C and –D 25,57,58. 
Retroviral or transgenic overexpression of either VEGFR3 ligand in mice is sufficient to 
induce lymphangiogenesis in the areas of misexpression 59-61. VEGF-C null mice show 
normal specification of LECs, but absence of LEC budding and formation of primary lymph 
sacs due to the absence of the source of VEGF-C in the mesenchyme 55. In contrast, 
VEGF-D knockout mice have no discernible lymphatic defect, suggesting that it does not 
play a crucial role in lymphatic development 62. Neuropilin2 (Nrp2) is a nonsignaling 
transmembrane receptor that acts as a co-receptor for VEGFR3 and is expressed in veins 
and lymphatic vessels 63. Nrp2 null mice show absence of small lymphatic vessels and 
capillaries during development, but blood vessels and larger collecting lymphatic vessels 
develop normally, suggesting that Nrp2 is selectively required for the formation of small 
lymphatic vessels and capillaries 63. Recently it has been shown that interaction between 
Nrp2 and VEGFR3 mediates lymphatic tip cell extension and guided sprouting of lymphatic 
vessels in response to VEGF-C 64. In addition to VEGF-C and VEGF-D, adrenomedullin 
(AMD) signaling is required for normal LEC proliferation and disruption of AMD signaling 
results in edema and embryonic lethality. LEC specification occurs normally but lymph sacs 
are hypoplastic and lined with thin LECs 65.  
The initial lymphatic vascular plexus undergoes extensive expansion and remodeling 
that goes on postnatally. Various genes have been shown to play important roles during this 
remodeling. Mutations in the forkhead transcription factor 2 (FOXC2) cause lymphedema-
distichiasis, an autosomal dominant disorder characterized by lymphedema with onset 
around puberty and a double row of eyelashes (distichiasis) 66. FOXC2 is expressed in 
lymphatic progenitors budding from the cardinal vein, jugular lymph sacs, lymphatic 
collectors and capillaries, as well as in podocytes and developing eyelids 66. Foxc2-/- mice 
die embryonically after E12.5 and demonstrate cardiac and skeletal abnormalities. Foxc2+/- 
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mice develop generally normal but have characteristics reminiscent of lymphedema-
distichiasis in humans, such as distichiasis and hindlimb lymphedema 67. The lymphedema 
phenotype is caused by an abnormal pattern of the lymphatic vessels, increased pericyte 
investment, agenesis of lymphatic valves and lymphatic dysfunction 68. So, FOXC2 is 
essential for the morphogenesis of lymphatic valves and the establishment of pericyte-free 
lymphatic capillaries. In the latter process FOXC2 cooperates with VEGFR3 68,69. 
Compound Foxc1+/-;Foxc2-/- embryos show reduced numbers of Prox1 positive cells 
budding from the cardinal vein and abnormal formation of lymph sacs 69. This indicates that 
the FOXC transcription factors are also important for the initial sprouting of LECs from the 
cardinal vein. Another important mediator, necessary for the remodeling and maturation of 
the lymphatic network, is EphrinB2 70. More precisely, the PDZ interaction site of EphrinB2 
appears to be crucial, since mice homozygous for a deletion of the PDZ interaction site 
(ephrinB2V/V) exhibit major lymphatic defects. These mice have normal blood vascular 
remodeling, but fail to remodel the primary lymphatic capillary plexus into a hierarchical 
vessel network, have hyperplasia, and lack luminal valves 70. The PDZ domain effectors 
that are required to mediate the lymphatic function of EphrinB2 are not yet known. 
Lymphatic vessels return lymph fluid to the blood, but both vascular systems connect 
only at the left and right subclavian vein. In the remainder of the body it is critical that both 
systems are close together but remain separated. The correct separation of blood and 
lymphatic vessels is mediated by the adaptor protein SLP-76 (SRC homology 2 – domain 
containing leukocyte protein of 76 kDa) and the tyrosine kinase SYK (Spleen Tyrosine 
Kinase) (Figure 2). Both molecules are mainly expressed by hematopoietic cells. Mutant 
mice show abnormal shunting between lymphatics and blood vessels resulting in blood 
filled lymphatics 71,72. How SLP76- and SYK-signaling pathways in hematopoietic cells 
mediate this function has remained unknown for a long time. Very recently however, a link 
has been made with the role that was described for podoplanin in the developmental 
separation of the blood and lymphatic circulation 73. Interaction of endothelial podoplanin in 
the developing lymph sacs with circulating platelets form the cardinal vein induces platelet 
activation and aggregation. These platelet aggregates are thus built up at the separation 
zone of podoplanin positive lymph sacs and cardinal veins, thereby closing the junction 
between them 73. Lack of SYK or SLP-76 affects the capacity of platelets to activate 
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integrins, and to undergo aggregation and activation 74. Therefore, the formation of the 
separating platelet plug is compromised in mutants with deficiencies of these proteins. A 
similar mutant phenotype of blood-filled lymphatics was observed in Plcg2 (Phospholipase 
C2) mutant mice 75. Also this phenotype can be brought back to deficient platelet 
aggregation as Plc2 is phosphorylated by SYK and SLP-76 71,74. SYK, SLP-76 and Plc2 
act downstream of CLEC-2, a podoplanin-specific receptor on platelets that is responsible 
for platelet aggregation induced by podoplanin 76,77. However, SYK deficiency causes much 
faster and more severe blood-lymphatic abnormalities compared to those seen in 
podoplanin null mice 78,79. SYK-expression was additionally identified in myeloid cells that 
express VEGF-C and –D and that show strong lymphangiogenic activity upon 
transplantation into the skin 80. Loss of SYK results in elevated VEGF-C/-D production and 
lymphatic hyperplasia, which leads to direct contact of BECs and LECs and ultimately to the 
formation of blood-lymphatic junctions 80. 
 
 
1.3 LYMPHATIC DEVELOPMENT IN ZEBRAFISH 
1.3.1 Zebrafish as a small animal model  
Zebrafish, or Danio rerio, is a small (adults 3-5 cm) tropical freshwater fish belonging 
to the Cyprinidae family. It is an important vertebrate model organism in scientific research 
for studies on vertebrate development and gene function. It has been used in many fields 
including developmental biology, oncology, toxicology, genetics, neurobiology, etc because 
of its numerous advantages for use in the lab as a model system. Zebrafish have a very 
rapid generation, they grow from embryo to free-living animal in less than 5 days, and within 
36 hours post fertilization (hpf) precursors to all major organs have been established. 
Because of the transparency of the embryos, development of multiple organ systems and 
tissues can be easily viewed and analyzed. At about 3 months of age the fish are fertile, 
with females being able to spawn hundreds of eggs every week all year long. This high 
fecundity and rapid generation makes zebrafish an ideal model organism for high-
throughput screenings of chemical compounds or gene knockdown (see below). Moreover, 
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its genetic code is almost completely sequenced and annotated 
(www.sanger.ac.uk/Projects/D_rerio) and several well-characterized mutants have been 
established and are commercially available (Znomics, www.znomics.com). Also other 
resources like transgenic fish lines, antibodies, protocols, etc have been collected in an 
online biological database and made publicly available (Zebrafish Information Network 
(ZFIN, zfin.org) and Zebrafish International Resource Center (ZIRC, zebrafish.org)).  
Genetic manipulation of zebrafish embryos is relatively easy. By injecting morpholino 
antisense oligomers in the 1-4 cell stage, genes can be knocked down for up to 4 days by 
blocking translation of mRNA (ATG-targeting morpholino) or splicing of pre-mRNA (splice-
site targeting morpholino) 81. Several techniques exist to generate stable transgenic 
zebrafish lines like retroviral transduction, recombination-mediated insertion via a 
transposase (e.g. Tol2) or integrase system (e.g. C31), restriction-enzyme mediated 
insertion (e.g. I-SceI meganuclease), etc. Currently, the most frequently used technique in 
zebrafish is the transposon-based integration with the Tol2 transposable element of the 
medaka fish Oryzias latipes 82. The gene of interest is cloned into the Tol2 transposon 
element and the DNA vector containing this construct is then injected into 1-cell stage 
embryos together with mRNA encoding the Tol2 transposase 83.  Recently, a new technique 
had been established to make specifically targeted knockouts in endogenous zebrafish 
genes. By using engineered zinc finger nucleases (ZFN), targeted knockout mutations can 
be generated in zebrafish genes based on non-homologous end-joining-mediated repair of 
ZFN-induced DNA double-stranded breaks 84-86. A final practical advantage of using 
zebrafish as a model organism is the fact that due to their small size they require relatively 
little housing space and maintenance costs are low.  
 
1.3.2 Zebrafish as a new model to study vascular and lymphatic 
development 
Zebrafish embryos, and more specifically the transgenic line Fli1:eGFPy1 which 
expresses GFP in all ECs 87, have been used extensively to study vertebrate vascular 
development. For a long time it was assumed that zebrafish did not have a lymphatic 
system. However, recently, several groups independently showed the presence of a 
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lymphatic system with physical and functional properties reminiscent of the mammalian 
system 6,7. The thoracic duct (TD), which forms between the dorsal aorta (DA) and posterior 
cardinal vein (PCV), was the first identified lymphatic in zebrafish and has been reported to 
express Prox-1 and contain anchoring filaments 7,88. This vessel also functionally drains 
interstitial dyes and has therefore been generally considered to be the first perfused lymph 
vessel in zebrafish 6,7. Further studies in Fli1:eGFPy1 zebrafish embryos postulated that 
LECs arise primarily from venous BECs in the parachordal vessel (PAV) 7, which forms at 
the horizontal myoseptum from sprouts coming from the PCV 89. However, a recent study 
has documented that the TD and other lymph vessels in the trunk arise from a non-
lumenized aggregation of “parachordal lymphangioblast (PL)” cells (termed so because of 
their role as TD precursors); this structure, which transiently forms at the horizontal 
myoseptum, is distinct from the PAV, that develops only much later beyond 6 dpf 90. High-
resolution imaging indicates that this string of PL cells is anatomically transiently connected 
to the venous system. Indeed, of the secondary sprouts that arise from the PCV between 
30 to 50 hpf, approximately half (on average one per two unilateral somite segments) 
migrate radially in the ventral-dorsal direction to the horizontal myoseptum (Figure 3A,A’); 
these sprouts exist only transiently 89,90. At the horizontal myoseptum, the cells of these 
sprouts then migrate tangentially in the anterior-posterior direction to form the PL string (36 
to 60 hpf; Figure 3B,B’). Since the secondary sprouts, which give rise to the PL string, 
participate in the process that ultimately leads to the formation of the TD, they have been 
termed “lymphangiogenic secondary sprouts” 90. Indeed, the lymphangiogenic sprouts and 
PL cells give rise only to lymphatics but not to blood vessels, are not labeled in the 
arterial/venous kdr-l:mCherryRed marker line 90, and fail to form upon silencing of genes 
that regulate lymphangiogenesis in mice and humans, e.g., Ccbe1 90,91, Vegf-c 92, Vegfr-3 92 
and Synectin (93, manuscript under revision). However, we cannot clearly demonstrate that 
these structures already have a true lymphatic identity and express lymphatic marker genes 
(see Results). The other secondary sprouts from the PCV connect to the primary 
intersomitic vessels (ISVs) (Figure 3B), which thereby become intersomitic veins (vISV) 
(Figure 3C); these sprouts have therefore been termed “angiogenic secondary sprouts” 89,90.  
From 60 hpf onwards, the PL cells switch to radial migration again, and navigate 
both ventrally and dorsally alongside arterial intersomitic vessels (aISVs), whereby they 
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form structures, that later persist as lymphatic intersomitic vessels (LISVs) (Figure 3C). 
These radially migrating cells will be termed LISV-PLs to distinguish them from the cells in 
the PL string. Once ventrally migrating LISV-PLs reach their final location in between the DA 
and PCV, they switch again to tangential migration, grow towards each other and fuse to 
establish the TD (3 to 6 dpf; Figure 3D,D’). While lymphangiogenic secondary sprouts 
migrate at a distance from and independently of aISVs 90, LISVs always navigate alongside 
aISVs, almost “creeping” over them in their initial dorsal and ventral trajectory, but never 
track alongside vISVs. This close association of LISVs with aISVs raises the question 
whether aISVs act as guidance templates for navigating LISVs-PLs, an issue that was also 
addressed in this thesiswork (see Results).  
Until now, it has not been possible to unambiguously detect Prox-1 in the 
lymphangiogenic secondary sprouts or PL cells (likely because of insufficient sensitivity of 
the in situ technique in combination with very low expression levels), yet, a number of 
findings suggest a role of these structures in lymphatic development. Indeed, PL cells 
contribute only to lymphangiogenesis but not to angiogenesis, are not labeled in the kdr-
l:mCherryRed line which marks only arterial and venous endothelial cells (ECs) 90, and fail 
to form upon silencing of genes that regulate lymphangiogenesis in mice and humans, e.g., 
Ccbe1 90,91, Vegf-c 90 and Prox-1 (unpublished). Since in the present project we were able to 
provide evidence for a role of Notch in lymphatic development, but not to provide 
unambiguous insight in the molecular basis of lymphatic competence, specification or 
differentiation, we refer to the lymphangiogenic secondary sprouts and PL cells as 
structures with a “lymphangiogenic” developmental potential (indicated by the light green 
color in Figure 3), without, however, claiming that they already are specified or differentiated 
to established lymphatic structures (indicated by the dark green color in Figure 3).  
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Figure 3: Schematic drawing of lymphatic development in zebrafish embryos. The 
schemes and photos show lateral views of a segment of the embryo trunk 
spanning 1-4 intersomitic vessels. For detailed description, see text. DA, dorsal 
aorta; DLAV, dorsal longitudinal anastomosing vessel; DLLV, dorsal longitudinal 
lymph vessel; ISV, intersomitic vessel; aISV, arterial ISV; LISV, lymphatic ISV; 
vISV, venous ISV; PCV, posterial cardinal vein; PL, parachordal lymphangioblast 
string; TD, thoracic duct. Permanent lymphatic structures (LISV, TD) are labeled 
dark green; transient lymphangiogenic structures (lymphangiogenic secondary 
sprouts; PL cells) are labeled light green. 
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2 NOTCH SIGNALING 
2.1 THE NOTCH SIGNALING PATHWAY 
2.1.1 Pathway 
The Notch signaling pathway defines an evolutionary cell  interaction mechanism that 
was first described in Drosophila and is highly conserved from the nematode (roundworm) 
Caenorhabditis elegans to human. The Notch gene was discovered in 1917 by Tomas Hunt 
Morgan in a strain of the fruit fly Drosophila melanogaster with notches in their wingblades 
94. Sequencing of the gene and its molecular characterization was only undertaken in the 
1980s 95,96. The Notch gene encodes a 300kDa single-pass transmembrane receptor. It is 
composed of a hetero-dimer with a large extracellular portion that is non-covalently linked to 
a smaller piece that contains a short extracellular region, a single transmembrane-pass and 
a small intracellular region (Figure 4A). The two portions are translated as a single gene 
product but are posttranslationally cleaved by a furin-like convertase during intracellular 
trafficking in the Golgi complex 97,98. The extracellular domain contains 29-36 tandem 
epidermal growth factor (EGF)-like repeats and three cystein-rich Notch/LIN-12 repeats. 
EGF11 and 12 are known to mediate ligand binding 99. The intracellular domain contains six 
tandem ankyrin repeats, a glutamine-rich domain, a RAM23 domain (protein-protein 
interactions), a PEST sequence (proline-glutamate-serine-threonine-rich region) and a 
nuclear localization signal (NLS) 96. In mammals four different receptors have been 
identified (Notch1, Notch2, Notch3, Notch4) whereas in zebrafish five homologues exist 
(Notch1a and Notch1b are homologous to Notch1, Notch6 is homologous to Notch2 and 
Notch5 is the homologue of Notch3, there is no homologue identified for Notch4)  100,101.  
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Figure 4: The Notch signaling pathway (A) General structure of the Notch 
receptors and ligands (from 102). (B) Schematic overview of the canonical Notch 
signaling pathway (from 103). For details: see text. 
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The Notch receptors interact with transmembrane ligands of the Delta or Jagged 
family. Five ligands have been identified in mammalian cells (Delta-like1 (Dll1), Dll3, Dll4, 
Jagged1, Jagged2). In zebrafish eight ligands have been identified thus far (Delta-A, -B, -C, 
-D, Dll4, Jagged1a, Jagged1b, Jagged2). Interaction with the EGF-like repeats of the Notch 
receptor occurs through a conserved Delta:Serrate:Lag-2 (DSL) domain (Figure 4A). In 
theory all ligands can interact with all Notch receptors, however activity of the Notch 
receptor can by modified by O-fucosylation of the EGF repeats (mediated by O-
fucosyltranserase-1) 104,105 and specificity of ligand-receptor interactions can be regulated 
by members of the fringe gene family 106,107. Fringe acts in the Golgi apparatus as a -1,3-
N-acetylglucosaminyltransferase enzyme that further modifies the O-fucosylated EGF 
repeats of the Notch receptor and alters the ability of Notch to bind its ligand Delta. 
Generally, modification of the Notch receptor by Fringe makes it more sensitive to activation 
by Delta ligands and less sensitive to Jagged ligands 106. There are three mammalian 
Fringe homologues: Manic Fringe, Lunatic Fringe and Radical Fringe 107. 
 
2.1.1.1 Canonical Notch signaling pathway 
Notch ligands and receptors are expressed in different combinations in most, if not all, 
cell types. Upon interaction of a receptor and a ligand on neighboring cells, proteolytic 
activation of the Notch receptor is triggered (Figure 4B). Endocytosis of the ligand on the 
signal-sending cell exerts a pulling force on the receptors in the signal-receiving cells, which 
enables processing of the Notch receptor by the activity of a disintegrin and 
metalloproteinase (ADAM) 108,109. This initial extracellular proteolytic cleavage induces a 
second cleavage in the transmembrane domain by the -secretase complex, a large 
proteinase complex made of presenilin (PS)-1 or -2, nicastrin, Pen-2 and Aph-1). The result 
of both proteolytic cleavages is the release of the Notch intracellular domain (NICD) 110,111. 
NICD is translocated to the nucleus where it interacts with the transcription factor of the 
CSL (CBF1, Suppressor of Hairless (Su(H)), Lag-1) family, also known as the 
recombination signal sequence-binding protein (RBP-j) 111 (Figure 4B). This interaction 
leads to removal of transcriptional repressors from and attraction of additional 
transcriptional activators to the complex, resulting in transcriptional activation of genes of 
  INTRODUCTION 
 25 
the Hes and Hey families 112 (Figure 4B). In turn, Hes and Hey proteins are transcriptional 
repressors that block the expression of genes that generally drive cells to adopt a certain 
differentiated fate.  
It has been suggested that the endocytosis of the ligand may have consequences in 
terms of signaling in the ligand cell itself and that this leads to a reverse signaling 
mechanism 113-115 (Figure 4B). However, very little is known on the molecular mechanism 
and functions of this reverse signaling pathway.  
 
2.1.1.2 Non-canonical Notch signaling pathways 
In the vast majority of processes in which Notch signaling is involved, the Notch 
receptor is activated by a DSL-type ligand, which leads to changes in gene expression via 
binding of NICD to the CSL transcription factor. However, there are some exceptions where 
Notch signaling does not operate as this canonical trio. 
Other proteins have been suggested to act as Notch ligands. F3/contactin and NB-3, 
two neural cell adhesion molecules, have been identified as alternative functional ligands of 
the Notch receptor 116,117. Both ligands induce a downstream Notch signaling cascade via 
Deltex1 as a transcriptional regulator and mediate commitment of neural precursor cells to 
oligodendrocytes (OL), oligondendrocyte precursor cell (OPC) differentiation and OL 
maturation, whereas canonical DSL/Notch/CSL signaling regulates OPC generation and 
maintenance 116,117. Besides a role of Deltex as transcription factor in a CSL-independent 
branch of Notch signaling 118, it can also promote Notch signaling by binding to the ankyrin 
repeats of the Notch intracellular domain and acting as an E3 ubiquitin ligase that promotes 
recycling of non-ligand bound endocytosed Notch receptors and antagonizes lysosomal 
degradation 119. However, in some cells, including lymphoid cells and neurons, Deltex 
antagonizes Notch signaling, further complicating the picture and indicating that the function 
of Deltex may depend on the cellular and developmental context 120.  
Several other examples of CSL-independent Notch signaling have been described. 
One of these is the interaction of activated NICD with the mTOR-Rictor complex 
(mammalian target of rapamycin (mTOR) and the rapamycin independent companion of 
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mTOR (Rictor)), which leads to the activation of the kinase Akt/PKB and inhibition of 
apoptosis in mammalian cells 121. It has been shown that this function requires Notch 
processing as well as nuclear localization of NICD, but is independent of the CSL 
transcription factor 121. The process of muscle cell differentiation is inhibited by Notch 
activation. However, this process does not require CSL-binding as mutant forms of Notch1 
lacking the CSL interaction sequence were able to block myoblast differentiation and 
activated Notch1 did not induce CSL activation as shown by a CSL luciferase reporter 
assay 122. Notch is present on growth cones of extending axons in Drosophila and can 
regulate axon guidance. It has been proposed that Notch may directly regulate the actin 
cytoskeleton via interactions with a protein complex that includes the axonal tyrosine kinase 
Abl 123. Possibly Notch promotes axon extension by physically recruiting the Abl accessory 
protein Disabled, which binds directly to the intracellular domain of the Notch receptor 123. 
The Abl tyrosine kinase and its associated proteins play a direct role in the regulation of 
growth cone motility during axonogenesis 124. This requirement for Notch in axon patterning 
was shown to be genetically independent from its function in the control of cell identity 123. 
 
2.1.1.3 Interaction of the Notch pathway with other signaling cascades 
To add another level of complexity, the Notch signaling pathway interacts with many 
other signaling pathways like VEGF, Wnt, Hedgehog (Hh) and Transforming Growth Factor 
(TGF)- / Bone Morphogenetic Protein (BMP) signaling. These complex and delicate 
interactions allow integration of these pathways into highly ordered and complex molecular 
networks that regulate embryonic development but also immune and vascular responses in 
the adult 125,126. 
The cross-talk between the VEGF and Notch pathways is explained further in detail.  
The Wnt signaling pathway is initiated by interaction of a Wnt ligand with its Frizzled 
receptor and leads to the stabilization of -catenin by inhibition of glycogen-synthase 
kinase-3 (GSK3). In the absence of activated Wnt signaling -catenin is targeted for 
degradation by phosphorylation through a complex containing GSK3, adenomatous 
polyposis colon protein (APC) and Axin-1. Stabilized -catenin translocates to the nucleus 
where it forms a complex with transcription factors of the T cell factor (TCF) / Lymphoid 
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enhancer-binding factor (LEF) family and activates target gene expression (reviewed in 127). 
An inhibitory cross-talk exists between the Notch and the Wnt signaling pathway at different 
levels. The Wnt ligand can bind to the extracellular domain of Notch 128, the Notch 
intracellular domain can interact with the intracellular Wnt pathway component Disheveled 
129 and PS-1 interacts with -catenin 130,131. It has also been described that Wnt signaling 
induces Notch ligand expression and thus prevents Notch pathway activity in Wnt-activated 
cells 132. 
In vertebrates three Hh ligands exist: Sonic hedgehog (Shh), Indian hedgehog (Ihh) 
and Desert hedgehog (Dhh). In the absence of Hh ligands, the cell-surface transmembrane 
receptor Patched (Ptc) blocks the activity of Smoothened (Smo), another transmembrane 
protein. Binding of Hh to Ptc blocks its function, which allows Smo to accumulate and inhibit 
the proteolytic tranformation of Gli transcription factors from the activator form to the 
repressor form (reviewed in 133). One of the downstream targets of Hh-activated signaling is 
the Wnt protein 134. Both Notch and Hh signaling pathways are implicated in the regulation 
of differentiation and proliferation, but precisely how the two interact in regulating cellular 
processes is poorly understood. Depending on the cellular environment, their effects differ 
and their interaction can be positive or negative 135. 
The TGF-/BMP pathway involves TGF- and BMP ligands, two types of receptors 
(type I and II) and the signal transducing Smads. On activation, the receptor complex 
phosphorylates and activates receptor-regulated Smads (R-Smads). The activated R-
Smads interact with Smad4 and accumulate in the nucleus, where the Smad complex 
interacts with other factors to regulate target gene expression. TGF-/BMP signaling is 
closely intertwined with the Wnt pathway, but also interacts with many other signaling 
pathways like Hh and Notch 136. TGF- can induce the expression of Notch ligands, and 
TGF-/BMP and Notch synergistically regulate common target genes by direct interaction of 
NICD and Smad. These and other synergistic and antagonistic interactions of both 
pathways are reviewed in 136 
 
 
CHAPTER I   
 28 
2.1.2 Functions 
The Notch signaling pathway is important for cell-cell communication and is mainly 
involved in activation of gene regulation mechanisms to control multiple cell differentiation 
processes during embryonic and adult life. The best-known mechanism by which Notch 
regulates differentiation is via a process called ‘lateral inhibition’ (Figure 5A). This concept 
explains that when, within a pool of progenitor cells, a cell adopts a particular fate it inhibits 
its immediate neighbors from acquiring the same fate and instructs them to maintain their 
undifferentiated state. Initially, all progenitor cells are equivalent and express both Notch 
ligands and receptors. Due to stochastic reasons or intrinsic or extrinsic factors that are not 
always clear, one cell starts expressing higher levels of ligand than its neighbors. This cell 
becomes the ‘signal-sending’ cell that will adopt a certain phenotype and by activating the 
Notch signaling pathway in its neighbors prevents these ‘signal-receiving’ cells from 
acquiring the same phenotype. This is possible, due to the stabilization and amplifications 
of the differences in expression levels of ligand and receptor. Via a feedback-mechanism in 
the ‘signal-receiving’ cells, activation of the Notch receptor reduces ligand expression, 
thereby amplifying the initial small differences in levels of ligand expression and pushing 
these cells even more in a ‘signal-receiving’ mode and thus under control of the signals sent 
by the initial differentiating cell 137. By activation of the Notch receptor, the ‘signal-receiving’ 
cells induce expression of Hes/Hey transcription factors, which are transcriptional 
repressors that prevent expression of differentiation-inducing factors. In this way only the 
few ‘signal-sending’ cells can adopt a differentiated state whereas the differentiation 
pathway is suppressed by Notch signaling in the surrounding cells. This process creates a 
‘salt-and-pepper’ pattern of different cell types. Recent findings indicate that this model of 
lateral inhibition is too simplistic and that the pattern dynamically changes in time due to 
oscillations in Notch signaling 138. An example of lateral inhibition is the maintenance of 
neuronal progenitors in the nervous system 137,138. 
A second effect of Notch signaling is lineage decision making. A well-studied 
example is the B- versus T-cell fate decision in the immune system. This process is 
accomplished by asymmetric segregation of regulators upon division of a precursor cell into 
two daughter cells (Figure 5B). Examples of such regulators are Numb and Neuralized 
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(Neur). Numb inhibits the Notch receptor through a mechanism that involves endocytosis of 
the receptor 109. Neur on the other hand is an E3-ligase that ubiquitylates the Delta ligand 
and promotes its endocytosis 139. It has been suggested that this could enhance signaling 
by promoting the activation of Notch receptors. The asymmetric segregation of these 
regulators confers distinct cell fates to the daughter cells. 
Lastly, Notch signaling can form boundaries between different regions or establish 
niches for maintaining specific cell types. An example is limb formation, where at the apex 
dorsal and ventral ectodermal cells confront each other and induce by Notch signaling 
formation of specialized cells that produce signals organizing outgrowth of the limb bud 140. 
Another example is the formation of rhombomeres in the vertebrate hindbrain 141. Somite 
formation seems to be a similar process in which boundaries are created. However, Notch 
plays multiple roles in this complex process that also differs between species. Underlying 
the process of segmentation there is a temporal oscillation in the expression of so called 
‘clock genes’ in the unsegmented presomitic mesoderm at the tail end of the embryo 142. 
The clock genes comprise components of the Notch, Wnt and FGF pathways. Especially 
Hes7 and Lunatic Fringe play important roles in regulating the oscillations through a 
negative feedback loop (Figure 5C), however, the nature of the ultimate generator and 
pacemaker of the oscillations is not entirely clear 143. In mice, Notch signaling is required 
both for maintenance of the synchronic somitogenesis oscillation waves and for the 
formation of sharp somite boundaries 144. In zebrafish embryos it was recently shown that 
Notch signaling functions only to synchronize the clock gene oscillations in neighbouring 
cells, but inhibition of Notch is not sufficient to interrupt the generation of a segmented body 
plan 145. In mouse the sharp boundaries of Delta expression and Notch activation seem to 
be necessary to guide somite segmentation. In the anterior PSM, Notch activity and Lunatic 
Fringe waves are no longer regulated by Hes7, but become under the influence of the 
transcriptional regulator Mesp2 and a clear boundary is created where two non-equivalent 
groups of cells confront one another 146 (Figure 5C). Notch signaling from one group to the 
other group can confer a distinctive character on a band of cells along the boundary 
between the two populations. Finally, Notch signaling is also involved in the formation of the 
anterior-posterior polarity within each somite 147. 
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Figure 5: Notch signaling functions. (A) Lateral inhibition. All cells within an 
equivalence group are in a particular state (yellow) and possess similar amounts of 
Notch and Delta. A combination of intrinsic and extrinsic signals induces a new cell 
state (light red) and breaks this balance by increasing the abundance of Delta in 
one or a few cells (dark red). Consequently, Notch signaling is activated in 
neighboring cells, suppressing the alternative fate and reverting these neighboring 
cells to their original fate through lateral inhibition. (adapted from 
scienceblogs.com/pharyngula/2006/12/notch.php). (B) Lineage decision. 
Regulation of Notch signaling by asymmetric segregation of Numb into the 
daughter cells upon cell division. Delta (D) / Notch (N) signaling occurs between 
the two daughter cells. Numb (Nb) inhibits Notch signaling and thus prevents 
Notch signaling in the Numb-containing daughter cell (adapted from 148).(C) 
Boundary formation. In the posterior PSM, Notch signaling activates expression 
of Lfng and Hes7. Positive and negative feedback loops generate oscillations of 
Notch activity. In the anterior PSM, Notch activity and Lfng expression are regulatd 
by. As a result, Notch activity and Lfng waves are arrested and a boundary is 
created, which produces the next segmental boundary (adapted from 146). 
 
 
 
2.2 NOTCH SIGNALING IN VASCULAR DEVELOPMENT 
During the last decade, several studies have shown the importance of Notch signaling 
during different steps of vascular development 102. The first evidence came from the fact 
that several components of the Notch pathway are expressed in the endothelium and in the 
surrounding mural cells. Notch1 is broadly expressed in many tissues, including the heart 
and vascular ECs 149. Expression of Notch4 is mainly restricted to the vascular system 150-
152. Notch3 is predominantly expressed in vascular smooth muscle cells 153. Four of the five 
mammalian Notch ligands (Jagged1, Jagged2, Dll1 and Dll4) are expressed in vascular 
ECs 149,154,155 and Jagged1 is also expressed in smooth muscle cells surrounding the 
arteries 156.  
Further evidence for a role of Notch signaling in vascular development came from 
several in vivo studies in which genes of the Notch pathway were inactivated or 
overexpressed 102,157. Homozygous deletion of Notch1 in mice causes embryonic lethality as 
early as day E10.5 due to severe vascular remodeling defects in the yolk sac, the placenta 
and the embryo proper 149. Targeted knockout in the endothelium causes the same 
phenotype 158. Strangely, although Notch 4 is specifically expressed in the arterial 
endothelium 152, Notch4-null mice develop normally and are fertile. However, double 
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homozygous deletion of Notch1 and Notch4 causes vascular defects that are more severe 
than those observed in single Notch1-null mice 149. Even more interesting is the fact that 
overexpression of an activated form of Notch4 in the endothelium leads to angiogenic 
defects similar to those observed in Notch1/Notch4 double knockout mice 159 and in adult 
mice, expression of constitutively activated Notch4 is associated with arteriovenous 
malformations (i.e. abnormal connections between arteries and veins) 160. Taken together, 
these findings indicate that the Notch signaling pathway needs to be finely tuned to regulate 
normal embryonic vascular development and that maintenance of proper Notch signaling is 
also required during adult life. Similarly, deletion of some of the Notch ligands is 
embryonically lethal. Mice lacking Dll1, Dll4 or Jagged1 die from vascular defects and 
severe haemorrhage 161-165. Among these mutants, the Dll4 mutant displays the most 
severe vascular defects with deletion of even a single gene leading to lethality at E10.5 in 
most genetic backgrounds 161,162,164. Interestingly, the only other gene that was previously 
described to show heterozygous lethality due to vascularization defects is VEGF-A 166,167. 
Mutations in downstream Notch effectors also trigger vascular defects. Deletion of RBP-J 
results in growth retardation by E8.5 and death by E10.5 due to abnormal placental 
development 168. Mice lacking PS-1 and PS-2 or PS-1 alone exhibit vascular defects 169,170.  
And finally, combined deletion of the Hey1 and Hey2 downstream Notch targets similarly 
results in vessel malformation 171.  
Interestingly, all knockout mutants showed defective remodeling of the primary 
vascular plexus, indicating that Notch is dispensable for the initial vasculogenesis process 
(i.e. de novo formation of blood vessels from endothelial progenitor cells), but plays a 
crucial role during vascular remodeling through angiogenesis (i.e. sprouting from pre-
existing vessels). These studies clearly demonstrate that Notch signaling plays a crucial 
role in angiogenesis. The molecular and cellular mechanisms by which Notch signaling 
regulates different steps of blood vessel formation are described in the following sections. 
 
2.2.1 Arterial differentiation 
Initial studies in zebrafish have shown that Notch signaling is essential for arterial 
differentiation 172-175. The first indication came from a study of a mutant zebrafish strain 
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identified in an ENU-mutagenesis screening, the gridlock (grl) mutant, that lacks circulation 
in the trunk 175. The grl mutation was identified and positioned to be in a gene homologous 
to the mouse Hey2 gene. Gene expression analysis showed that grl is expressed as 
bilateral mesodermal stripes as early as the 10 somite stage, before vessel formation. 
Some of these grl-expressing cells migrate toward the midline to form the primordium of the 
DA at the 24 somite stage. By 30 somites, when blood begins to flow, grl is expressed 
strongly throughout the DA, whereas no grl-expressing cells are found in the vein 175. Later 
on, the same group showed, by lineage tracking in zebrafish embryos, that angioblast 
precursors for the trunk artery and vein are spatially mixed in the lateral posterior 
mesoderm. Progeny of each angioblast however are restricted to either the artery or the 
vein, indicating that these early angioblasts are already fated to the arterial or venous 
identity. This arterial-venous decision is guided by a notch-grl pathway 174. Knockdown of grl 
or ovexpression of a dominant-negative form of Su(H) (DNA-binding mutant Su(H)-DBM) 
specifically blocks formation of the DA and expanded the PCV 174. Furthermore, these 
morphant embryos, as well as the mindbomb (mib) mutant fail to express the arterial marker 
genes ephrinb2, notch5 and deltaC in the DA. In contrast, the venous markers flt4 and 
ephb4 are ectopically expressed in the DA. Remarkably, expression of other arterial marker 
genes, like tbx20 and grl are not affected in these mutants. 172,174. Activation of the Notch 
pathway by heat shock-inducible overexpression of the Notch1a intracellular domain in 
double transgenic hsp70:Gal4;UAS:Notch1a-ICD zebrafish embryos did not affect arterial 
marker gene expression but venous marker gene expression in the PCV was diminished 
172. Therefore, Notch signaling plays an important role in the expression of artery-specific 
genes and repression of a venous cell fate program within the DA. However, activation of 
the Notch pathway does not induce arterial cell fate identity ectopically, indicating that 
Notch signaling is cooperating with other pathways to mediate arterial differentiation. It was 
further shown that Sonic hedgehog (Shh) and vegf act upstream of the Notch pathway 
during arterial endothelial differentiation 173. Shh is expressed in the notochord and induces 
expression of vegf in the somites at the time of angioblast migration. Vegf induces 
expression of notch5, thereby inducing arterial differentiation and blocking venous 
differentiation in a subset of angioblasts (Figure 6) 173,176. A recent study shows that arterial 
and venous angioblasts initially form a single common precursor vessel and that the 
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embryonic artery and vein are formed by selective angioblast sprouting 177. This sorting and 
segregation of arterial and venous angioblasts was shown to be regulated by a repulsive 
interaction of EphrinB2 and EphB4, which are expressed in arterial-fated and venous-fated 
progenitors, respectively, and orient the direction of progenitor cell migration 177.  
Also in mammals Notch has been shown to be important for arterial development. 
Two Notch receptors, Notch1 and Notch4 are predominantly expressed in arterial ECs of 
early mouse embryos 149. As described above knockout of Notch1, Notch1;Notch4 or 
overexpression of an activated form of Notch4 leads to embryonic lethality due to vascular 
defects 149,159. Overexpression of constitutively active Notch4 in adult mice leads to 
arteriovenous malformations that are accompanied by ectopic expression of the arterial 
marker EphrinB2 in veins 160. Dll4 is the only vascular specific ligand expressed in the DA at 
E8.5 and is thus believed to be the ligand for Notch1 and Notch4 during early vascular 
development. Dll1 is expressed in arterial ECs at a later stage (E13.5) and continues to be 
restricted to arterial ECs in adults and is required for maintenance of arterial identity 154,178.  
Notch signaling is required for induction of arterial differentiation. However, venous 
differentiation is not a default pathway that is actively repressed by the Notch pathway to 
induce arteries. In order to obtain venous differentiation, the EC has to actively repress 
Notch signaling through COUP-TFII, a member of the orphan nuclear receptor superfamily, 
indicating that vein formation is also genetically programmed 179. Endothelial-specific 
knockout of COUP-TFII leads to embryonic lethality by E12 due to vascular defects, 
including haemorrhage and thin and dilated vessels. Furthermore, mutant veins ectopically 
expressed Jagged1, Notch1, Neuropilin-1 (Nrp-1) and EphrinB2 179. Endothelial-specific 
overexpression of COUP-TFII also induces angiogenesis defects and results in the 
formation of large, fused, disorganized vessels without arterial-venous distinction. It has 
therefore been proposed that COUP-TFII suppresses Nrp-1 expression and inhibits Notch 
signaling in normal venous endothelium. Without the effects of Nrp-1 and Notch signaling, 
factors important for venous differentiation are expressed and venous identity is maintained. 
Removal of COUP-TFII activates the expression of arterial markers leading to acquisition of 
arterial identity 179.  
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Figure 6: A model for arterial differentiation in zebrafish (from 176). 
Schematic cross-sections through the trunk of a zebrafish embryo are shown. 
(A) At the 10-somite stage (ss), Shh expression in the notochord drives the 
expression of vegf in the surrounding somitic tissue. At this time, angioblasts 
arise from the dorsal lateral mesoderm (green) and come into close proximity to 
the source of Vegf. (B) By 18 ss, in mid-somitogenesis, local Vegf activates the 
Notch pathway, probably through the induction of notch5 in the developing 
dorsal aorta, therefore inducing the expression of ephrinb2a. Vascular 
progenitors migrate towards the midline, with the arterial progenitors leading the 
way (shown in purple). (C) By 24 h post-fertilization, in late somitogenesis, vein 
markers become downregulated in the arteries (red circle represents dorsal 
artery).  
LPM, lateral plate mesoderm; No, notochord; NT, neural tube; S, somite. 
CHAPTER I   
 36 
2.2.2 Tip cell selection 
Angiogenesis is the sprouting of vessels from pre-existing ones. A newly forming 
sprout is composed of different endothelial cell types: tip cells and stalk cells (Figure 7) 180.  
Tip cells continuously ‘scan’ the environment for guidance cues with their filopodia, long 
finger-like structures. In this way they can sense gradients of guidance cues and determine 
the direction of the growing sprout. Stalk cells are the cells trailing behind the tip cell and 
are responsible for elongation of the sprout. They proliferate, form junctions, lay down 
extracellular matrix and form a lumen. A third type of endothelial cells, the phalanx cells, are 
the quiescent cells lining the vessel once the new branches have consolidated 181. They are 
termed phalanx cells because of their smooth cobblestone monolayer that resembles a 
phalanx formation of ancient Greek soldiers. They are covered by pericytes, stick to each 
other via tight junctions and are embedded in a thick basement membrane.  
 
 
Figure 7: Schematic overview of a sprouting vessel. (left) Different types of 
ECs in a vessel sprout growing towards a source of VEGF. (right) Molecular 
mechanisms regulating tip and stalk cell identity. (adapted from 180) 
 
  INTRODUCTION 
 37 
Notch signaling is involved in the selection of ECs that become the leading tip cell 
during vessel branching. As described above, all ECs in a blood vessel express various 
Notch receptors and ligands. When a blood vessel is exposed to a VEGF gradient, the 
process of selection and induction of a tip cell begins 182. The cell that becomes exposed to 
the highest level of VEGF will be selected to become a tip cell (Figure 7). By binding to 
VEGFR2, VEGF induces the expression of Dll4. Dll4 then binds to and activates the Notch 
receptor in the neighboring ECs, leading to downregulation of VEGFR2 in these cells. 
Thereby these cells become less responsive to the VEGF gradient and thus the VEGF-
induced expression of Dll4 is dampened in these cells. This process is a clear example of 
lateral inhibition, whereby in a pool of equivalent ECs one cell is selected to become a tip 
cell that prevents its neighbors from becoming a tip cell as well and instructs them to be a 
stalk cell 183. This molecular process was unraveled independently by several groups by 
studying the process of postnatal angiogenic sprouting in the mouse retina 184-187. They all 
observed Dll4 expression at the leading front of the vascular plexus and found that inhibition 
of Dll4/Notch signaling resulted in an increased vascular density due to excessive 
sprouting. This hyperproliferation is dependent on VEGF and sprouting can be abolished by 
blocking VEGF/VEGFR2 interaction with antibodies or with soluble VEGFR1 186,187. Similar 
findings were described in the zebrafish ISV sprouting model where inhibition of the Notch 
pathway by DAPT treatment (a -secretase inhibitor that blocks Notch signaling by 
interfering with presenilin function 188) or morpholino knockdown of Su(H) or Dll4 induces 
hyperbranching of the ISVs and leads to an increased number of ECs in the ISVs 189,190. In 
contrast, inducible activation of the Notch pathway in the Hsp70:Gal4;UAS:Notch1a-ICD 
line blocks sprouting of the ISVs 190. In zebrafish, Vegfr3 is expressed in the tip cells of the 
primary ISVs and knockdown of Vegfr3 can partially rescue the Su(H) knockdown 
phenotype 190. Later, also in mice, VEGFR3 was shown to be expressed in blood vessels 
undergoing angiogenesis, most strongly in the leading tip cells 191. Dll4-induced Notch 
signaling downregulates Vegfr3 expression and blocking VEGFR3 signaling can counteract 
hyperproliferation upon Notch inhibition 191. Similarly in zebrafish, Dll4 functions to suppress 
the ability of developing intersomitic arteries to respond to Vegfc-driven Flt4 signaling and 
blocking Vegfc/Vegfr3 signaling rescues the Dll4 morphant hyperbranching phenotype in 
the ISVs 92. More recently it was described that Jagged1 antagonizes the function of Dll4 in 
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sprouting angiogenesis 192. This activity of Jagged1 depends on Fringe, which modifies the 
Notch receptor in stalk ECs and reduces activation by Jagged1, while enhancing Delta-
mediated signaling. Jagged1 is expressed strongly in stalk cells but not or only weakly in tip 
cells. Jagged1 promotes angiogenesis by increasing tip cell numbers as an antagonist of 
Dll4/Notch signaling and prevents that low levels of coexpressed Dll4 in stalk cells can 
activate Notch in neighboring ECs 192.  In this way Dll4 and Jagged1 control the tightly 
balanced process of angiogenic sprouting.  
Because of the crucial role of Dll4/Notch signaling in angiogenic sprouting, several 
groups have studied the role of this pathway in tumor development. The neovascularization 
of tumors through the angiogenic ingrowth of blood vessels from the surrounding tissue is 
one of the hallmarks of cancer that promotes tumor growth and metastasis. Dll4 is 
prominently expressed in tumor blood vessels in a VEGF-dependent manner 193-195. 
Blocking Dll4/Notch signaling, either by a monoclonal anti-Dll4 antibody or by soluble Dll4 
fused to the Fc domain of IgG, leads to increased vascular density within the tumor 
186,194,196. Paradoxically, despite this increased vascularization, tumor development is 
delayed 197. This is because the resulting vessels are poorly functional, resulting in the 
tumors being more hypoxic 186,194,196,198. These findings demonstrated that the stimulation of 
non-productive angiogenesis by blocking Dll4 could be used as a novel strategy for 
targeting tumor-induced angiogenesis, complementing anti-angiogenic therapeutic 
approaches 103. However, despite the positive results of Dll4 blockade in preclinical studies, 
this novel anti-angiogenic strategy has very recently raised important safety concerns 
because of pathological activation of ECs, disruption of normal organ homeostatis and 
induction of vascular tumors 199. Dll4 signaling appears to be essential for maintaining 
endothelium in the liver in a quiescent state and disruption of the pathway results in severe 
liver pathology 199. Furthermore, chronic Dll4 blockade in rats results in subcutaneous 
tumors with features of vascular neoplasms, and lesions containing regions of necrosis can 
be found in heart and lung tissue 199. Therefore, refined strategies might be necessary to 
exploit this pathway as a tool to disrupt tumor angiogenesis without causing prohibitive side 
effects. 
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2.2.3 Mural cell differentiation and maturation 
Blood vessels not only consist of ECs, but also mural cells. The latter are derived from 
the mesenchyme and coat the endothelial cell tube. Mural cells can either be pericytes in 
the microvasculature or smooth muscle cells (SMCs) in the larger vessels. SMCs form 
multiple concentric layers around arteries and veins, whereas pericytes form a single, often 
discontinuous cell layer. Interactions between ECs and mural cells serve to stabilize 
nascent capillary vessels, provide survival factors for ECs, inhibit EC proliferation, promote 
mural cell differentiation and guide vascular network remodeling 200.  
Several signaling pathways are involved in mural cell recruitment, maturation and 
differentiation: TGF-, PDGF-B/PDGFR-, EphrinB2, sphingosine-1-phosphate and Notch 
signaling 201,202. The Notch3 receptor is highly expressed in pericytes and vascular SMCs of 
arteries and Notch3-null mice show defective maturation of SMCs and have enlarged 
vessels due to the lack of mural cells 202,203. Similarly, patients with mutations in Notch3 
suffer from CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts 
and Leukoencephalopathy) syndrome, a pathology that causes stroke and dementia and is 
associated with degeneration of SMCs 204. Also modulation of Dll4 signaling in tumor 
models has been described to result in deficient pericyte coverage 196,198. Possibly this is 
caused by decreased EphrinB2 expression in pericytes which is required for their 
recruitment to vessels 205-207.  
Endothelial cell - mural cell contact induces expression of Notch3 in mural cells, which 
is dependent on expression of Jagged1 in ECs 156. Indeed, endothelial-specific deletion of 
Jagged1 results in striking deficits in vascular SMCs confirming the important role of 
endothelial Jagged1 to regulate the development of neighboring SMCs 208. The increased 
expression of Notch3 in mural cells is accompanied by upregulation of SMC differentiation 
marker genes. However, this effect is only observed in mural cells that already express 
SMC marker genes, indicating that activated Notch signaling upon contact with an EC 
partner induces proper SMC maturation 156. Notch3-negative arterial SMCs are altered in 
size and shape and fail to properly associate with ECs. Proliferation and survival however 
are not affected 203. PDGFR was shown to be a direct Notch target gene 209. PDGF-
B/PDGFR- signaling is required for recruitment of mural cells. PDGF-B is secreted by the 
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endothelium of angiogenic sprouts and is bound to the extracellular matrix where it serves 
as an attractant for migrating pericytes, which express PDGFR-. In addition, PDGF-B 
stimulates proliferation of SMCs and induces mural cell fate in undifferentiated 
mesenchymal progenitor cells 210. Therefore it is suggested that Notch affects maturation of 
mural cells indirectly via its effects on PDGF signaling 209. 
Very recently it was described that Notch signaling together with TGF- signaling is 
also required for differentiation of mesenchymal stem cells into SMCs 211. Both TGF- and 
Notch activation induce the upregulation of SMC marker gene expression. More specifically, 
TGF- induces the expression of Jagged1 in mesenchymal stem cells, which is necessary 
for the upregulation of various SMC markers. This suggests that Notch signaling mediates 
TGF- regulation of mesenchymal stem cell differentiation into SMCs 211.  
 
2.2.4 Role of Notch in postnatal vascular development 
From the above it is clear that the Notch signaling pathway plays a crucial role 
during different steps of embryonic vascular development, but Notch signaling was also 
found to be essential for vascular development during postnatal and adult life. Blood vessel 
growth is induced postnatally under different physiological and pathological conditions, like 
wound healing, inflammation, ischemia, cancer, etc. Blood vessels in adult tissues are 
mainly formed through angiogenesis, the sprouting of pre-existing blood vessels. However, 
there is scientific debate about the contribution in adults of vasculogenesis, the process by 
which progenitor stem cells differentiate to ECs and give rise to de novo formed blood 
vessels and that occurrs during embryonic life 212. Bone marrow-derived cells have been 
identified in peripheral blood in adults and shown to participate in new vessel formation 
213,214. These cells were termed endothelial progenitor cells (EPCs). Despite the controversy 
concerning the existence of EPCs (see further), a role for Notch has been described in both 
postnatal neoangiogenesis and angiogenesis through sprouting. 
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Figure 8: Notch signaling in EPC-mediated neovascularization. In the BM niche, 
Jagged-1 is expressed in stromal cells and modulates the development and 
functional kinetics of EPCs, which express Notch receptors. This interaction 
influences EPC proliferation, differentiation, mobilization, and ultimately EPC-
mediated active neovascularization in ischemic sites. (from 215) 
 
In the bone marrow (BM), EPCs differentiate from hemangioblastic stem cells, a 
common stem cell for EPCs and hematopoietic stem cells (HSCs) 216. They are mobilized 
into the blood stream upon signaling by cytokines and growth factors, such as granulocyt-
macrophage colony stimulating factor (GM-CSF) and VEGF-A, and are recruited to sites of 
hypoxia or wounding where they interact with tissue-specific cells and contribute to the 
formation of new blood vessels. In the BM niche, Notch ligands, especially Jagged-1 and 
Dll1, are expressed in osteoblasts, stromal cells and ECs 217,218 (Figure 8). The interaction 
between osteoblasts expressing Notch ligands and HSCs expressing Notch receptors is 
one of the molecular mechanisms regulating HSC self-renewal and maintenance 219. 
Similarly, Notch signaling is involved in EPC biology in the BM niche 220. It was shown that 
CHAPTER I   
 42 
loss of Jagged-1 ligand in mice, but not Dll1, leads to an impairment of proliferation, 
survival, differentiation and mobilization of BM-derived EPCs, resulting in a reduced 
therapeutic capacity of EPCs for vasculogenesis and vascular regeneration in ischemic 
tissues 220. Therefore, signaling between stromal cells expressing the Notch ligand Jagged-
1 and EPCs expressing Notch receptors seems to be essential to drive immature BM cells 
to commit and differentiate into functional EPCs. Furthermore, Notch signaling may not only 
be involved in the interaction of EPCs with the BM niche, but also play pivotal roles in the 
peripheral tissues by regulating homing, on site differentiation and integration of EPCs into 
the target tissues 215. 
Recent discoveries in both mice 221 and humans 222 have led to questions and 
discussions about the existence of EPCs. In contrast, other recent evidence indicates that 
EPCs are important in tumour angiogenesis and metastasis 223,224. Further, despite the 
findings of some studies that have shown a correlation between low numbers and 
funcitionality of EPCs and higher risk of cardiovascular disease, therapeutic strategies using 
transplantation of BM-derived cells has shown at best only moderate effects (reviewed in 
212). It has been suggested that the described EPCs may indeed contribute to the 
angiogenic processes but are not real progenitors of adult endothelium 212. Rather, the 
primary contribution of these BM-derived monocytic cells is not by incorporating themselves 
into the newly forming vessels, but by migrating to the site of neoangiogenesis where they 
deliver signals that activate pericytes, which in turn secrete mediators that stiumulate 
migration and proliferation of local ECs 225. Nevertheless, Notch signaling plays a critical 
role in mobilization of BM-derived cells, whatever role these cells play at the site of 
neovascularization. 
Besides its function in neovascularization, Notch signaling also plays a role in both 
physiological and pathological postnatal angiogenesis whereby sprouting occurs from 
existing blood vessels, for example during hypoxia, wound healing, inflammation and tumor 
growth. In a model of hindlimb ischemia it was shown that blood flow recovery and 
neovascularization were impaired in global or endothelial specific heterozygous Notch1+/- 
mice, but not in Notch4-/- mice 226. Upon ischemic injury, Notch1 expression is induced in the 
endothelium. VEGF is well known to be upregulated in response to hypoxia and to promote 
  INTRODUCTION 
 43 
angiogenesis in ischemic tissues 227. Through the phosphatidylinositol 3-kinase (PI3K)/Akt 
pathway, VEGF induces -secretase mediated cleavage and activation of Notch1, which is 
critical for VEGF-induced EC proliferation, migration and survival 226. The Notch ligand Dll1 
has also been described as a critical regulator of postnatal angiogenesis 178. Its expression 
in the arterial endothelium is strongly upregulated during ischemia and heterozygous Dll1+/- 
mice, which survive to adulthood, show reduced formation of collateral arteries and fail to 
restore blood flow in a hindlimb ischemia model, similar to the Notch1+/- mice 178. 
Similar to developmental angiogenesis, Notch signaling is involved in tip cell selection 
during postnatal angiogenesis to control sprouting of new vessels from pre-existing ones. 
As described above, during development, this process is critically regulated by Dll4-
mediated Notch signaling. During inflammation-induced angiogenesis however, an 
upregulation of Jagged1 was observed in ECs becoming tip cells 228. Jagged1 expression is 
induced by the inflammatory cytokine tumor necrosis factor (TNF) through an NFB-
dependent mechanism. Paradoxically, at the same time TNF blocks VEGFR2 signaling, 
thus blocking the VEGF-driven angiogenic response. However, this concomitant tip cell 
selection and angiogenesis inhibition functions to prime ECs for sprouting once the initial 
inflammatory wave has passed 228. These findings suggest that during inflammatory 
angiogenesis Jagged1 plays a role similar to that of Dll4 during developmental tip cell 
selection. Tumor angiogenesis may represent a mixture of physiologic and inflammatory 
angiogenesis as both Dll4 and Jagged1 are upregulated on tumor vasculature 195,228. The 
effects of blocking Dll4/Notch signaling during tumor-induced angiogenesis are described 
above. 
 
2.3 NOTCH SIGNALING IN LYMPHATIC DEVELOPMENT 
Intriguingly, despite the venous origin of lymph vessels, several molecular players, 
involved in arterial EC fate specification, have been implicated in lymphangiogenesis. 
EphrinB2 is initially a specific marker of arterial ECs 172, yet, becomes a lymphatic marker 
later in development, and regulates lymphangiogenesis 70. The forkhead transcription 
factors, Foxc1 and Foxc2 are required for arterial cell fate specification, but subsequently 
regulate sprouting of LECs from veins 69. Foxc2 is also involved in maturation of lymphatic 
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vessels. It is expressed in the luminal valves and loss of function results in failure to form 
valves and recruit SMCs to lymphatic collecting ducts 68. Remarkably, both EphrinB2 and 
the Foxc1/2 transcription factors can be linked to the Dll4/Notch signaling pathway. Notch 
regulates arterial differentiation, in part through upregulation of EphrinB2 expression in 
arterial ECs 172. Moreover, in vitro co-culture experiments have shown that specifically Dll4 
stimulation, but not Jagged1 markedly induced EphrinB2 expression in venous ECs 207. 
Foxc1 and Foxc2 were shown to induce the expression of Notch1, Notch4, Dll4 and Hey2 
69,229. The regulation of Dll4 and Hey2 occurs via direct interaction of the Foxc transcription 
factors to Foxc-binding sites in both promoters 69,229. The activity of Foxc proteins in the 
activation of the Dll4 and Hey2 promoters is further enhanced by VEGF-mediated PI3K and 
ERK/MAPK pathways 229. Furthermore, Foxc1-/-;Foxc2-/- double knockout mice exhibit 
arteriovenous malformations and loss of arterial marker gene expression 69. Taken together, 
it seems that the Foxc transcription factors act upstream of Notch and EphrinB2 signaling in 
the regulation of arterial specification. The involvement of both Foxc1/2 and EphrinB2 in 
lymphatic development and their regulatory relationships to Notch signaling in arterial 
development raises the question whether Notch signaling is also involved in lymphatic 
development and even more, whether Notch signaling is generally involved in differentiation 
away from the venous identity towards either an arterial or lymphatic fate, possibly 
dependent on co-regulation by other thus far unknown factors. Very recently, Notch1 and 
Notch4 were found to be expressed in normal and tumor LECs and Notch1 is activated in 
lymphatic endothelium of invasive mammary micropapillary carcinomas 230. Furthermore, 
cultured LECs express some of the Notch receptors (Notch-1, -2 and -4), ligands (Dll1, 
Jagged1, Jagged2) and downstream targets (Hey1 or -2) 231,232.  
As described above Notch signaling induces arterial differentiation and suppresses 
venous identity 172. COUP-TFII directs differentiation towards a venous fate by blocking 
Notch signaling 179. At a later stage venous ECs can differentiate into lymphatic ECs by 
expression of additional key regulators like Sox18 and Prox1 39. Interestingly, the venous 
regulator COUP-TFII also appears to be essential for LEC specification and maintenance of 
the LEC phenotype 233,234. Its expression was shown in cardinal vein-derived sprouting 
LECs and newly formed lymphatic vessels in mouse embryos 233,234. COUP-TFII physically 
interacts with Prox1 to form a transcription factor complex that regulates several lineage-
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specific genes including VEGFR3, FGFR3 and Nrp-1 233,234. In most cases both transcription 
factors were found to co-regulate expression of their target genes, however, they can also 
counter-regulate target gene expression, as was shown for Nrp-1 233. Furthermore, the 
effect of COUP-TFII on Prox1-mediated regulation of VEGFR3 was shown to be different in 
BECs (negative) and LECs (positive), indicating the high level of complexity and cell type-
dependency of this system 234. The co-regulatory effect of Prox1 and COUP-TFII on the 
expression levels of Notch pathway components has not been described.  
Vascular-specific deletion of COUP-TFII blocks venous differentiation and LEC 
formation 35,235. Recently, it was shown that the lost venous identity, but not the loss of 
LECs, can be rescued by simultaneous deletion of Rpbj 235. These findings seem to indicate 
that, unlike arterial-versus-venous specification, lymphatic-versus-venous specification is 
not dependent on canonical CSL-dependent Notch signaling 235. However, it should be 
noted that only a few of the Rpbj-null mice generated in this study survived, possibly 
pointing to an incomplete deletion of Rbpj in the analyzed mouse embryos, which might be 
sufficient for LEC specification. The same group showed that COUP-TFII is involved in a 
three-phased regulation of Prox1 expression 235. The initiation of Prox1 expression was 
shown to be dependent on COUP-TFII expression. The subsequent maintenance phase of 
Prox1 expression is dependent on the interaction of Prox1 with another nuclear receptor. 
Most likely a Prox1-COUP-TFII interaction is required since COUP-TFII was shown to be 
required also for maintenance of Prox1-expression in early differentiating LECs. Finally, 
later maintenance of Prox1, beyond E13.5, becomes independent of COUP-TFII 235. 
However, another study showed that conditional loss of COUP-TFII at E12.5 leads to loss 
of lymphatic markers and upregulation of BEC markers, but expression of Prox1 was 
unchanged 236. Thus, this indicates that already at E12.5 maintenance of Prox1 expression 
is COUP-TFII independent and that COUP-TFII regulates LEC identity independent of 
Prox1 236. Further, COUP-TFII is also involved in VEGF-C-induced lymphangiogenic 
activities, including proliferation and migration and this role is mediated, at least in part, by 
direct stimulation of Nrp-2 expression 236. Finally, COUP-TFII also seems to be essential for 
pathological neo-lymphangiogenesis in adult mice as inactivation of COUP-TFII in a tumor 
model results in inhibition of tumor lymphangiogenesis 236. Another group 237 recently 
investigated the regulatory relationship among the three endothelial cell fate regulators 
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(Notch, COUP-TFII and Prox1), which remarkably co-reside in LECs 45,230,233. They found 
that these regulators are under an exquisite feedback control mechanism and dynamically 
cross-regulate each other in established LECs 237. This finding could explain the remarkable 
cell fate plasticity of LECs 46-48,238,239. Notch signaling represses the expression of Prox1 and 
COUP-TFII in post-developmental LECs. In turn, Prox1 and COUP-TFII repress VEGFR-2 
and Nrp-1, thereby attenuating VEGF signaling, which is known to induce the Notch 
pathway 237. The authors propose that LEC fate may not be governed by a two-way turn 
ON-OFF switch, but rather by a dial switch that allows a gradient increase or decrease in 
the LEC fate force 237. The implications for and interpretation of these recent findings in light 
of our own data have been thoroughly discussed in the Discussion section. 
Another interesting link between Notch signaling and lymphatic structures was found 
in Kaposi’s sarcoma pathology. Kaposi’s sarcoma is a type of cancer affecting lymphatic 
endothelium that is caused by infection with the Kaposi sarcoma herpes virus (KSHV). 
Infection of BECs with KSHV leads to their lymphatic reprogramming with induction of 
lymphatic-specific genes and downregulation of blood vascular genes 238,239. Recently it has 
been shown that KSHV-infection of LECs induces expression of Dlll3, Dll4, Jagged1, 
Notch3 and Notch4 and the Notch target genes Hes1 and Hey1 240,241. A role for Dll4 and 
Jagged1 was suggested in the pathogenesis process by suppressing the cell cycle in 
adjacent non-infected LECs, thereby providing a growth advantage to infected over 
uninfected LECs 240. However, another study describes induction of expression of the 
endothelial precursor cell marker CD133 and several mural cell markers after KSHV 
infection of LECs, suggesting dedifferentiation and trans-differentiation processes 241. In any 
case, these studies indicate a potential role for Notch signaling in LECs in regulating 
proliferation and/or differentiation processes. 
 Despite all these indications of a possible role for Notch signaling in 
lymphangiogenesis, so far, no lymphatic phenotype was reported in mouse embryos 
carrying homo/heterozygous deletions of different Notch signaling components that are 
involved in vascular development (Notch1 164, Notch1/Notch4 164, Jagged1 165, Dll4+/- 
161,162,164, Hey1/Hey2 171, PS1/PS2 169,170). However, these mutant mice die due to vascular 
defects at E9.5-10.5, a time point at which lymphatic development is only just initiated. In 
  INTRODUCTION 
 47 
this study we have therefore analyzed the effects of inhibiting Notch signaling on lymphatic 
development in the zebrafish and tadpole models. These small aquatic animals are less 
dependent on normal vascular development and can survive several days without a fully 
functional circulatory system, thus allowing the analysis of the lymphatic developmental 
process after Notch inhibition. 
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The relationship between “arterial” factors and lymphangiogenesis, as well as the 
anatomical congruence between arteries and lymphatics (see Introduction p 40) prompted 
us to investigate whether Notch signaling, known to induce arterial endothelial fate 172-
174,177,240,242-244, also regulates lymphatic development. Notch and its ligand Dll4 seemed 
intriguing candidates, given their well-described role in vessel branching 184,187,189,190,194,245.  
The general aim of this thesis was therefore to determine whether the Notch signaling 
pathway in general, and more specifically Dll4/Notch signaling, is involved in lymphatic 
development, and if so, to assess which steps during the lymphangiogenesis process are 
regulated by this pathway.  
 
AIM 1: Does inhibition of Notch signaling interfere with normal lymphatic 
development in the zebrafish and Xenopus model? 
To answer this question we first performed general inhibition of the Notch pathway by 
means of the chemical compound N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-
butyl ester (DAPT) in zebrafish embryos and tadpoles. DAPT is a well known -secretase 
inhibitor, that blocks all canonical Notch signaling. The compound was added to the tank 
water of the embryos at early developmental stages, and the effect on lymphatic 
development was followed over time. In the tadpole model, the formation and functionality of 
the caudal lymph vessels was studied. In the zebrafish model, the formation of the thoracic 
duct was analyzed in these initial experiments, since this is the major lymphatic vessel in the 
zebrafish trunk, that is easily observable, and since this is the ultimate outcome within the 
first 5 to 6 days of normal lymphangiogenesis.  
 Secondly, we more specifically studied the involvement of the different Notch 
pathway components by performing a morpholino knockdown screening in zebrafish, 
targeting the different Notch receptors (Notch-1a, -1b, -5, -6) and ligands (Delta-A, -B, -C, -
D, Dll4) known in zebrafish and several of the downstream effectors (PS-1, PS-2, 
Su(H)a/Su(H)b).   
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AIM 2: What is the mechanism by which Notch signaling is affecting 
lymphangiogenesis? 
After having observed an effect of Notch inhibition on lymphatic development, the next 
step was to determine exactly which steps of the lymphatic developmental process are 
regulated by Notch signaling. For those morpholinos that impaired thoracic duct formation, 
the earlier steps of lymphatic development were studied. Earlier steps entail (i) parachordal 
lymphangioblasts (PL) string formation, (ii) lymphangiogenic sprouting from the PCV to form 
this PL string and concomitant formation of arterial or venous ISV connections, and (iii) 
navigation of LISV-PLs from the PL string to the TD position along their arterial template 
(Figure 3). 
Further in vitro experiments were performed to determine if blocking Notch signaling 
affects venous-to-lymphatic differentiation, LEC migration, proliferation or sprouting.  
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1 ZEBRAFISH EXPERIMENTS 
1.1 HUSBANDRY & TRANSGENIC LINES 
Adult fish were maintained under standard laboratory conditions. Embryos were kept 
at 28°C in 0.3x Danieau  (embryo water) supplemented with phenylthiourea (PTU) to prevent 
pigmentation 246.  
Transgenic zebrafish lines used were Fli1:eGFPy1 87, Flt1:YFP 90, kdr-l:mCherryRed 90, 
Tp1:eGFPxFli1:DsRed 247 and intercrosses.  
 
1.2 COMPOUND INHIBITOR TREATMENT 
A 10 mM stock solution of N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-
butyl ester (DAPT; -secretase inhibitor IX; Calbiochem) in DMSO was diluted in embryo 
water to the indicated treatment concentrations. Embryos were dechorionated by 
trypsinization (Sigma, 1.5 mg/ml in PBS) at 24 hpf and incubated in 6.25 to 25 μM DAPT in 
embryo water at different stages between 24 and 72 hpf. DMSO was added to the lower 
concentrations to equalize total DMSO to 0.25% in all conditions. Control embryos were 
incubated in 0.25% DMSO in embryo water.  
 
1.3 MORPHOLINO INJECTION OF ZEBRAFISH EMBRYOS 
Gene-specific antisense morpolino oligos were purchased from Gene Tools (LLC, 
Corvallis). Sequences are listed in Table 1. For reasons of consistency, we used the 
zebrafish nomenclature 173: zebrafish Notch-5 and -6 are mammalian homologues of Notch-
3 and -2, respectively, while zebrafish Notch-1a and -1b are duplicated mammalian 
orthologues of Notch-1 100,101. For the previously unpublished morpholinos, silencing 
efficiencies of morpholinos directed against the ATG region were determined as previously 
described using an in vitro luciferase reporter assay 32 and were confirmed (not shown). 
Morpholinos were injected into single- to four-cell stage zebrafish embryos, using 
procedures as previously described 90,246 and embryos were further incubated in embryo 
water at 28°C until 4 - 12 dpf with feeding from 7 dpf onwards. All data shown in the 
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manuscript were obtained after injection of 1.5 to 20 ng of morpholino, as indicated. Control 
embryos were injected with control morpholino (Gene tools, LLC) (Table 1)or injection buffer 
(0.1% phenol red).  
 
TABLE 1: MORPHOLINO OLIGONUCLEOTIDE SEQUENCES 
MO MO sequence Target Ref 
DeltaAATG 5’-CGCCGACTGATTCATTGGTGGAGAC-3’ Start site  
DeltaBATG 5’- CGCCATCTCGCTCACTTTATCCTAA-3’ Start site  
DeltaCATG 5’- GCACGTTAATAAAACACGAGCCATC-3’ Start site  
DeltaDATG 5’- AACAGCTATCATTAGTCGTCCCATG-3’ Start site  
Dll4ATG 5’-GAGAAAGGTGAGCCAAGCTGCG-3’  Start site  
Dll4SPL 5’-TAGGGTTTAGTCTTACCTTGGTCAC-3’ Exon6/intron6  189 
Jag1aATG 5’-GTCTGTCTGTGTGTCTGTCGCTGTG-3’ 5’ UTR  
Jag1bATG 5’-CTGAACTCCGTCGCAGAATCATGCC-3’ Start site  
Jag2ATG 5’-TCCTGATACAATTCCACATGCCGCC-3’ Start site  
Notch-1aATG 5’-TTCACCAAGAAACGGTTCATAACTC-3’ Start site 248,249 
Notch-1bATG 5’-ATGCATTCCTTCTTATGGATAGTCC-3’ Start site  
Notch-1bSPL 5’-AATCTCAAACTGACCTCAAACCGAC-3’ intron28/exon29  189,250 
Notch-5ATG 5’-ATATCCAAAGGCTGTAATTCCCCAT-3’ Start site 189,251 
Notch-6SPL 5’-AGGTGAACACTTACTTCATGCCAAA-3’ exon7/intron7  189,251 
PS-1ATG1 5’-CCGGGATCATAGAAACAGCGGGAAC-3’ 5’ UTR  
PS-1ATG2 5’-CATTCTGCACTAAATCAGCCATCGG-3’ Start site  
PS-2ATG 5’-CTCTTCACTGTCTGAGGTATTCATG-3’ Start site 252 
Prox1ATG1 5’-TGGAACTGTTATTGTGCCATCTTCG-3’ 5’UTR  
Prox1ATG2 5’-ATGTGCTGTCATGGTCAGGCATCAC-3’ Start site 7 
Prox1SPL 5-CTTGGATGTGAAATTCGGAAGGTTA-3’ intron1/exon2  
Sox18ATG 5-ATATTCATTCCAGCAAGACCAACAC-3’ Start site 253 
Su(H)ATG 5-CAAACTTCCCTGTCACAACAGGCGC-3’ Start site 190,254 
Su(H)aATG 5-CGCCATCTTCACCAACTCTCTCTAA-3’ Start site 254 
Su(H)bATG 5-CGCCATCTTCCACAAACTCTCACCA-3’ Start site 255 
control MO 5'-CCTCTTACCTCAGTTACAATTTATA-3' Standard control MO (Gene Tools)  
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1.4 SCREENING METHODS FOR EVALUATION OF LYMPHATIC DEVELOPMENT 
AND FUNCTIONALITY 
1.4.1 Scoring of TD and PL string formation in zebrafish  
Live screening and quantification of thoracic duct (TD) formation was performed on 
anesthetized Fli1:eGFPy1 embryos (a few drops of 4 mg/ml Tricaine (Sigma) stock solution in 
5 ml embryo water) at 6 dpf when this vessel was completely developed in control embryos. 
DAPT treated fish were screened at 4 dpf, since screening at 6 dpf was unfeasible because 
fish became opaque due to loss of trunk circulation and edema and many fish died between 
4 and 6 dpf. For screening, images were acquired using Zeiss AxioVision 4.6 software on a 
Leica DM RBE fluorescence stereomicroscope equipped with a Zeiss AxioCam MrC5 digital 
camera (Carl Zeiss, Munich, Germany; Leica Microsystems, Wetzlar, Germany). For 
reasons of standardization and to correct for slight differences in embryo size, the 
percentage of thoracic duct formation was quantified by scoring its percentile presence in 10 
consecutive somite segments in the trunk after the junction of DA and PCV (i.e. somites 5-
15, see Figure 9). For screening of thoracic duct formation, only embryos with normal overall 
morphology and normal trunk circulation were included. All data are based on scorings of 
33-185 embryos per condition, generated in at least 3 independent experiments. Because 
the penetrance of the lymphatic phenotype was variable, we also determined the fraction of 
embryos with severe, intermediate, subtle or no lymphatic defects for each treatment dose. 
Since parachordal lymphangiobast (PL) cells develop initially from lymphangiogenic 
secondary sprouts in a segmented pattern (Figure 3) 90, screening of PL string formation in 
the 10-somite segment of the trunk was performed in a similar manner at 52-56 hpf.  
 
1.4.2 Functional assessment of the thoracic duct 
For functional studies, anesthetized larvae were subcutaneously injected with 1 nl 
fluorescent dextran (2.5 mg/ml) into the muscle mass of the posterior trunk by using glass 
capillaries and a conventional microinjection setup 6. Uptake of the dye in the thoracic duct 
was monitored. (this assay was performed in collaboration with the lab of S. Schulte-Merker, 
Utrecht, the Netherlands) 
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1.4.3 Time lapse imaging 
Embryos were mounted in 0.5% low melting point agarose in a culture dish with a 
cover slip replacing the bottom. Imaging was performed with a Leica SP2 or SP5 confocal 
microscope using a 10x, 20x or 40x objective with digital zoom. Timelapse analysis was 
compiled using ImageJ software (http://rsb.info.nih.gov/ij/). Time points were recorded every 
10 minutes for the stated time period. A heated stage maintained the embryos at 
approximately 28.3 °C.  
 
1.4.4 Isolation of zebrafish LECs 
1.4.4.1 LEC labeling 
LEC labeling was performed on anesthetized (a few drops of 4 mg/ml Tricaine (Sigma) 
stock solution in 5 ml embryo water) Fli1:eGFPy1 zebrafish larvae of 3-4 weeks old. 
Tetramethyl-rhodamine-dextran (TRITC-dextran; molecular weight 2000 kDa) was injected 
intramuscularly into the tail somites. After 3-4 days the dye had been drained by the 
lymphatics and was taken up by the LECs through pinocytosis. 
 
1.4.4.2 Fluorescence-associated cell sorting (FACS) 
To obtain single cell supspensions, tails of at least 10 LEC labeled fish were collected, 
washed with distilled water, chopped, and incubated in 0.25% trypsin at 28°C until almost 
completely digested. The reaction was stopped by addition of 100μl fetal calf serum (FCS) to 
inhibit the trypsin and the cell suspension was loaded on top of a Cell strainer tube with blue 
filter cap (40μm; BD Biosciences) for filtration. After pelleting of the cells (5min, 200g), the 
cell suspension was washed with 1ml Dulbecco’s PBS (dPBS) + 2% FCS and viable cells 
were counted using trypan blue exclusion. After pelleting, the cells were resuspended at a 
density of 106 cells/ml in FACS buffer (dPBS + 1% FCS – filtered). 
Cells were sorted using a FACSAria (Becton Dickinson), taking care to exclude 
possible doublets or cell clusters. Non-injected GFP+ Fli1:GFPy1 and TRITC-injected GFP- 
embryos were used as controls for proper compensation and gate setting. On average 
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25000 GFP+TRITC+ LECs and 50000 GFP+TRITC- BECs were sorted directly in lysis buffer 
from the RNeasy kit (Qiagen; RLT containing 1% -mercaptoethanol). 
 
 
2 XENOPUS LAEVIS EXPERIMENTS 
2.1 HUSBANDRY & TRANSGENIC LINES 
Sexually mature adult frogs were purchased from Nasco Biology (Fort Atkinson, WI) 
and housed in tanks with chlorine- and chloramines-free water. Frogs were kept in a 12h 
day/night cycle in a temperature-controlled environment. Transgenic Flk1:eGFP Xenopus 
laevis founderline frogs expressing green fluorescent protein (GFP) in blood and lymphatic 
vasculature were generated by restriction enzyme mediated insertion (REMI) transgenesis 
256 using the promoter sequence of the Xenopus laevis gene VEGFR-2 (Flk1) driving eGFP 
(257, manuscript in preparation). Flk1:eGFP transgenic embryos were obtained by natural 
mating of hormonally induced Flk1:eGFP females and wild-type males. Hormonal induction 
of ovulation was performed by pre-priming female adults with 200 units pregnant mare 
serum gonadotrophin (Folligon, Intervet) at least 4 days before priming. Priming was done at 
least 12 hours prior to egg collection, via a lymph sac injection with 500 units of human 
chorionic gonadotrophin (Chorulon, Intervet).  The developing embryos were staged 
according to Nieuwkoop and Faber 258, kept in tadpole growth medium (0.1x Marc’s Modified 
Ringer’s (MMR) medium: prepared from a 10x MMR stock solution containing 1M NaCl, 
20mM KCl, 10mM MgSO4, 20mM CaCl2, 50mM hepes, pH7.4) at 18°C until gastrulation was 
completed and from there on at 22°C 32. 
 
2.2 XENOPUS LAEVIS COMPOUND INHIBITOR TREATMENTS 
At developmental stage 26-28 258 DAPT (Calbiochem) was added to the tank water at 
concentrations ranging from 25μM to 100μM. Control tadpoles were treated with the 
corresponding amount of DMSO. Compound/DMSO and growth medium were refreshed 
every day.  
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2.3 SCREENING METHODS FOR EVALUATION OF LYMPHATIC DEVELOPMENT 
AND FUNCTIONALITY 
2.3.1 Live screening 
At developmental stage 45 (5 dpf) the tadpoles were analyzed using a Zeiss SV11 
stereomicroscope for heart beating, blood flow, lymph heart (LH) beating, and the presence 
or absence of edema and blood spots. In addition, the GFP positive blood and lymph 
vasculature in the trunk region was documented with a Zeiss Lumar V.12 fluorescence 
steromicroscope equipped with an AxioCam MrC5 (Zeiss) digital camera and controlled with 
AxioVision 4.6 software (Zeiss).  
 
2.3.2 Functional assessment of the lymph vessels 
Lymphangiography was performed as described 32 on anesthetized (in 0.02% 3-
aminobenzoic acid ethyl ester (MS-222: Sigma, St. Louis, Missouri) dissolved in 0.1xMMR) 
stage 42-45 tadpoles placed on agarose gel in a petridish. The dye used was tetramethyl-
rhodamine-dextran (TRITC-dextran; molecular weight 2000 kDa). Pictures were taken within 
10 minutes of injection to avoid dye extravasation on a Zeiss Lumar V.12 fluorescence 
steromicroscope equipped with an AxioCam MrC5 (Zeiss) digital camera and controlled with 
AxioVision 4.6 software (Zeiss) 
 
 
3 CELL CULTURE EXPERIMENTS 
3.1 MAINTENANCE  
Monkey kidney COS cells were grown in standard DMEM medium (Lonza, Invitrogen) 
supplemented with 10% FBS, 2 mM glutamin, 100 U/ml penicillin, and 0.1 mg/ml 
streptomycin (Lonza). Human umbilical venous endothelial cells (HUVEC) cells (Lonza, 
Invitrogen, Merelbeke, Belgium), HUVEC/COS co-cultures, dermal (HMVEC-DLy) and lung 
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(HMVEC-LLy) lymphatic endothelial cells (Lonza, Invitrogen) were grown in EGM2-MV 
medium (Lonza, Invitrogen) at 37°C.  
 
3.2 COCULTURE ASSAY 
COS cells stably expressing full length human Dll4 (COSDll4) or expressing GFP 
(COSCTR) were prepared using the retroviral constructs LZRSpBMN-DLL4 and LZRSpBMN-
WT, respectively 259. HUVECs were co-seeded with COSDll4 or COSCTR cells in 6-wells at a 
density of 200,000 cells each, grown for 24 hours and harvested for RNA analysis by 
quantitative RT-PCR using human gene-specific primers (Table 2).  
 
3.3 PROLIFERATION ASSAY 
Primary LEC (HMVEC-DLy or HMVEC-LLy; Lonza, Invitrogen) were starved overnight 
in EGM2 medium (Lonza, Invitrogen) containing 0.1% serum and no growth factors 
(starvation medium). The starved cells were seeded at 2,000 cells per well in 96-well 
microtiter plates, after which proliferation was induced with fully supplemented EGM2-MV 
medium with or without increasing concentrations of DAPT (20-60 μM). Proliferation was 
measured as the number of viable cells after further culturing for 48 hours, expressed in % 
of DMSO control. Viable cells were quantified using the Rapid Cell Proliferation assay 
(Calbiochem, San Diego, CA).  
 
3.4 MIGRATION ASSAYS 
3.4.1 Scratch wound migration assay 
Confluent monolayers of LECs growing in 0.1% gelatin-coated wells of a 24-well plate 
were starved overnight, pretreated in starvation medium containing 30 μM DAPT or 0.3% 
DMSO (control), scratch wounded and photographed (T0). The cells were further incubated 
for 24 hrs and photographed again (T24). Migration distance (gap width at T0 minus gap 
width at T24; 10 measurements per wound at regular intervals along the wound) was 
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determined by image analysis using KS300 morphometry software, and is expressed 
relative to the control (DMSO).  
 
3.4.2 Transwell migration assay in conditions of Notch inhibition 
LECs were pretreated with DAPT (60 μM) or vehicle (DMSO) in starvation medium 
overnight, seeded at 30,000 cells per transwell on 0.1% gelatin-coated transwells in 
starvation medium with DAPT or DMSO, and cultured for 2 hours until adherence. Migration 
was induced by transferring the transwell insets into wells (bottom well) containing fully 
supplemented EGM2-MV medium with 100 ng recombinant human VEGF-C (Reliatech, 
TecoMedical NL, Nijkerk, the Netherlands), and DAPT or DMSO. Background migration was 
determined by including transwells with starvation medium in both the top and bottom well 
(baseline). After culturing for 16 hours, the non-migrated cells on the top side of the transwell 
filters were wiped off using PBS-soaked cotton swabs, and the transwells were fixed with 1% 
p-formaldehyde. The transwell filters were cut out and mounted upside-down on micrsocope 
slides with DAPI containing mounting medium. The filters were photographed under DAPI 
fluorescence at 20x magnification, and the nuclei were counted as a measure of migrated 
cells. Five transwells were prepared per condition and five optical fields were counted and 
averaged per transwell filter.  
 
3.4.3 Transwell migration assay in conditions of Notch activation 
LECs were starved overnight and seeded at 30,000 cells per transwell on transwell 
filters coated with BSA or with the extracellular domain of Dll4 (Dll4-ECD; R&D Systems 
Europe Ltd., Abingdon, UK) to activate the Notch pathway as described 206. Further 
manipulation was as described above, using starvation medium in all top wells and fully 
supplemented medium containing VEGF-C in all bottom wells except for the baseline 
conditions. The filters were photographed under DAPI fluorescence at 10x magnification, 
Five transwells were prepared per condition and one cen tral optical field was counted per 
transwell filter. 
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3.5 BEAD SPROUTING ASSAY 
HMVEC-DLy or HMVEC-LLy (Lonza, Invitrogen) cells were coated on Cytodex3 
microcarriers (Amersham) by mixing beads and cells at a ratio 1/400 in full growth medium. 
This mixture was incubated for 4 hours at 37°C and mixed gently from time to time. Then the 
beads were transferred to a T25 cell culture flask and grown overnight in full growth medium. 
The next day the beads were washed 3 times with full growth medium and resuspended at a 
density of 800 cell-coated beads per ml in 0.4% methyl cellulose. One volume of bead 
solution was mixed with three volumes collagen solution (44% rat tail collagen (Roche), 1x 
DMEM, 0.033 N NaOH, 0.2M Hepes, 5% serum) and dispensed in a 96 well plate 
(100μl/well). After 30 minutes of solidification an equal volume (100μl) of full growth medium 
was added containing double concentrations of treatment reagents (DAPT or DMSO; final 
concentration of DAPT was 30 or 60μM). Sprouting was monitored over time and medium 
(supplemented with treatment agents) was refreshed every 2 to 3 days. 
 
 
 
4 MOLECULAR BIOLOGY 
4.1 RNA EXTRACTION 
Total RNA from cultured cells was isolated using the RNeasy Kit (Qiagen, Germany) 
according to the manufacturer’s protocol.  Total RNA from zebrafish embryos was isolated 
by disrupting the tissue with a needle in Trizol reagent (Invitrogen, Belgium) and snap-
freezing. Additional purification was done using the RNeasy MiniElute Cleanup Kit (Qiagen, 
Germany) according to the manufacturer’s protocol. Total RNA from FACS sorted 
GFP+TRITC+ LECs and GFP+TRITC- BECs from LEC-labeled zebrafish larvae, sorted 
directly in lysis buffer (RNeasy kit; RLT containing 1% -mercaptoethanol), was prepared 
using the RNeasy kit (Qiagen). 
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4.2 CDNA PREPARATION 
cDNA from cultured cells and whole zebrafish embryos was prepared using the 
Quantitect Reverse Transcription kit (Qiagen, Germany). cDNA from FACS-sorted zebrafish 
cells was prepared using the SuperScriptIII kit from Ambion, which is better suited for small 
amounts of RNA. 
 
4.3 QUANTITATIVE REAL-TIME PCR 
Primer-sets and FAM™-TAMRA dye-labeled probes (Eurogentec, Belgium) were 
designed for zebrafish Her1 and -actin and for human HES1, HEY1, HEY2, NRARP, VEGFR3, 
PROX-1, LYVE-1, EPHRINB2, SOX18, COUP-TFII, NEUROPILIN-1, CD31, VE-CADHERIN and 
ENDOGLIN (listed in Table 2). PCR reactions were carried out on a 7500 Fast Real-time PCR 
system (ABI, Germany). Each sample was analyzed in duplicate along with specific 
standards and no template controls. Amplifications were carried out using 2X TaqMan® 
Universal PCR Master Mix or 1x TaqMan® SYBR Green Universal Mix PCR reaction buffer 
(Applied Biosystems). Calculations of the initial mRNA copy numbers in each sample were 
made according to the cycle threshold (Ct) method. The copy numbers of the analyzed 
mRNAs were normalized using zebrafish or human -actin mRNA levels.  
  MATERIALS & METHODS 
 65 
TABLE 2: QRT-PCR PRIMER AND PROBE SEQUENCES 
Zebrafish genes 
HER1 For 
Rev 
Probe 
5’-CAT CGA GGG CCT GGA CAA-3’ 
5’-AGG CGT AGC TAT TGA GAT GTG AAA-3’ 
5’-FAM-ACA GAT CCC CTC CGC ATC CGT CTG-TAMRA-3’ 
NRARPA For 
Rev 
Probe 
5’-ATC ATG AGC CAG GCG GAT AT-3’ 
5’-TTT ACC GCC TCC TGG AAG ACT-3’ 
5’-FAM-ACG TGC TCG GCG CCG CA-TAMRA-3’ 
PROX1 For 
Rev 
Probe 
5’-TCG TCC AAC CAC CTC AGT CA-3’ 
5’-AGG GAC AAG GAC AAG CCT TCA-3’ 
5’-FAM-ATC GTT CCA TCT CAC CAA CAC ACC CAG-TAMRA-3’ 
NOTCH1B For 
Rev 
Probe 
5’-AAC AAC CAA GAT CTT TCC CAT ATA CA-3’ 
5’-GCT CTA GCC ATT CGC ATT GAC-3’ 
5’-FAM-TTT GAT CCA TTG CCT CCA CGT CTC ACT-TAMRA-3’ 
DLL4 For 
Rev 
Probe 
5’-CTT CAC CGG ACC CCT CTG T-3’ 
5’-TGG AAG CGG TCT TGA GTT TCT C-3’ 
5’-FAM-ATA CTA CGC CGT CAC AGC GCC CG-TAMRA-3’ 
β-ACTIN For 
Rev 
Probe 
5’-TGG TAT GGG ACA GAA AGA CAG CT-3’ 
5’-TTG GGT ACT TCA GGG TCA GGA-3’ 
5’-FAM-TCT TGC TCT GAG CCT CAT CAC CAA CG-TAMRA-3’ 
Human genes 
HES1 Hs00232622_m1  (Premade Taqman Gene expression assays, Applied 
Biosystems) 
HEY1 Hs00232618_m1  (Premade Taqman Gene expression assays, Applied 
Biosystems) 
HEY2 Hs00232622_m1  (Premade Taqman Gene expression assays, Applied 
Biosystems) 
NRARP Hs01104102_s1   (Premade Taqman Gene expression assays, Applied 
Biosystems) 
VEGFR3 For 
Rev 
Probe 
5’-TTC CTG GCT TCC CGA AAG T-3’ 
5’-AGG CCA AAG TCA CAG ATC TTC AC-3’ 
5’-FAM-ACC TGG CTG CTC GGA ACA TTC TGC-TAMRA-3’ 
PROX-1 For 
Rev 
Probe 
5’-GTG CTT TGG CGA CGT CAT C-3’ 
5’-TCA GTG GAA CTG GCC ATC TG-3’ 
5’-FAM-TTC CGA ACC CCC TGG ACA CCT TTG-TAMRA-3’ 
LYVE-1 For 
Rev 
Probe 
5’-CAA AGA TCC CAT ATT CAA CAC TCA A-3’ 
5’-GGG ATG CCA CCG AGT AGG TA-3’ 
5’-FAM-CTG CAA CAC AAA CAA CAG AAT TTA TTG TCA GTG 
ACA-TAMRA-3’ 
EPHRINB2 Hs00970627_m1  (Premade Taqman Gene expression assays, Applied 
Biosystems) 
SOX18 For 
Rev 
5’-AGA ACC CGG ACC TGC ACA-3’  (Sybr Green qRT-PCR) 
5’-CAG CTC CTT CCA CGC TTT G-3’  
COUP-TFII Hs00819630_m1  (Premade Taqman Gene expression assays, Applied 
Biosystems) 
NEUROPILIN2 Hs00187290_m1 (Premade Taqman Gene expression assays, Applied 
Biosystems) 
NEUROPILIN1 For 
Rev 
Probe 
5’-TGT GAA GTG GAA GCC CCT ACA-3’ 
5’-GGC CTG –GTC GTC ATC ACA TT-3’ 
5’-FAM-CCG ACC ACT CCC AAC GGG AAC TTG-TAMRA-3’ 
CD31 For 
Rev 
5’-TCT GCA CTG CAG GTA TTG ACA A-3’ (Sybr Green qRT-PCR) 
5’-CTG ATC GAT TCG CAA CGG A-3’ 
VE-CADHERIN  Hs00174344_m1  (Premade Taqman Gene expression assays, Applied 
Biosystems) 
ENDOGLIN   Hs00164438_m1  (Premade Taqman Gene expression assays, Applied 
Biosystems) 
β-ACTIN Hs99999903_m1 (Premade Taqman Gene expression assays, Applied 
Biosystems) 
β-ACTIN For 
Rev 
5’-TGG CAC CAC ACC TTC TAC AAT G-3’ (Sybr Green qRT-PCR) 
5’-TAG CAA CGT ACA TGG CTG GG-3’ 
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5 HISTOLOGY 
5.1 WHOLE-MOUNT IN SITU HYBRIDIZATION  
5.1.1 In situ hybridization on zebrafish embryos 
For whole-mount in situ hybridizaiton, dechorionated embryos were fixed overnight in 
4% paraformaldehyde at 4°C and stored in methanol. In situ hybridization using antisense 
probes for EphrinB2a 260, Vegfr3 261, Notch-1b, Notch-6, Dll4, Dab2 90,253, Tbx20 262,263, 
Cmlc2 or MyoD 264 was performed as described 264. Briefly, embryos were rehydrated in 
graded methanol series and washed in PBST 0.1%, permeabilized in Proteinase K (10μg/ml 
in PBST), refixed for 20 minutes in 4% paraformaldehyde at room temperature and washed 
several times in PBST. Embryos were prehybridized for at least 1 hour in hybridization buffer 
(50% formamide, 5x SSC, 0.1% Tween20, 0.5 mg/ml Torula (yeast) RNA, 50g/ml heparin, 
add 460 μl 1 M citric acid per 50 ml for pH 6.0) at 68°C and hybridized overnight at 68°C in 
hybridization solution containing probe (1/500 to 1/2000 dilution). The next day, embryos 
were washed 2x 30 minutes at 68°C in pre-warmed 50% formamide in 2x SSCT, 15 minutes 
in pre-warmed 2x SSCT, 2x 30 minutes in pre-warmed 0.2x SSCT and 5 minutes in MABT 
(100 mM maleic acid, 150 mM NaCl, pH7.5 containing 0.1% Tween20) at room temperature. 
Blocking was performed for at least 1 hour in block solution (2% DIG-block (Roche) in 
MABT) and embryos were incubated overnight at 4°C in anti-DIG-AP antibody (1/2000 in 
blocking solution). Finally, the embryos were washed 4x 15 minutes in MABT at RT and 
stained in BM purple staining substrate (Roche). Staining was monitored over time and 
stopped by washing the embryos in PBST several times and refixing for several hours in 4% 
paraformaldehyde. Embryos were stored in 70% glycerol. Stained embryos were paraffin- or 
plastic-embedded, sectioned and counterstained with nuclear fast red.  
 
5.1.2 In situ hybridization on Xenopus embryos 
In situ hybridization on Xenopus embryos was performed according to Harland’s protocol 
265. The probe used was a DIG-labeled (DIG RNA labeling kit, Roche) antisense RNA 
fragment targeted against xProx1 (nt +190 till +1139 in reference to the ATG start codon). 
As a negative control the sense probe was used. Briefly, embryos were fixed overnight at 
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the desired stage in Memfa fixative (3.7% paraformaldehyde, 100mM MOPS, 2mM EGTA, 
1mM MgSO4 in DEPC treated MQ water) at 4°C and rinsed in EtOH. Fixed embryos can be 
stored in absolute EtOH at -20°C. Embryos were rehydrated and permeabilized in 10μg/ml 
Proteinase K (Roche) in PBST 0.1% for at least 10 minutes, depending on the 
developmental stage. To reduce non-specific binding of the probe, embryos were treated 
with acetic anhydride in 0.1M triethanolamine. After a short postfixation in 3.5% 
formaldehyde in PBST 0.1%, the embryos were prehybridized at least 10 minutes at 60°C in 
25% hybridization buffer (50% formamide, 5x SSC, 1mg/ml Torula RNA, 100μg/ml heparin, 
1x Denhardt’s, 0.1% Tween20, 5mM EDTA) in PBST 0.1%. Hybridization was performed 
overnight at 60°C in hybridization buffer containing 0.5 μg/ml of probe. The morning after, 
the embryos were blocked in MAB-BR (100mM maleic acid, 150mM NaCl, pH7.5 with 2% 
blocking reagent) after which they were incubated for at least 4 hours in MAB-BR 
supplemented with 20% heat-inactivated sheep serum containing a 1/2000 dilution of anti-
DIG-AP antibody. After extensive washes in MAB, staining was done in darkness with BM 
purple substrate (Roche). Staining was monitored over time and the chromogenic reaction 
was stopped by washing the embryos with PBST and postfixation in Memfa fixative 
overnight at 4°C. Afterwards, embryos were bleached in bleaching solution (0.5% SSC, 5% 
formamide, 1.5% H202), cleared in 100% EtOH, rehydrated and stored in 100% glycerol. 
 
5.2 IN SITU HYBRIDIZATION ON CRYOSECTIONS OF ZEBRAFISH EMBRYOS 
Zebrafish embryos were fixed overnight in 4% paraformaldehyde at 4°C and 
subsequently kept overnight in 20% sucrose containing a drop of eosine. Embryos were 
embedded in tissue-freezing medium (Neg -50, Richard Allan Scientific), snap frozen and 
10μm sections were made on a cryo-microtome (Leica CM3000). 
The slides were washed 4 times for 10 minutes in PBST 0.3%, pre-hybridized in 
hybridization buffer (1mg/ml Torula RNA, 50% deionized formamide, 1x salt (for 100mL: 
11.4g NaCl, 1.4g Tris-HCl, 0.134g Tris Base, 0.69g NaH2PO4.2H2O, 0.71g Na2HPO4, 10mL 
EDTA, H2O), 50% dextran sulphate, 1x Denhardts) for at least one hour at 68°C and 
incubated overnight with probe diluted 1/200 – 1/1000 in hybridization buffer. The next day 
the slides were washed 1x 15 minutes and 2x 30 minutes in washing buffer (50% 
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formaldehyde, 1x SSC, 0.1% Tween20) and 2x 30 minutes in MABT 0.1%. Subsequently, 
the slides were blocked in 2% DIG-block (Roche) in MABT and incubated overnight in anti-
DIG-AP antibody diluted 1/2000 in DIG-block. Finally, the slides were washed 4x 20 minutes 
in MABT 0.1% and incubated for several days in BM purple staining substrate (Roche). 
 
5.3 IMMUNOSTAINING 
Immunostaining was performed using standard protocols. Antibodies used for Prox1 
immunostaining in zebrafish were from Abcam, Reliatech, AngioBio and Chemicon 7,266-268. 
 
 
6 STATISTICAL ANALYSIS 
Absolute values were used to calculate means and SEMs. Each gene-specific 
morpholino (or compound dose) was always compared to the control morpholino or vehicle 
in every single experiment. Pairwise comparisons were performed between the different 
doses by two-sided t-test unless otherwise specified. The asterisks on the figures represent 
the treatment difference at a significance level of P<0.05. To determine the penetrance of 
the phenotype, we counted the number of zebrafish embryos, exhibiting the different 
severities of morphant phenotype. Chi-square analysis was used to determine whether the 
severity distribution differed between treatment groups.  
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1 INHIBITION OF NOTCH SIGNALING IMPAIRS LYMPHATIC 
DEVELOPMENT IN ZEBRAFISH EMBRYOS AND TADPOLES 
1.1 GENERAL INHIBITION OF THE NOTCH PATHWAY BLOCKS 
LYMPHANGIOGENESIS IN AQUATIC ANIMAL MODELS 
In a first attempt to explore a role for Notch signaling in lymphatic development, we 
took advantage of the fact that activation of the Notch receptor, which requires proteolytic 
cleavage by the -secretase complex to release the intracellular domain, can be selectively 
blocked by chemical -secretase inhibitors 269. A well known -secretase inhibitor, that has 
been previously used to block Notch signaling in aquatic models is N-[N-(3,5-
difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT) 188. DAPT was retracted 
from a screening of compounds that were tested for their ability to inhibit amyloid  (A) 
production, which is formed by -secretase mediated proteolytic carboxy-terminal cleavage 
of the amyloid precursor protein (APP) 270. Overproduction of the fibrillogenic 42 amino acid 
A-variant (A42) is the primary cause of plaque formation in the brain during Alzheimer’s 
disease 271. The primary mechanism of action of DAPT is via functional inhibition of the -
secretase complex 270, more specifically by targeting the catalytic subunit, the aspartyl 
protease presenilin 272. Unlike other -secretase inhibitors, DAPT has remarkably low activity 
against structurally related presinilin-like aspartyl proteases, like Signal Peptide Peptidase 
(SPP) 273. Therefore, DAPT is considered to be the most specific -secretase inhibitor 274. 
 
1.1.1 Zebrafish 
Embryos of the transgenic Fli1:eGFPy1 zebrafish line, which expresses GFP in blood 
and lymph vessels 6,7,87, were exposed to the -secretase inhibitor DAPT at early stages. At 
4 dpf the formation of the thoracic duct (TD), the first and major axial lymph vessel in the 
zebrafish trunk, was analyzed 6,7 (for details on the formation and developmental stages of 
the lymph and blood vessels, see Introduction p. 19 and Figure 3).  
Since Notch signaling is involved in somitogenesis and angiogenesis 275, and since the 
TD originates from the PCV 7,90, inhibition of Notch could impair lymphatic development 
indirectly by affecting vascular development or the intersomitic migration pathways of PL 
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cells. To avoid such secondary effects, and to study more selectively a primary effect of -
secretase inhibition on lymphangiogenesis, we first determined in pilot experiments a 
tolerable concentration range of DAPT (6.25-25 M) and analyzed at which developmental 
stage the embryos were best exposed to DAPT. At these concentrations DAPT did not affect 
arterial-venous differentiation of the DA and PCV as the expression pattern of arterial and 
venous marker genes (EphrinB2a and VEGFR-3, respectively) was normal by whole mount 
ISH staining (Figure 14Q-R). Consistent with previous findings 172,189,190, DAPT caused 
impaired somite development, axial vessel malformations and hyperbranching of ISVs when 
administered at early developmental stages. Major vascular and morphological defects could 
be avoided by using a concentration of maximally 25μM DAPT and initiation of the treatment 
at later developmental stages. Based on these developmental criteria we initially selected 43 
hours post-fertilization (hpf) for our studies. Although at this stage lymphangiogenic 
sprouting from the PCV has already started and PL formation is ongoing (see Figure 3), we 
observed impaired formation of the TD.  
TD formation was scored by measuring the length over which the TD had formed by 4 
dpf, when the lymph vessel was nearly completely established in control embryos. 
Screening of DAPT treated embryos at 6 dpf, when TD formation is completed in control 
embryos, was not feasible because DAPT-treated embryos became opaque due to loss of 
trunk circulation and edema and many fish died between 4 and 6 dpf. For reasons of 
standardization and correction for slight differences in embryonic size, the data were 
expressed as % of the length of the fragment of the trunk analyzed, i.e. the 10 consecutive 
somite segments in the trunk after the junction of DA and PCV (somites 5-15; Figure 9). To 
further avoid that the documented defects reflected secondary effects of vascular 
malformation on lymphatic development, only embryos with normal axial blood flow were 
screened for TD formation in all further experiments. Treatment of embryos with DAPT dose-
dependently lowered mRNA transcript levels of the Notch-regulated target genes zHer1 and 
zNrarpA, indicating that Notch receptor activity was effectively inhibited (Figure 10). 
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Figure 9: Method of TD quantification. DA, dorsal aorta; DLAV, dorsal 
longitudinal anastomosing vessels; ISV, intersomitic vessel; PCV, posterial cardinal 
vein; PL, parachordal lymphangioblast string; TD, thoracic duct. TD formation was 
quantified by measuring the length over which it formed in 10 consecutive somite 
segments (i.e. somites 5-15; demarcated by the green rectangle). Confocal images 
of control and morphant Fli:eGFPy1 embryos are depicted in the insets. Inset a: in 
the control embryo, a continuous TD formed over all 10 somite segments (100% TD 
formation; green arrowheads). Inset b: severely morphant embryo, in which the TD 
formed over only 10% (green arrowhead). Inset a’ and b’: schematic redrawing of 
the DA, TD and PCV in the embryo shown in inset a and b, respectively, with the 
TD or TD segment marked in green. Scale bars: 100 μm. 
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Figure 10: Verification of Notch pathway silencing. Quantitative RT-PCR 
analysis of the Notch target genes zHer1 and zNrarpA on cDNA of DAPT treated 
zebrafish embryos. Data are shown as number of mRNA copies per 105 copies of 
z-actin. RNA was extracted from 3 dpf zebrafish embryos treated from 43 hpf 
onwards with increasing concentrations of DAPT or with DMSO (0.25%, open bar). 
Expression of zHer1 (A) and zNrarpA (B) were reduced dose-dependently in 
DAPT-treated zebrafish embryos indicating that the Notch signaling pathway is 
effectively inhibited. Data are an average of 3-5 independent experiments. Error 
bars represent SEM. *, P<0.05. 
 
 
Embryos exposed to 25 M DAPT at 43 hpf had a curved trunk and regularly exhibited 
hemorrhages in the head (Figure 11A-B), characteristics previously observed after Notch 
pathway knockdown 170,172,190,276. Fluorescent analysis of live Fli1:eGFPy1 embryos at 4 dpf 
showed normal development of the trunk blood vasculature, but a dose-dependent 
impairment of TD formation (Figure 11C-D). At 25 M DAPT, 53% of the analyzed embryos 
completely lacked a TD (N = 102), another 39% of embryos formed short TD fragments over 
10-30% of its normal length, only 8% formed a relatively large TD fragment over 30-90% of 
the normal length and no embryos were observed with a normal TD (Figure 11E). The DAPT 
effect was dose-dependent and specific, as treatment with control vehicle (0.25% DMSO) 
did not adversely affect TD formation (Figure 11E). Interestingly, the finding that lymphatic 
defects were observed at lower DAPT concentrations than needed to induce vascular 
malformations, suggests a higher sensitivity of lymphangiogenesis over angiogenesis for 
Notch signaling.  
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Figure 11: DAPT treatment of zebrafish embryos impairs thoracic duct 
development. (A,B) Bright field pictures of live embryos at 4 dpf, showing curved 
body and hemorrhages in the head (arrow) in DAPT (25 μM) treated zebrafish (B) 
as compared to control DMSO (0.25%) treated fish (A). (C-D) Confocal images of 
GFP+ vessels in the trunk of 4 dpf Tg(Fli1:EGFP)y1 zebrafish embryos, revealing 
the formation of a normal lymphatic thoracic duct (TD) in the control embryo (C; 
yellow arrowheads) but not in the DAPT treated embryo (D; yellow asterisks). 
Small sprouts on the ISVs can be observed in the upper part of the DAPT treated 
embryos (D; red arrows). (E) Quantitative analysis of TD defects after treatment 
with different doses of DAPT or control DMSO. 
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1.1.2 Xenopus laevis 
In order to confirm our findings in the zebrafish model in a second, independent animal 
model, we also studied the role of Notch signaling in Xenopus tadpoles 

, which develop an 
elaborate lymphatic system and were previously validated as a genetic model to study 
lymphangiogenesis 32. More particularly, we used tadpoles of a newly developed transgenic 
Xenopus laevis line, i.e. Flk1:eGFP, that expresses eGFP under control of the frog VEGFR-
2/Flk1 promotor in both blood and lymphatic vessels  (257, manuscript in preparation).  
To block the Notch pathway, tadpoles were treated with DAPT (25-50 M; at higher 
doses, the compound precipitated) and the effect on vascular and lymphatic development 
was analyzed by live screening under bright light microscopy, by whole-mount in situ 
hybridization for xProx-1 to visualize the caudal lymph vessels at stage 42, by fluorescence 
microscopy of GFP+ vessels at later stages, and by functional lymphangiography. We 
focused our analysis on the formation of the ventral (VCLV) and dorsal caudal lymph vessel 
(DCLV) in the tail. These major trunk vessels are formed primarily by LECs that 
transdifferentiate from the BECs of the PCV and migrate ventrally or dorsally to coalesce at 
the ventral margin or dorsal roof, grow out laterally, and interconnect to form a continuous 
VCLV or DCLV 32. To minimize effects on general development, which might secondarily 
affect vascular development, tadpoles were exposed to DAPT from stage 26-28 onwards (2 
dpf), i.e. at the initiation of the first lymphatic structures 32. 
Live screening by bright field microscopy at stage 45 (corresponding to 5 dpf) revealed 
that DAPT induced edema around the cardiac region, blood spots in the brain, ventralized 
body shape and eye deformity (Figure 12A-B), resembling features of the phenotype after 
DAPT treatment in zebrafish (Figure 11A-B). At 25 or 50 M DAPT, 41% and 54% of 
tadpoles exhibited some abnormalities in blood flow (usually slowed down, or occasionally 
absent in the dorsal longitudinal anastomosing vessel, DLAV). By fluorescence microscopy, 
the overall architecture of the GFP+ blood vasculature appeared, however, largely normal, 
suggesting that the blood vessels formed, but had a smaller lumen (as observed previously 
                                                

 Studies in the Xenopus model were performed with the collaboration of Wouter Vandevelde and Annelii Ny 
(Vesalius Research Center, Leuven) 
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in mice upon inhibition or loss of Notch signaling 161,162,164) and, therefore, were 
hypoperfused.  
In situ hybridization for xProx-1 at stage 42 (representing the oldest stage at which 
whole-mount in situ hybridizations can be reliably performed in tadpoles) revealed lymphatic 
defects in DAPT-treated tadpoles. In control embryos, Prox-1+ LECs are aligned in a 
continuous DCLV and VCLV, nearly over the entire length of the trunk (Figure 12C). By 
contrast, in DAPT-treated tadpoles (25-50 M), the DCLV was only partially formed and 
consisted of isolated clusters of Prox-1+ LECs, discontinuously and non-homogeneously 
distributed over the length of the DCLV (Figure 12D). While fluorescence imaging of the 
Flk1:eGFP tadpoles revealed close alignment of the DCLV and DLAV in control tadpoles 
(Figure 12E), partial separation of the DCLV and DLAV was frequently observed in DAPT-
treated tadpoles (Figure 12F), which may signify (microscopic) lymphedema. The VCLV 
appeared largely normal, at least by this analysis (Figure 12G-H) (see also below). 
Quantification of the lymphatic defects at stage 45 confirmed a disorganized, irregular and 
fragmented DCLV in 76% and 83% of tadpoles treated with 25 or 50 M DAPT, respectively, 
while control tadpoles always developed a normal DCLV (Figure 12I). The VCLV was 
usually present at both DAPT concentrations tested (Figure 12G-H); as shown below, this 
lymph vessel was, however, severely dysfunctional at the highest DAPT concentration. 
Since the VCLV develops at a slightly earlier developmental stage than the DCLV 32 (and 
only a few hours after addition of DAPT), we speculate that its formation might not have 
been impaired as severely as that of the DCLV. With respect to formation of the latter 
vessel, DAPT had more time to penetrate into the tadpole and reach higher (sufficient) levels 
to impair its formation.  
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Figure 12: DAPT impairs lymphatic vessel formation in Xenopus tadpoles. 
(A,B) Bright field pictures of live embryos at stage 45 (5 dpf), showing curved 
body, hemorrhages in the head (arrow) and malformed eyes in a DAPT (25 μM) 
treated tadpole (B) as compared to a control DMSO (1 %) treated tadpole (A). 
(C,D) Whole-mount in situ hybridization for xProx-1, revealing incomplete 
formation of the DCLV (arrowheads) in stage 42 tadpoles treated with 50 μM 
DAPT (D) as compared to normal  formation of the DCLV in control tadpoles (C). 
(E-H) Fluorescent analysis of blood and lymph vessels in transgenic Flk1:eGFP 
tadpoles at stage 45. Areas in the trunk corresponding to the boxed areas in 
panels A or B are shown. In DMSO treated tadpoles, both the DCLV (E) and the 
VCLV (G) developed normally. Treatment with 25 μM DAPT resulted in a 
hypoplastic, disorganized and discontinuous DCLV (F), while the VCLV (H) had a 
grossly normal appearance. The partial separation of the DCLV and DLAV (F) may 
signify (microscopic) lymphedema. (I) A dose-dependent increase in the severity of 
the DCLV phenotype could be observed. The graph represents the percentage of 
tadpoles scored according to the following categories of DCLV defects (n=30-33): 
normal development of the DCLV (open bars); normal development of the anterior 
part of the DCLV, but partial fragmentation of the posterior part (light gray bars); 
normal development of the anterior part of the DCLV, but fragmentation of the 
entire posterior part (dark gray bars); total fragmentation of the entire DCLV (black 
bars). (J-N) Lymphangiography of stage 45 tadpoles revealing dysfunction of the 
DCLV and VCLV after DAPT treatment (L-N) in contrast to normal controls (J,K). 
Panel L shows a representative tadpole treated with 25 μM DAPT, displaying 
complete failure of drainage of the injected red fluorescent dye; panel M shows a 
tadpole in which the dye was initially taken up by backflow (i.e. in the direction 
away from the heart) in the DCLV but instantaneously diffused out, indicating 
leakiness of the vessel. Panel N shows a representative tadpole treated with 50 
μM DAPT, with dysfunction of the DCLV and - despite its normal appearance 
(yellow arrows) - the VCLV. White arrowheads in panels J-N indicate injection site 
of the fluorescent dye. DCLV, dorsal caudal lymph vessel; DLAV, dorsal 
longitudinal anastomosing vessel; PCV, posterior cardinal vein; VCLV, ventral 
caudal lymph vessel. Scale bar represents 200 μm in panels A and B; 100 μm in 
panels C,D, J-N; 50 μm in E-H. In all panels, the tadpoles are oriented with their 
heads and lymph hearts facing left. 
 
 
Recent publications on the role of Notch in angiogenesis stressed the importance of 
determining the perfusion, and not simply the presence, of blood vessels, because 
morphologically detectable vessels may be hypoperfused and not functional 197. We 
therefore determined the functional capacity of the lymph vessels to drain an injected red 
dye by lymphangiography at stage 45. When scoring the DCLV in ten tadpoles treated with 
25 M DAPT, the dye was either not drained at all (4 tadpoles; Figure 12L), drained only 
over a very short distance (5 tadpoles; not shown), or was initially absorbed, but then 
drained in the reverse orientation and rapidly leaking out, indicating that this lymph vessel 
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was dysfunctional (Figure 12M). At 50 M DAPT, the dye was not drained at all in the 
majority of embryos tested (Figure 12N). A similar analysis revealed that the VCLV, despite 
its apparent normal morphological appearance, failed to drain the dye in all tadpoles treated 
with 50 M DAPT, suggesting that its lumen was hypoplastic (Figure 12N). In all control 
tadpoles, both the DCLV and VCLV were fully functional (Figure 12J-K). Thus, similar to 
zebrafish, general inhibition of the Notch pathway impairs lymphatic development in 
Xenopus tadpoles. 
 
 
1.2 ANALYSIS OF THE ROLE OF NOTCH PATHWAY COMPONENTS IN ZEBRAFISH 
BY SPECIFIC MORPHOLINO KNOCKDOWN 
Since pharmacological inhibition of the Notch pathway by DAPT blocks all canonical 
Notch signaling pathways and additionally affects other -secretase mediated pathways (see 
higher), we wanted to analyze more specifically which Notch ligand/receptor pairs and 
downstream regulators are required for lymphatic development. Small animal models like 
zebrafish and Xenopus allow easy targeted knockdown of gene expression by injection of 
fertilized eggs with morpholino antisense oligonucleotides. For this project all further 
experiments were focused on the zebrafish model. 
Morpholino oligomers are used as an antisense technology tool to specifically knock 
down the expression of a targeted gene. Morpholinos are small (~25 bases) antisense RNA 
fragments with an altered backbone structure, where nucleic acid bases are bound to 
morpholine rings instead of deoxyribose rings, and linked through phosphorodiamidate 
groups instead of phosphates. This structure is very stable and enables a strong binding of 
morpholinos to their target sequence. Morpholinos do not induce degradation of their RNA 
targets but act via ‘steric blocking’ of either the translation-initiation site (ATG-binding 
morpholinos and 5’-UTR morpholinos binding upstream but close to the ATG) or a splice-site 
(splice-blocking morpholinos).  
In order to analyze the contribution of the different Notch ligands, receptors, and 
regulators or downstream effectors to lymphatic development, we specifically knocked down 
the single genes in zebrafish embryos and analyzed TD formation.  
  RESULTS 
 81 
As Notch-family members have been implicated in angiogenesis 183, we used 
submaximal doses of all morpholinos to minimize secondary effects of vascular 
malformations on lymphatic development (referred to as “incomplete silencing” and “Notch 
hypomorphants”). In addition, only morphant embryos with a normal size, trunk circulation 
and blood flow, and without developmental delay, tissue malformations, general edema or 
toxic defects (not shown) were included in the screening. 
 
1.2.1  Ligands: Knockdown of Dll4 impairs development of the thoracic duct 
Dll4 knockdown (Dll4KD) inhibited the formation of the TD. Upon injection of a 
morpholino affecting Dll4 mRNA splicing (Dll4SPL; 10 ng), the TD failed to form at all by 6 dpf 
in up to 52% of the morphant embryos, indicating that lymphatic development was 
completely aborted (Figure 13 A-C). In another 27% of Dll4SPL embryos, the TD formed over 
only 10 to 30% of its normal length, while in another 15% of morphant embryos, the TD 
formed over 30 to 90% (Figure 13C). As explained above, initiation of TD formation occurs 
via sprouting of lymphangiogenic secondary sprouts at discrete locations alongside the PCV, 
i.e. on average one per two unilateral somite segments. Thus, if the TD formed over only 
20% of its entire length, then TD development was in fact completely aborted in eight out of 
ten somites analyzed. We speculate that the variably penetrant lymphatic phenotypes and 
spectrum of defects in the Notch hypomorphants is due to a combination of reasons, 
including the use of a submaximal dose of morpholino (incomplete silencing), technical 
limitations of injecting an identical dose of morpholino, genetic differences of the morphant 
embryos analyzed (outbred background; we have observed 10-fold variable expression 
levels for Dll4 in single zebrafish embryos (not shown)), uneven dispersion of morpholinos 
upon daughter cell division, and variable timing of venous/lymphatic secondary sprout 
formation along the PCV (occurring within a time window of 30 to 50 hpf). As a result, 
achieving the necessary degree of silencing below the critical biological threshold at the 
distinct sprouting locations along the PCV becomes stochastic in such experimental 
conditions. The observed phenotypic defects were dose-dependent, but for reasons of 
brevity, only the highest dose is shown.  
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Follow-up studies at later stages (up to 12 dpf) revealed that, in embryos with 
intermediate defects, the few LECs that did arise and formed parts of the TD, were unable to 
reconstitute the entire TD and could not compensate for the lymphatic failure in nearby 
somites (not shown). Dll4KD embryos without TD at 6 dpf also failed to form a TD, even 
partially, at later stages (Figure 13D,E), indicating that lymphatic development was not 
simply delayed, but aborted.  
 
 
 
Figure 13: Dll4 knockdown impairs TD formation. A-B, D-E, Confocal images 
of GFP+ vessels in the trunk of 6-dpf (A,B) or 12 dpf (D,E) Fli1:eGFPy1 embryos. 
The control embryos have a normal TD (yellow arrowheads in A and D), while the 
TD is entirely absent in the Dll4KD (B, E). Yellow asterisks denote absence of the 
TD; red arrowheads indicate hyperbranching of the upper part of the ISVs. C, Bar 
graphs, representing the percentage of embryos that develop a normal TD (grey), 
a TD over 30-90% (lilac) or over 10-30% (blue) of its normal length, or completely 
lack any TD (dark blue) in the indicated fraction of control embryos (N=122) or 
Dll4KD embryos (N=80; 10 ng Dll4SPL; P<0.001 versus control by Chi-Square test). 
F,G, Lymphangiography in the trunk of 7-dpf kdr-l:mCherryRed embryos revealed 
normal uptake and drainage of a green dye by the TD in the control embryo 
(yellow arrowheads in F), but not in the Dll4KD embryo (yellow asterisks in G).Scale 
bars: 50 μm. 
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Lymphangiography in 7-dpf kdr-l:mCherryRed Dll4KD embryos # (in which the kdr-like 
promoter drives expression of mCherryRed in the blood vessels while lymph vessels are not 
labeled) revealed no drainage of green fluorescent dye in the region where the TD normally 
forms, confirming that the lack of a GFP+ TD in Fli1:eGFPy1 Dll4KD embryos was not due to 
reduced expression of this marker, but to actual absence of the vessel itself (Figure 13 F,G). 
Also, partial TD fragments did not take up injected dye, indicating that they are not functional 
(not shown).  
The lymphatic defects in Dll4KD embryos were specific, as no overt changes in the 
formation and differentiation of the DA and PCV were noticeable (Figure 14A-H). Consistent 
with previous reports 92,189, some hyperbranching of the primary ISVs was detected in Dll4KD 
hypomorphant embryos, but to a variable degree and in only 20% of Dll4KD embryos (red 
arrowheads in Figure 13B,E); hence, TD defects were detected in the majority of Dll4KD 
embryos that did not exhibit any signs of ISV hyperbranching. Also, no abnormalities in heart 
or somite development were observed (as analyzed by in situ staining for Cmlc2 (Cardiac 
Myosin Light Chain 2) and MyoD (Myogenic Differentiation 1), respectively; not shown).  
Similar TD defects were obtained with a second morpholino, targeting the ATG region 
of Dll4 (Dll4ATG), thereby confirming the specificity of the Dll4KD phenotype (not shown). 
Silencing of the other Notch ligands DeltaA-D, Jagged-1a/b or Jagged-2 did not induce 
lymphatic defects (not shown).  
 
 
 
 
 
 
 
 
                                                
# experiments performed by the Schulte-Merker lab (Hubrecht Institute-KNAW and University Medical Center, 
Utrecht, the Netherlands) 
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Figure 14: Normal arterial-venous differentiation after inhibition of Notch 
signaling. A-R, Arterial-venous differentiation of the large axial vessels was 
evaluated upon incomplete silencing of the components of the Dll4/Notch signaling 
pathway that were shown in this study to affect lymphatic development. Therefore, 
whole-mount embryos were in situ stained for arterial (EphrinB2a; Tbx20 262,263) and 
venous (Vegfr3; Dab2 253,277) markers in control embryos (A-D) and in Dll4KD (10 ng 
Dll4SPL; E-H), Notch-1bKD (15 ng Notch-1bSPL; I-L), Notch-6 (15 ng Notch-6SPL; M,N), 
PS-1 (15 ng PS-1ATG1; O,P) or DAPT-treated (25 μM; Q,R) hypomorphant embryos. 
Staining was performed at 28 hpf (few hours prior to secondary sprout formation) 
for EphrinB2a, Vegfr3 and Tbx20, and at 48 hpf for Dab2, when arterial and venous 
differentiation of the DA and PCV were completed. Overall, expression of arterial 
markers in the DA and of venous markers in the PCV was comparable in control 
and morphant embryos. Also, note that there is no ectopic expression of these 
markers. The DA is indicated by a red vertical bar, while the PCV is denoted by a 
blue vertical bar. DA, dorsal aorta; PCV, posterior cardinal vein. Scale bar, 
representative for all panels: 100 μm. 
 
 
1.2.2 Notch receptors: Notch-1b (and Notch-6) regulate formation of the 
thoracic duct 
Silencing of the different Notch receptors known in zebrafish using the mopholino 
knockdown strategy showed that knockdown of Notch-1a or Notch-5, zebrafish orthologues 
of mammalian Notch-1 and Notch-3, failed to cause any lymphatic defects (not shown). 
However, incomplete silencing of Notch-1b and, to a lesser extent, of Notch-6, impaired TD 
formation (Figure 15). Of note, the mammalian orthologues of these genes, Notch-1 and 
Notch-2, respectively, are expressed in LECs 47,231,232. Complete loss of TD formation was 
observed in 30% of the embryos at the highest dose of the Notch-1bSPL morpholino (15 ng; 
Figure 15C). In another 31% of Notch-1bSPL embryos, the TD formed in only one to three of 
the ten somites analyzed. Similar lymphatic defects were obtained with a morpholino 
directed against the transcription start site (Notch-1bATG) (not shown). The TD also failed to 
form in 14% of Notch-6SPL embryos (15 ng; Figure 15C). Combined silencing of Notch-1b 
and Notch-6 yielded more severe lymphatic defects, suggesting cooperation of both 
receptors (not shown). Since Notch-1b down-regulation resulted in more penetrant defects in 
lymphatic development, we further focused our analysis on Notch-1bKD. Incomplete 
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knockdown of the Notch receptors also did not affect, or only minimally influenced the 
formation, differentiation and morphogenesis of blood vessels (Figure 14I-N and not shown). 
 
 
 
 
 
Figure 15: Inhibition of Notch-1b, Notch-6 or PS-1 impairs TD formation: A-B, 
Confocal images of GFP+ vessels in the trunk of 6-dpf Fli1:eGFPy1 embryos. The 
control embryo has a normal TD (yellow arrowheads in A), while the TD is entirely 
absent in the Notch1bKD (B). Yellow asterisks denote absence of the TD; red 
arrowheads indicated minimal hyperbranching of the upper part of the ISVs. C, Bar 
graphs, representing the percentage of embryos that develop a normal TD (grey), a 
TD over 30-90% (lilac) or over 10-30% (blue) of its normal length, or completely 
lack any TD (dark blue) in the indicated fraction of control embryos (N=185 in C, 78 
in D) or Notch-1bKD (N1bKD) embryos (N=84; 15 ng Notch-1bSPL; P<0.001 versus 
control; C), Notch-6KD (N6KD) embryos (N=63; 15 ng Notch-6SPL; P<0.001 versus 
control; C), PS-1KD embryos (N=65; 2.5 ng PS-1ATG1; P<0.001 versus control; D). 
Scale bars: 50 μm 
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1.2.3 Notch activators and mediators  
Presenilin-1 (PS-1) is the catalytic subunit of the -secretase complex that activates 
Notch through proteolytic cleavage 278. Consistent with the results obtained upon treatment 
with DAPT, silencing of PS-1 by injection of an ATG-blocking or a splice-binding morpholino 
similarly impaired TD formation (Figure 15D and not shown), without deregulation of blood 
vessel differentiation (Figure 14O-P). The role of PS-1 was specific, as silencing of PS-2 did 
not cause lymphatic defects, neither did combined double knockdown of PS-1 and PS-2 
exacerbate the PS-1KD phenotype (not shown). Therefore, PS-1 but not PS-2 seems to be 
involved in lymphatic development.  
Suppressor of Hairless (Su(H)) is the transcription factor involved in canonical Notch 
signaling. In zebrafish, two isoforms of Su(H) are present, Su(H)a and Su(H)b. A morpholino 
targeting both isoforms was lethal at low concentrations. Silencing of the single Su(H) 
isoforms at concentrations that did not induce malformation in most of the injected embryos 
did not induce lymphatic defects (not shown). This could argue against a role for canonical 
Notch signaling in lymphatic development. However, we cannot exclude that higher dosages 
of morpholino can impair lymphangiogenesis. Su(H) binds to recognition sequences in the 
promoters of Notch target genes. When Notch signaling is not activated, the Su(H) 
transcription factor is bound by several co-repressors. Upon activation of the Notch receptor 
the intracellular domain binds the DNA-bound Su(H) transcription factors, thereby replacing 
the co-repressors and recruiting co-activators 112. Thus, Su(H) functions both as an 
transcriptional repressor and activator during inactive and active Notch signaling, 
respectively. It is therefore not surprising that knockdown of Su(H) induces more severe 
defects than general inhibition of the Notch pathway by DAPT treatment. If Su(H)KD yields 
too severe embryonic malformations, this precludes trustworthy analysis of the lymphatic 
vasculature. 
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2 NOTCH SIGNALING REGULATES EARLY STAGES OF 
LYMPHATIC DEVELOPMENT IN ZEBRAFISH 
2.1 NOTCH SIGNALING IS CRITICAL DURING EARLY STAGES OF LYMPHATIC 
DEVELOPMENT 
Having established that Notch signaling is a conserved mechanism in aquatic species, 
required for the formation of lymph vessels, we sought to explore the mechanisms whereby 
Notch regulates lymphangiogenesis. We first analyzed in zebrafish whether Notch signaling 
is required during the early steps of lymphatic development or rather regulates migration and 
assembly of LECs in a continuous TD (which starts at 3 dpf and is nearly accomplished in 
the trunk by 4 dpf). We therefore exposed zebrafish embryos to 25 M DAPT at various 
developmental stages between 24 and 72 hpf. As mentioned above, the early treatment 
stages frequently induced other developmental defects leading to malformations, loss of 
blood circulation and edema. However, only the least affected embryos with a largely normal 
morphology and blood circulation in the major axial vessels at 4 dpf were analyzed for TD 
formation. This experiment indicated that DAPT inhibited the formation of the TD maximally 
when added during the initial processes of lymphatic development (24-30 hpf), but became 
progressively less effective at later stages (Figure 16).  DAPT treatment at 56 hpf still 
resulted in 20% of embryos (N = 50) with complete abortion of TD formation (Figure 16). At 
this stage PL string formation is nearly completed in control embryos and LISV-PL migration 
is being initiated. These findings indicate that Notch signaling is important during the earliest 
stages of lymphatic development, but also seems to play a role beyond PL string formation. 
Remarkably, DAPT treatment at 72 hpf was ineffective in blocking outgrowth and assembly 
of the first TD fragments into a continuous TD (Figure 16). This was not due to insufficient 
inhibition of Notch signaling at 72 hpf, as zHer1 expression in embryos treated with 25μM 
DAPT at 72 hpf was still significantly decreased to 26% of the expression level in control 
embryos (N=3; p<0.05) as indicated by RT-PCR analysis at 4 dpf (not shown).  
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Figure 16: the effect of Notch inhibition by DAPT on lymphatic development 
becomes less pronounced at later stages. Bar graphs, representing the 
percentage of embryos that develop a normal TD (grey), a TD over 30-90% (lilac) 
or over 10-30% (blue) of its normal length, or completely lack any TD (dark blue) in 
the indicated fraction of embryos treated with DMSO (N=30) or 25μM DAPT 
started at 24 hpf (N=30), 30 hpf (N=32), 43 hpf (N=44), 56 hpf (N=50) or 72 hpf 
(N=66). Treatments started at 24, 30, 43 and 56 hpf resulted in significantly 
different distributions of TD formation compared to DMSO treated controls 
(P<0.001).  
 
 
2.2 DLL4/NOTCH SIGNALING IS REQUIRED FOR PL STRING FORMATION 
Since DAPT treatment results in overall blockade of Notch signaling and also inhibits 
other -secretase dependent pathways, this pharmacological approach likely also affects 
other developmental processes. Therefore, we further proceeded by analyzing the effect of 
morpholino knockdown on the different steps of lymphatic development. 
As described above LECs from the TD are derived from the PL string, a transient 
source of LEC precursors at the horizontal myoseptum (Figure 3). To characterize the role of 
Notch signaling in earlier steps of lymphatic development, we first analyzed whether 
silencing of Notch also impairs development of PL cells, as they directly contribute to TD 
formation. Since PL cells develop initially from lymphangiogenic secondary sprouts in a 
segmented pattern, we used a similar quantification method as employed for analysis of the 
TD. At 52 hpf, formation of the string of PL cells was still proceeding in control embryos 
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(already completely formed in 53% and largely completed in another 40% of the embryos; 
Figure 17A-B). By contrast, in Dll4SPL embryos, the PL string was completely absent in 38% 
and formed only in a few segments in another 27% of embryos (Figure 17A,C). Notably, 
largely comparable fractions of Dll4SPL embryos exhibited similar types of severe, 
intermediate or subtle PL string and TD lymphatic defects (compare Figure 17A with Figure 
13C), suggesting that the TD defects were, at least in part, attributable to defects in the initial 
formation of the PL string.  
A similar absence of the PL string was observed when using the Dll4ATG morpholino 
(not shown), or upon knockdown of Notch-1b (Figure 17A) or Notch-6 (not shown). These 
findings indicated that Notch signaling acts in part at very early steps of lymphatic 
development prior to formation of the perfused lymphatics.  
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Figure 17: Incomplete silencing of Notch blocks PL string formation A, Bar 
graphs, representing the percentage of embryos at 52 hpf, which develop a normal 
PL (grey), a PL over 30-90% (pink) or over 10-30% (red) of its normal length, or 
completely lack any PL (dark red) in the indicated fraction of control embryos 
(N=73), Dll4KD embryos (N=55; 10 ng Dll4SPL; P<0.001 versus control) or Notch-
1bKD (N1bKD) embryos (N=49; 20 ng Notch-1bATG; P<0.001 versus control). B,C, 
Confocal images of Fli1:eGFPy1 embryos at 56 hpf, showing normal PL formation 
in the control embryo (arrowheads in B), but complete absence in the Dll4KD 
embryo (asterisks in C). D,E, Whole-mount in situ staining for Tie2 at 50 hpf, 
revealing a normal number of secondary sprouts (arrowheads) in the control (D) 
and Dll4KD (E) embryo. Scale bars: 50 μm 
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2.3 DLL4 SILENCING REDUCES THE FRACTION OF LYMPHANGIOGENIC 
SECONDARY SPROUTS  
Since the PL string at the horizontal myoseptum is formed by lymphangiogenic 
secondary sprouts from the PCV, we also studied whether inhibition of Notch signaling might 
even act at an earlier stage, i.e., during branching of these lymphangiogenic secondary 
sprouts. Whole-mount staining for Tie2 
#
, which marks all secondary sprouts 92, showed a 
normal total number of secondary sprouts from the PCV in all Dll4KD embryos analyzed 
(N=20; 50 hpf; Figure 17D-E). Half of these secondary sprouts, i.e. the angiogenic sprouts, 
normally connect to the primary arterial ISVs that loose their arterial connection to the DA 
and become venous ISVs (Figure 3). The other half of the secondary sprouts, the 
lymphangiogenic sprouts grow to the level of the horizontal myoseptum where they deliver 
the PL cells after which the connection between the PL string and the PCV disappears 
(Figure 3). Despite the normal total number of secondary sprouts, high resolution imaging of 
the trunk vasculature in 4-dpf Fli1:eGFPy1 embryos revealed alterations in the proportion of 
primary ISVs that adopted a venous phenotype (vISVs), based on the criterion that they 
were connected to the PCV. As expected, in control embryos, approximately half of the ISVs 
were connected to the PCV (vISVs, % of total ISVs: 54 ± 1.3%; N=49 embryos). In contrast, 
in Dll4SPL embryos, a larger fraction of ISVs was connected to the PCV and therefore venous 
(vISVs, % of total ISVs in all Dll4SPL embryos analyzed: 82 ± 1.8%; N=97, P<0.05 versus 
control). Similar findings were obtained in Notch-1bSPL embryos (vISVs, % of total: 69 ± 
2.7%; N=27, P<0.05 versus control). These findings, and the observation that silencing of 
Dll4, Notch-1b or Notch-6 aborted PL string formation in a substantial fraction of morphant 
embryos, indicated that a fraction of secondary sprouts, that would normally have been 
lymphangiogenic, were angiogenic, thereby impairing TD formation (see scheme in Figure 
25A,B).  
We provided additional experimental support for the aforementioned model by using 
high resolution video-imaging of a double transgenic reporter line, the Flt1:YFPxkdr-
l:mCherryRed line 
#
. The kdr-l:mCherryRed transgene labels arterial and venous ECs, 
whereas the Flt1:YFP marker exclusively labels arterial ECs 90. Hence, in the Flt1:YFPxkdr-
                                                
#
 whole-mount in situ staining for Tie2 and imaging of the Flt1:YFPxkdr-l:mCherryRed line was performed by the 
Schultle-Merker lab (Hubrecht Institute-KNAW and University Medical Center, Utrecht, the Netherlands) 
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l:mCherryRed line, venous cells are red (CherryRed+) and arterial cells are yellow 
(YFP+CherryRed+) in merged images. Once a primary aISV adopts a venous identity when 
being “co-opted” by a secondary venous angiogenic sprout, this vessel gradually changes its 
pattern of marker expression and becomes venous. In control embryos, those primary aISVs 
that became connected with a venous secondary sprout and thus adopted a venous identity, 
indeed progressively lost their “arterial” yellow color and acquired a “venous” red color (blue 
arrows in Figure 18A-A”), while the other half of the aISVs remained connected with the DA 
and retained their yellow color (white arrows in Figure 18A-A”). Closer inspection revealed 
that, upon establishing a connection with a venous secondary sprout, the arterial ECs of the 
aISV became gradually replaced by venous ECs from the secondary sprout in a ventral-to-
dorsal direction. In contrast, in Dll4KD embryos with severe lymphatic defects, nearly all 
yellow aISV connections with the DA disappeared (see the single white arrow in Figure 18B-
B”), and were gradually replaced by red vISV connections with the PCV (blue arrows in 
FigureB,B”). Thus, the imagings confirmed that a supernumerary fraction of angiogenic 
sprouts is formed in Dll4KD embryos at the expense of lymphangiogenic sprouts, that would 
otherwise go on to form the PL string. 
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Figure 18: Notch silencing reduces the fraction of lymphangiogenic sprouts. 
A,B Confocal images of the trunk vasculature in Flt1:YFPxkdr-l:mCherryRed 
embryos, where kdr-l:mCherryRed marks both venous and arterial vessels in red 
(A,B), Flt1:YFP labels arterial vessels in green (A’,B’), and the merged images 
show arterial vessels in yellow (green-red) and venous vessels in red (A”,B”). 
Lateral view images of the entire embryo were taken, such that the ISVs at both 
the left and right side of the embryo are shown, partially superimposed onto each 
other. Embryos were imaged at 54 hpf, when secondary sprouts had already 
connected to the primary ISVs, and the latter were in the process of changing their 
arterial to venous identity in a ventral-to-dorsal pattern. In control embryos (A-A”), 
on average half of the aISVs became connected to the PCV and thus acquired a 
venous identity, thereby progressively losing their green arterial signal (blue 
arrows in A’) and thus becoming marked in red only (blue arrows in A,A”), while 
the other half of the aISVs remained connected to the DA and labeled in green 
(white arrows in A’) and thus in yellow on the merged images (white arrows in A”). 
By contrast, in the Dll4KD embryo shown (B-B”), most ISVs lost their green arterial 
marker in a ventral-to-dorsal direction (blue arrows in B’,B”; note the single white 
arrow), and became marked in red only, while loosing their yellow label (blue 
arrows in B”). White arrow in B-B” denotes a residual aISV retaining its green (B’) 
or yellow (B”) label. Scale bar in A, representative for all panels, is 50 μm. 
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2.4 ACTIVATION OF NOTCH BY DLL4 PROMOTES LYMPHATIC 
CHARACTERISTICS IN VITRO 
To evaluate whether activation of Notch in venous ECs would induce lymphatic 
properties, we cultured human umbilical venous ECs (HUVECs, which express Notch 
receptors including NOTCH-1, but negligible levels of PROX-1; not shown) on a feeder layer 
of monkey COS cells, expressing DLL4 (COSDll4) or a control vector (COSCTR), and analyzed 
by RT-PCR with human gene-specific primers the expression of lymphatic markers. As 
shown in Figure 19, several well-known direct Notch target genes (HEY1, HEY2, HES1, 
NRARP) were upregulated in HUVECs, when cultured on COSDll4 feeder cells as compared 
to control COSCTR feeder cells, indicating that Notch signaling was activated. Furthermore, 
COSDll4-activated HUVECs expressed elevated levels of the lymphatic markers PROX-1, 
VEGFR3, LYVE-1 and SOX18 (Figure 19). Expression of EPHRINB2 has been implicated in 
development of both arterial vessels and collecting lymphatics (not capillaries) 70,172. 
Furthermore, it should be noted that EPHRINB2 has also been shown to be a direct Notch 
target gene in endocardial cells, having CSL-binding sites in its promoter 279 and could 
therefore also be considered to belong to the group of direct Notch targets. Expression of 
COUP-TFII, which is expressed in both venous and lymphatic ECs 234, is also upregulated, 
but levels of other blood vessel markers (NEUROPILIN-1, ENDOGLIN, VE-CADHERIN, 
CD31) were not or only minimally affected (Figure 19). This upregulation of lymphatic 
markers was abolished by treatment of the cells with DAPT (30 M; not shown).  
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Figure 19:  Activation of Notch by Dll4 promotes lymphatic characteristics in 
vitro. Quantitative RT-PCR analysis of HUVECs, co-cultured with COS cells stably 
expressing hDll4 (COSDll4) or a control vector (GFP; COSCTR), confirming 
upregulation of Notch target genes (HES1, HEY1, HEY2, NRARP; blue bars) and 
revealing enhanced lymphatic marker expression (VEGFR3, PROX-1, LYVE-1, 
EPHRINB2, SOX18; green bars), while vascular genes such as NEUROPILIN-1, 
CD31, VE-CADHERIN or ENDOGLIN (red bars) were only minimally affected. COUP-
TFII, which is expressed in venous and lymphatic ECs, was also upregulated. 
Results are represented as fold change in HUVEC/COSDll4 co-culture versus 
HUVEC/COSCTR. Mean±SEM; N= 3-11; *, p < 0.05. 
 
 
2.5 IS NOTCH INVOLVED IN LYMPHATIC SPECIFICATION IN ZEBRAFISH? 
The lymphatic differentiation process in mammals has been described to occur in 
different steps (reviewed in 39; Figure 2). Sox18 expression marks a subpopulation of venous 
ECs in the cardinal vein that are competent to obtain a lymphatic identity. An unknown factor 
or stimulus induces Prox1 expression in a subset of these competent venous ECs, which 
initiates commitment towards LEC differentiation. These cells start migrating away from the 
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cardinal vein towards VEGF-C signals to form the initial lymph sacs. During migration these 
cells become even further committed, i.e. determined to the LEC lineage by expressing 
additional LEC markers, such as Nrp2, Foxc2, Podoplanin, Ang2 and EphrinB2. From the 
lymph sacs, LECs sprout and migrate away to form the whole lymphatic vascular network. 
These growing lymphatic vasculature branches further mature and their LECs are only 
completely differentiated near the time of birth when they express the complete profile of 
lymphatic marker genes. Of all these lymphatically expressed genes, only overexpression of 
either Sox18 or Prox1 in BEC are shown to be sufficient to induce lymphatic differentiation 
46,47,50. Thus, Sox18 and Prox1 are, at present, the most important known regulators of 
lymphatic development. Therefore, in order to answer the question whether Notch is 
involved in the processes of lymphatic specification or commitment, we have analyzed the 
expression of Sox18 and Prox1 in control and Notch morphant embryos.  
 
2.5.1 Sox18 expression 
Sox18 has been described to be expressed in the DA and PCV at 24 hpf and in the 
primary ISVs sprouting from the DA 253,262,280. We have obtained similar expression patterns 
by whole mount in situ staining for Sox18 at 30 hpf (Figure 20A). At 38 hpf Sox18 expression 
is strongest at the interface between DA and PCV (Figure 20C). Both at 30 hpf and 38 hpf, 
stages spanning the secondary sprout formation from the PCV, we found no obvious 
alterations in the Sox18 expression pattern in control and Dll4KD embryos (Figure 20A-D), in 
agreement with previous findings that Sox18 expression was not affected in Mindbomb 
mutants that lack an E3 ubiquitin ligase crucial for Notch signal activation 262.  
However, it should be noted that a crucial role for Sox18 in zebrafish 
lymphangiogenesis, similar as in mice, has not been reported. To test this we have 
performed morpholino knockdown experiments using the previously described Sox18 
morpholino that combined with Sox7 morpholino blocks arterial-venous differentiation in 
zebrafish 253,262. Preliminary data using morpholino concentrations avoiding major vascular 
defects (15 ng Sox18ATG) did not show lymphatic defects in PL string formation nor TD 
formation (not shown). However, as the zebrafish genome underwent a duplication, it is 
possible that an as yet unidentified paralogue, mediates lymphatic specification. 
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Figure 20: Sox18 expression in control and Dll4KD embryos. A-D Whole-mount 
in situ staining for Sox18 at 30 hpf (A,B) and 38 hpf (C,D) in control embryos (A,C) 
and Dll4KD (10ng Dll4SPL) embryos (B,D), revealing normal expression of Sox18 at 
stages of lymphangiogenic sprout formation. Red bar indicates dorsal aorta (DA), 
blue bar posterior cardinal vein (PCV). Scale bar: 100 μm. 
 
 
2.5.2 Prox1 expression 
Previously, Prox1 expression was shown in the PCV, secondary sprouts from the 
PCV, the PL string (then termed parachordal vessel) and thoracic duct 7. However, despite 
numerous efforts and different staining techniques (whole mount ISH, ISH on cryosections, 
whole mount immunostaining, immunostaining on cryo- and paraffin sections) we  and 
others (Schulte-Merker lab 
#
, Gerhardt lab 

, Cotelli lab 

) have not been able to reproduce 
                                                
 we performed whole mount ISH, ISH on sections, immunostainings with different available antibodies 
#
 Schulte-Merker lab (Hubrecht Institute-KNAW and University Medical Center, Utrecht, the Netherlands) 
performed whole-mount in situ stainings for Prox1 

 Gerhardt lab (London Research Institute–Cancer Research, London, England) performed whole mount 
immunostainings for Prox1 
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these described staining patterns in zebrafish. This was not due to failure of the staining 
procedures, as in all approaches (ISH, immuonstaining), the other reported sites of Prox1 
expression (e.g. eye, neural tube, lateral line, muscle pioneer cells, pronephros 266,281,282) 
were stained (not shown). We have also analyzed the expression patterns of Prox1-like and 
Prox2, a paralogue and homologue, respectively, of Prox1, by whole-mount in situ staining 
to explore whether one of these zebrafish Prox genes might be the counterpart of 
mammalian Prox1 for zebrafish lymphangiogenesis. However, we did not detect expression 
in the lymphangiogenic and lymphatic structures at stages between 24 and 75 hpf (not 
shown). Several reasons can explain why we did not detect expression of any of the Prox1 
homologous genes in zebrafish. It is possible that expression of Prox1 was below the 
threshold of detection or in case of the lymhangiogenic sprouts and PL string, structures 
were too small to detect labeled cells. It could also be that the currently known zebrafish 
Prox1 homologues are not involved in lymphatic development. 
In an alternative strategy, we have tried to isolate the vascular and lymphatic EC 
fractions of Fli1:eGFPy1 embryos in order to perform RT-PCR expression analysis. 
Therefore, we adoped a technique that was established in our lab in the Xenopus laevis 
model (257, manuscript in preparation) which makes it possible to specifically label LECs. 
Briefly, this LEC labeling is performed by injecting TRITC-dextran dye intramuscularly in 
Fli1:eGFPy1 zebrafish embryos. The dye is drained by the lymphatics and specifically taken 
up by LECs (but not BECs), via a process of pinocytosis (‘cell drinking’) (Figure 21). In this 
way LECs become labeled red by the presence of intracellular dye-containing vesicles. 
FACS sorting of the cells of these embryos enables the isolation of the double red/green 
LEC fraction and the single green BEC fraction. Unfortunately, this LEC labeling technique 
only works efficiently in 3 to 4 week old embryos, making it impossible to use this technique 
to isolate the early-stage lymphangiogenic or lymphatic ECs, e.g. from the PL string, LISV or 
early TD. However, RT-PCR analysis on the LEC fraction of older embryos confirmed the 
presence of Prox1 mRNA in LECs in zebrafish, suggesting that, similar as in mammals, 
Prox1 is also a marker of lymphatic structures in zebrafish (not shown).  
 
                                                                                                                                                  

 Cotelli lab (the Department of Biology, University of Milan, Milan, Italy) performed whole-mount in situ stainings 
for Prox1 
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Figure 21: LEC labeling technique in zebrafish embryos. A 4 week old 
Fli1:eGFPy1 zebrafish embryo was injected intramuscularly in the tail with TRITC-
dextran. The dye is drained by lymphatics and taken up intracellularly by 
pinocytosis in LECs. In this way lymphatic structures (TD (thoracic duct), LISV 
(lymphatic intersomitic vessels) become labeled red making it possibly to separate 
the BEC fraction (GFP+) from the LEC fraction (GFP+/TRITC+) by FACS sorting. 
 
 
2.5.3 Inhibition of Prox1 impairs thoracic duct development 
The lack of an appropriate technique to detect Prox1 expression in the early 
lymphangiogenic structures raised concerns about the role of Prox1 in lymphatic 
commitment in zebrafish embryos. We therefore analyzed the effect of Prox1 knockdown on 
lymphatic development. Injection of a transcription-blocking morpholino, Prox1ATG1, resulted 
in dose-dependent impairment of both PL string and TD development. At the highest 
morpholino dose (10ng), TD formation was completely blocked in up to 45% of morphant 
embryos (N=86; Figure 22). Unfortunately, we were unable to confirm the specificity of these 
lymphatic defects with a second morpholino. A splice-blocking morpholino (Prox1SPL) was 
too toxic and lethal at low dosages. A second, independent ATG-binding morpholino 
(Prox1ATG2) did not impair TD formation. Therefore, we cannot draw firm conclusions on the 
role of Prox1 in lymphatic commitment in zebrafish. 
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Figure 22: Dll4 and Prox1 synergistically regulate TD formation. Bar graphs, 
representing the percentage of embryos that develop a normal TD (grey), a TD 
over 30-90% (lilac) or over 10-30% (blue) of its normal length, or completely lack 
any TD (dark blue) in the indicated fraction of control embryos (N=47) or embryos 
injected with a high dose of Prox1ATG1 (10ng, N=86), a low dose of of Prox1ATG1 
(2.5ng; N=30), a low dose of Dll4SPL (2.5ng; N=51) or a combination of these low 
dosages of Prox1ATG1 and Dll4SPL (N=33). TD defects after injection of a high 
dosage of Prox1ATG1, a low dosage of Dll4SPL or combined injection of Prox1ATG1 
and Dll4SPL were significantly different from control injections (P<0.001). 
 
 
 
2.5.4 Synergistic impairment of lymphatic development upon combined 
knockdown of Prox1 and Dll4 
Notwithstanding this controversy, we made use of the Prox1ATG1 morpholino to study 
whether Prox1 knockdown would aggravate Dll4 morphant phenotypes. Therefore, the effect 
of combined knockdown of Prox1 and Dll4 was analyzed using morpholino doses that did 
not or only minimally impair lymphatic development in the single knockdowns (2.5ng Dll4SPL; 
2.5 ng Prox1ATG1; Figure 22). Whereas single knockdown of either Dll4 or Prox1 did not or 
only minimally impair TD development at these low morpholino dosages (N= 51 and 30, 
respectively; Figure 22), combined knockdown completely blocked TD formation in 42% of 
embryos and reduced TD formation to less than 30% of its normal length in another 15% of 
embryos (N=33) (Figure 22). Similarly, PL formation was not impaired in the single 
knockdowns, but was completely blocked in 23% of double knockdowns and reduced to less 
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than 30% of its normal length in 31% of embryos (N=39) (not shown). These findings 
suggest that Prox1 and Dll4 act synergistically in regulating lymphatic development in 
zebrafish embryos.  
Together, the findings that Dll4-mediated activation of Notch signaling in BECs in vitro 
induces upregulation of lymphatic marker genes and that Prox1 and Dll4 synergistically 
regulate lymphatic development in zebrafish embryos, suggest a potential role for Dll4/Notch 
signaling upstream of or in parallel with Prox1 in lymphatic commitment. This would also 
explain the reduced formation of lymphangiogenic secondary sprouts upon Dll4/Notch 
inhibition. However, these data should be interpreted with care in view of the absence of 
confirmation by a second Prox1 morpholino.  
 
 
 
3 INHIBITION OF NOTCH SIGNALING IMPAIRS LYMPHATIC 
NAVIGATION 
3.1 SILENCING OF DLL4 IMPAIRS PL CELL MIGRATION ALONG AISVS 
We also explored whether Notch signaling might regulate the development of the TD 
by controlling LISV formation or migration, as the TD failed to form in a substantial fraction of 
Dll4SPL embryos (25%), even despite the fact that its precursor, the PL string, developed 
partially in these embryos. Also, as described above, addition of DAPT to zebrafish embryos 
at 56hpf, when the PL string is nearly completely formed, still completely blocked PL 
formation in 20% of treated embryos (Figure 16). High-resolution imaging revealed several 
types of LISV abnormalities in Dll4KD embryos, the most frequent being absence of LISVs 
along ISVs. Intriguingly, we have observed that in control embryos, LISV-PLs only migrated 
along aISVs but never along vISVs, suggesting that vISVs are not permissive (Figure 23A-
B). Since there were more vISVs and fewer aISVs in Dll4KD embryos, migrating LISV-PLs 
were deprived from their usual arterial template and could therefore not contribute to the 
formation of the TD (Figure 23C). Intriguingly, however, we also noticed that, even when 
residual aISVs formed in Dll4SPL embryos, LISV-PLs bypassed the aISV post, and failed to 
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turn and migrate along aISVs (Figure 23D). Indeed, when analyzing the fraction of aISVs 
that was accompanied by LISV-PLs in Dll4SPL embryos with a nearly complete PL string 
(over >90% of its length), as much as 49 ± 6% of these aISVs were not accompanied by 
LISV-PLs in Dll4SPL embryos (N=205 aISV), while only a few aISVs lacked accompanying 
LISV-PLs in control embryos (15 ± 4%; N=334 aISV; P<0.05).  
Other, much less frequent LISV defects included LISV-PLs that made the turn 
alongside the aISV, but stalled (Figure 23E), or even, in a few cases, misrouted LISV-PLs 
migrating along vISVs (Figure 23F). Stalling was observed for 9.2% and 2.7% of LISV that 
migrated up- or downward, respectively, along aISV in Dll4KD embryos (N=293 aISV), as 
compared to 1.8% and 0.7%, respectively, in control embryos (N=450 aISV). Misrouting 
along vISVs was only observed in 0.25% of vISVs in Dll4KD embryos (N=1617 vISV), 
however, this rare aberrant phenotype was never observed in control embryos (N=767 
vISV).  
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Figure 23: Incomplete silencing of Notch perturbs lymphatic navigation. 
Panels A-F are confocal images with accompanying schematic redrawing of the 
navigation routes of LISVs along aISVs or vISVs in control (A,B) and Dll4KD (C-F) 
Fli1:eGFPy1 embryos at 4 dpf. Permanent lymphatic structures (LISV, TD) are 
labeled dark green; transient lymphangiogenic structures (PL) are labeled light 
green. A,B, In control embryos, LISV-PLs navigate alongside aISVs and establish a 
continuous TD (arrowhead). Note how the LISV “creeps” over its aISV guidance 
template (A). LISV-PLs never navigate along vISVs in control embryos (B). C-F, 
Different types of navigation defects in Dll4KD embryos. C, In a large fraction of 
morphant somites, LISV-PLs lacked migration templates because fewer aISVs 
developed. As LISV-PLs do not normally migrate along vISVs, no TD was formed in 
these somites (asterisks). D, In other morphant somites, LISV-PLs bypassed the 
point of turning at the aISVs, and failed to switch to radial migration. E, In a small 
fraction of somites in Dll4KD embryos, LISV-PLs accomplished to make the turn and 
switched to radial migration, but then stalled shortly thereafter (red arrowhead 
denotes the arrested tip of a navigating LISV). F, In most Dll4KD embryos, vISVs 
were not permissive to guide LISV-PLs, but, occasionally, LISV-PLs erroneously 
navigated alongside a vISV. 
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3.2 NOTCH INHIBITION DOES NOT AFFECT INTRINSIC MOTILITY PROPERTIES OF 
LECS IN VITRO 
In the above-described defective migration phenotypes of absent or stalled LISV-PLs 
along residual aISVs templates (Figure 23C,E), LISV-PLs are present, however, they do not 
migrate. We have performed various in vitro studies to examine whether the intrinsic 
properties of LECs were altered after Notch inhibition and could therefore explain the 
defective migration of these cells. 
We have analyzed the effect of Notch inhibition and activation on cellular migration 
and motility by using different experimental setups. In the first place, we have performed a 
scratch wound migration assay in which the rate is measured at which a gap in a confluent 
layer of LECs is closed.  Inhibition of Notch signaling by treatment with DAPT had no effect 
on the rate of gap closure (Figure 24A). In agreement, neither activation of Notch signaling 
by growing the cells on Dll4-Fc coated plates 206 nor inhibition of Notch signaling by 
treatment with DAPT showed an effect in a transwell migration experiment that measured 
the migration of LECs through a porous membrane (Figure 24B-C).  
We also analyzed the effects of Notch inhibition on proliferation of LECs to verify (in an 
in vitro set up) whether reduced proliferation properties of PL cells upon Notch inhibition 
could explain the reduced presence of migrating LISV-PLs. Proliferation was measured by 
quantifying the amount of viable cells after culturing LECs for 48 hours in the presence or 
absence of DAPT. No effect of Notch inhibition on proliferation of LECs was found (Figure 
24D).  
Finally, we determined the effect of Notch inhibition on sprouting and capillary tube 
formation. LECs were coated on beads and embedded in a collagen gel. Sprouting was 
induced by addition of full growth factor supplemented medium. Addition of DAPT did not 
affect the length of the sprouts but an increased number of sprouts was observed (not 
shown), reminiscent of the increased vascular sprouting phenotype upon Notch inhibition 103. 
However, in vivo, we had not observed increased sprouting from or hypberbranching of the 
PL string in zebrafish upon Notch inhibition.  
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Figure 24: Inhibition of Notch does not affect in vitro proliferation and 
migration. A, Migration of LECs, analyzed using a scratch wound healing assay, 
was not inhibited by DAPT (30 μM). B, Transwell migration of LECs in response to 
culture medium containing 10% FBS and 100 ng/ml VEGF-C in the lower 
compartment was comparable, when cells were seeded on filters coated with BSA 
(control) or the extracellular domain of Dll4 (Dll4-ECD), previously shown to 
activate Notch signaling.9 C, Transwell migration of LECs in response to culture 
medium containing 10% FBS and 100 ng/ml VEGF-C in the lower compartment 
(“stimulated”) was not affected by DAPT (60 μM). D, Primary LECs of dermal 
(HMVEC-DLy) and lung (HMVEC-LLy) origin were starved overnight, after which 
proliferation was induced with full growth medium with or without increasing 
concentrations of DAPT (30-60 μM). Proliferation was measured as the number of 
viable cells after further culturing for 48 hours, expressed in % of control. Error 
bars represent SEM; N=5-11. 
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These in vitro evidences indicate that the intrinsic properties regulating movement of 
LECs were not affected. This may imply alterations in the migration scaffolds/templates 
formed by the aISV (see above). However, the arterial identity of the guiding ISVs does not 
seem to be affected. Indeed, despite their reduced number, the remaining aISV showed 
normal expression of the arterial marker Flt1 in the Flt1:eGFP reporter line 
#
 (Figure 
18B’,B”). Furthermore, initial arterial/venous differentiation was normal as shown by the 
normal expression of arterial and venous marker genes in the differentiated DA and PCV at 
28hpf at the highest morpholino and DAPT dosages used (Figure 14). Therefore, we believe 
that the reduction of migrating LISV-PLs is due to defective turning of LISV-PLs from 
tangential migration at the horizontal myoseptum to radial migration along the arterial 
guidance template and that this is probably due to loss of a recognition signal. This 
recognition signal might be Notch itself or an as yet unknown factor regulated by Notch 
signaling. 
 
 
4 EXPRESSION OF DLL4 AND NOTCH-1B IN ZEBRAFISH 
To examine the expression of Dll4 and Notch in order to relate it to the observed 
lymphangiogenic/lymphatic defects, we used whole-mount in situ hybridization in control 
embryos during the developmental processes that were affected in Notch hypomorphants. 
At 30 hpf, when secondary sprout formation starts, Dll4 was strongly expressed in the DA 
but undetectable in the PCV (Figure 25A,B), consistent with previous findings 92,189,190. 
Notch-1b was strongly expressed in the DA (Figure 25C,D), while a much weaker signal 
appeared dispersed in certain endothelial cells of the dorsal part of the PCV, though the low 
Notch-1b signal approached the detection limit of available techniques (Figure 25E). 
Expression of Notch-6 was at or below the threshold of detection of the in situ hybridization 
technique; when expression was detectable, a weak signal was observed in the axial 
vasculature consistent with its previously reported expression pattern (not shown) 283. Thus, 
                                                
#
 Imaging was performed by the Schultle-Merker lab (Hubrecht Institute-KNAW and University Medical Center, 
Utrecht, the Netherlands) 
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ligand and receptor appear to be expressed in the near vicinity of the emerging 
lymphangiogenic secondary sprouts. The limited resolution of in situ hybridization (whole-
mount or sections) did not allow us to evaluate possible expression in the thin 
lymphangiogenic secondary sprouts or the PL string. 
Dll4 and Notch-1b were also detected in primary ISVs by in situ hybridization at 30 hpf 
(Figure 25A,C), consistent with previous findings 189,190. Expression analysis by in situ 
hybridization becomes technically challenging or even impossible in embryos older than 2 
dpf. Therefore, to analyze expression in ISVs at later stages, when LISV-PLs migrate along 
aISVs (from 2.5 dpf onwards), we used the Tp1bglob:eGFPxFli1:DsRed line 

, in which all 
endothelial cells are red, and cells with canonical Notch activity are green (GFP expression 
is driven by a promotor containing 12 Su(H) DNA binding sequences 247). Imaging of this line 
at the time when PL cells make the turn and switch from tangential to radial ventral migration 
revealed that the DA and aISVs are yellow in the merged image, indicating that canonical 
Notch signaling was active in arterial vessels, but not in LISVs or vISVs (Figure 25F-F”’).  
Finally, RT-PCR analysis on sorted BEC and LEC fractions after LEC labeling of 4-
week old Fli1:eGFPy1 embryos (see above), confirmed low, but detectable expression levels 
of Notch-1b in lymphatic structures of older zebrafish (copies Notch-1b/105 copies -actin: 
6.9 ± 0.77, N=4).  
                                                
 Imaging of this line was performed by Karlien Hermans (Vesaius Research Center, Leuven) in the Lawson lab 
(Program in Gene Function and Expression, University of Massachusetts Medical School, Worcester) 
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Figure 25: Expression of Dll4 and Notch-1b in zebrafish. A-D, Whole-mount 
embryos at 30 hpf, when lymphangiogenic sprouting occurs, were stained for Dll4 
(A,B) or Notch-1b (C,D); panels B,D show cross-sections of the respective 
embryos. Primary ISVs are indicated by yellow arrowheads (A,C). A,B, Dll4 
expression was detected in the DA and primary aISVs, besides its known 
expression in the pronephric duct (white arrow in A). C,D, Notch-1b is strongly 
expressed in the neural tube (NT), and in the DA and primary aISVs. E, Sagital 
section of an embryo at 30 hpf, whole-mount stained for Notch-1b. Notch-1b is 
expressed in the DA and ISVs. A weak signal can be observed in dispersed cells 
at the dorsal side of the PCV. F, Confocal images of the trunk vasculature in 
untreated Tp1bglob:eGFPxFli1:DsRed embryos, in which Fli1:DsRed marks blood 
and lymph vessels in red (F) and Tp1bglob:eGFP labels cells with activated 
canonical Notch activity in green (F’). The merged image shows arterial vessels 
(DA; aISV) with active Notch in yellow (green-red), while the LISV are only red (F”). 
In the schematic representation, the lymphatic structures are indicated in green, 
Notch-activated vessels in yellow, and other vessels in grey (F”’). Representative 
images of the arterial activation of Notch in a 6-dpf embryo are shown (for 
technical reasons), but similar data were obtained at 60 hpf. Scale bars: 50 μm. 
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The cardinal finding of this study is that incomplete silencing or pharmacological 
inhibition of Notch signaling impairs lymphatic development in zebrafish and tadpoles. 
Mechanistic analysis in zebrafish indicates that Notch signaling regulates lymphatic 
development at two distinct steps, initially during the formation of lymphangiogenic sprouts 
and their descendent PL cells, which give rise to the TD (Figure 26A,B). At a later stage, 
Notch signaling is required for guided migration of LISV-PLs along aISVs (Figure 26C-C”’).  
In the following sections the novel findings that were generated during this PhD project 
are discussed in light of the existing literature. Our data clearly indicate that blocking Notch 
signaling in zebrafish abolishes lymphatic development at two stages. However, several 
unresolved issues require further study in order to unravel the exact mechanisms of how 
Notch signaling mediates its double role during lymphatic development in zebrafish, as 
further discussed below. Also, the current limitations of the main model that was used for 
this study, the zebrafish, are discussed, addressing potential further optimizations to render 
it even more powerful as a lymphatic model.  
 
 
1 ZEBRAFISH AS A MODEL TO STUDY LYMPHANGIOGENESIS 
This study was largely based on results obtained in the zebrafish model. The lymphatic 
system in zebrafish has only been discovered a few years ago 6,7 and the lymphatic 
developmental process in zebrafish embryos has not been characterized in detail. It remains 
to be determined if molecular regulation of lymphangiogenesis in zebrafish is similar to the 
mammalian situation and if the same key regulators are involved. We have performed a 
limited study on the role of the mammalian lymphatic competence regulator Sox18 50 in 
zebrafish. Its expression in the vasculature appears to be similar to mouse during early 
stages of vascular development 50,253,262,280. At the time of lymphangiogenic sprouting from 
the PCV, Sox18 is expressed in the PCV. However, it is not clear whether Sox18 is also 
expressed in the lymphangiogenic secondary sprouts and later in the PL string. Our 
preliminary data of Sox18 morpholino knockdown did not show a clear lymphatic defect. 
Secondly, we investigated the involvement of Prox1, the key lymphatic specification 
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regulator described in mammals 40,46-48. While Prox1 expression in early lymphangiogenic 
and lymphatic structures in zebrafish was reported previously 7, we nor several specialized 
collaborators with extensive expertise in zebrafish and/or Prox1 biology, were able to 
reproduce the previously described lymphangiogenic/lymphatic expression patterns. We 
have also analyzed the expression of the Prox1 homologues Prox1-like and Prox2, but 
found no expression in lymphatic structures. Remarkably, at later stages, when the 
lymphatic vessels have been properly established and are functional, expression of Prox1 
could be detected in sorted LECs. We also analyzed the effect of Prox1 inhibition in 
zebrafish and observed with one Prox1-targeting morpholino impairment of both PL string 
and TD formation. However, these phenotypic defects were not reproduced by two other 
independent morpholinos. Taken together, these data are somewhat puzzling and it remains 
to be elucidated whether mice and fish really differ in their molecular process regulating 
lymphangiogenesis. If differences exist, they are only partial, since knockdown or inhibition 
of other known lymhangiogenic factors, including Ccbe1 90,91, Vegf-c 6,92, Vegfr-3 6,92, and 
Synectin (93 manuscript under revision), cause impaired lymphangiogenesis, highlighting the 
conservation of several lymphatic regulators between zebrafish and mammals. With respect 
to Sox18 and Prox1, it is possible that due to the historic additional genome duplication in 
teleosts 284, other as yet unidentified paralogues for Sox18 and Prox1 may be active and 
play a redundant role. 
The problems encountered during the expression analyzes also point to an important 
obstacle that renders the use of the zebrafish model to study developmental processes 
ongoing beyond 2 dpf quite challenging. From this stage onwards, whole mount in situ 
staining in the trunk becomes difficult or even impossible. It appears that beyond a certain 
stage, the structure of the skin becomes impermeable for the RNA probes. Therefore, new 
techniques should be developed to overcome this hurdle. Also immunostaining remains 
difficult in zebrafish, since in most cases antibodies are developed against a mammalian 
antigen and often do not recognize the corresponding zebrafish protein. However, as a 
result of ZFIN society efforts raising this issue, two antibody companies (AnaSpec, Fremont, 
California; Abcam, Cambridge, Massachusetts) have recently announced to start the 
production of several zebrafish-specific antibodies. An alternative strategy to analyze 
lymphatic gene expression but to avoid difficult staining procedures would be the creation of 
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reporter lines expressing a fluorescent marker, regulated by e.g. the Sox18 or Prox1 
promoter. However, identification of the functional promoter elements remains challenging. 
This is especially the case for Prox1, where even for the mouse, none of the promoter 
sequences tested so far by us and others (personal communications) in reporter transgenes 
yielded LEC-specific expression. A large-scale promoter or gene trapping screening 285 
could be performed to identify specific lymphatic marker genes in zebrafish. This could also 
result in the establishment of lymphatic-specific reporter lines that would further advance the 
zebrafish as a model to study the lymphatic developmental process. 
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Figure 26: Schematic model of Notch in lymphatic development Scheme, 
illustrating the different types of lymphatic defects in Dll4KD embryos (for normal 
lymphatic development in control embryos, see Figure 3). Permanent lymphatic 
structures (LISV, TD) are labeled dark green; transient lymphangiogenic structures 
(lymphangiogenic secondary sprouts; parachordal lymphangioblasts) are labeled 
light green. A,B, REDUCED FRACTION OF LYMPHANGIOGENIC SPROUTS, resulting in 
underdevelopment or absence of the PL string, with accompanying 
overrepresentation of angiogenic secondary sprouts. C-C”’, LISV MIGRATION 
DEFECTS: C, As a result of the overrepresentation of vISVs, LISV-PLs are deprived 
of their normal aISV guidance template. C’-C”’, LISV formation is further impaired 
by additional navigation defects, most frequently because LISV-PLs cells bypass 
their turning point and never initiate ventral radial migration (C’), or occasionally 
make the turn but then stall (C’’). More rarely, navigating LISV-PLs become 
misrouted along vISVs (C”’). The most frequent defects are boxed in grey.  
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2 ROLE OF NOTCH IN LYMPHANGIOGENIC SECONDARY 
SPROUT FORMATION 
Our results reveal that Notch, in addition to its role in blood vessel morphogenesis and 
arterial development 180,244, also regulates lymphatic development. Up to half of the Notch 
hypomorphant embryos failed to form a TD without later rescue, indicating that lymphatic 
development in the trunk was aborted and not simply delayed. Treatment of zebrafish 
embryos with DAPT at different stages of lymphatic development revealed that upon early 
treatment, at stages before or during secondary sprouting from the PCV, most surviving 
embryos did not form a TD. This suggested an early role for Notch in lymphatic 
development. DAPT treatment in the tadpole model confirmed the impaired lymphatic 
development. The earliest identifiable abnormality in Notch-silenced zebrafish embryos, the 
increased fraction of venous ISVs, reflected a defect at the level of the secondary sprouts 
from the PCV, where fewer lymphangiogenic but more angiogenic sprouts developed 
(Figure 26A,B). The lymphangiogenic secondary sprouts give rise to the string of PL cells, 
which in turn form LECs of the TD. This explains the correlation of the shifted 
angiogenic/lymphangiogenic balance upon Notch silencing with defective formation of the 
PL and TD. The reduced fraction of lymphangiogenic sprouts could result from defects in 
LEC fate acquisition, migration, proliferation, survival and/or other cellular processes 
contributing to sprout formation and maintenance. How Notch signaling regulates lymphatic 
development remains unresolved, largely due to technical limitations in the zebrafish model, 
which have precluded us from determining the exact stages of lymphatic competence, 
specification and differentiation as defined during mammalian lymphangiogenesis 39. 
Therefore, and to avoid any overstatement, the PL-forming secondary sprouts from the PCV, 
as well as the PL string itself, were termed “lymphangiogenic” to denote their participation in 
lymphatic development. It is unknown whether ECs of these sprouts merely have the 
potential to become a LEC (“competence”), or are already programmed to become a LEC, 
albeit reversibly (“specification”) 39,286. However, a number of findings suggest that the early 
lymphangiogenic structures belong to the lymphatic lineage. Indeed, the lymphangiogenic 
sprouts and PL cells contribute only to lymphangiogenesis but not to angiogenesis, are not 
labeled in the kdr-l:mCherryRed line which marks only arterial and venous ECs 90, and fail to 
form upon silencing of genes that regulate lymphangiogenesis in mice and humans, e.g., 
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Ccbe1 90,91, Vegf-c 6,90, Vegfr-3 6,92, Synectin (93, manuscript under revision) and Prox-1 
(unpublished, this thesis). Although our findings that Notch upregulates LEC-specific 
markers in venous ECs in vitro could suggest a role for Notch in the acquisition of 
lymphangiogenic / lymphatic properties, other mechanisms remain possible.  
Based on the present and recent other studies, three possible (non-exclusive) models 
can be considered to explain our findings. A first explanation is that Notch silencing altered 
blood vessel development and, secondarily, influenced lymphatic development. Previous 
studies documented that arterial differentiation is impaired by inhibition of multiple Notch 
signaling pathways (for instance by a dominant negative Su(H)) 172, but not by selective 
silencing of Dll4 189,190. Our imaging and marker expression analyses are consistent with 
these findings and reveal that initial formation and differentiation of the PCV, DA and primary 
ISVs all occurred normally upon incomplete silencing of Notch signaling. Thus, at least by 
generally accepted criteria of arterial and venous identity, these blood vessels developed 
normally in Dll4KD and Notch-1bSPL embryos. Nonetheless, we do not exclude the possibility 
that subtle alterations in arterial characteristics of the primary ISVs might have favored 
supernumerary connections with secondary sprouts, thereby “entrapping” sprouts that would 
otherwise have remained lymphangiogenic. Also, Notch silencing resulted in a greater 
fraction of venous than arterial ISVs; since arterial ISVs act as guidance templates for LISVS, 
impaired migration of the latter was indeed attributable to such a change in arterial 
morphogenesis. However, an outstanding question is whether the aISV changes themselves 
were in fact not caused by defective formation of the lymphangiogenic sprouts in the first 
instance (reflected in model 2 and 3). Indeed, precisely because lymphangiogenic branches 
failed to develop in Notch morphants, venous angiogenic sprouts formed instead, which then 
connected to the primary ISVs and converted them to vISVs.   
A second model is that Dll4 and Notch are expressed by the same or adjacent arterial 
ECs within the DA and that this cis signaling induces the release of paracrine 
lymphangiogenic factors (such as EphrinB2, VEGF-D 10,287 or an unknown signal), that 
indirectly instruct venous ECs of the nearby PCV to induce lymphangiogenic sprout 
formation in a cell non-autonomous manner. A similar indirect model was proposed to 
explain segregation of the DA from PCV in zebrafish 177. Likewise, during LISV migration, 
  DISCUSSION 
 119 
release of a guidance signal from aISVs in response to Dll4/Notch signaling in arterial cells 
could assist navigation of LISVs to their target projection (see further).  
Finally, a third and perhaps the most appealing, but at this stage still speculative, 
explanation for our data is that arterial Dll4 in the DA signals in trans to Notch on ECs in the 
PCV, which lies in close juxtaposition at the time of lymphangiogenic sprouting. However, 
there are arguments in support and against this model. An argument in favour for a cell 
autonomous role of Notch in PCV cells is that activation of Notch by Dll4 upregulated several 
LEC-specific markers in venous ECs in vitro. Expression analysis experiments in vivo 
yielded indecisive results. Notch-1b expression was weakly detectable in dispersed dorsal 
PCV cells, but only at a very low level that approached the detection limit of the techniques 
used. Notch-1b was also measurable by RT-PCR in isolated LECs in older embryos, but this 
technique could not be used during early lymphatic development. We therefore acknowledge 
that the Notch-1b expression results represent a limitation of this study, which precludes us 
from drawing firm conclusions regarding a cell-autonomous role for Notch in 
lymphangiogenic sprouting.   
Another very recent study also documented a cell autonomous role for Notch 237, while 
a second did not 235. In LEC cultures, Notch signaling reprogrammed lymphatic to arterial 
cell fate, while Prox1 counteracted this force, thereby allowing fine-tuning of the LEC fate in 
a delicately balanced feedback 237. These findings should not necessarily be in contradiction 
to our findings, as these researchers analyzed reprogramming of fully differentiated LECs 
away from their lymphatic fate, while we used venous BECs to study programming towards 
the LEC fate in vitro. As the authors of this study mention 237, “LEC-fate may not be 
governed by a two-way turn ON-OFF switch, but rather by a dial switch that allows a gradient 
increase or decrease in the lymphatic cell fate force”. Reconciling these and our findings, it 
seems that Notch levels must be tightly controlled to induce and maintain LEC fate. Low 
levels of Notch signaling might be required to induce lymphatic fate in venous BECs and, 
once differentiated into LECs, Prox1 would then secure lymphatic fate by preventing 
overexpression of Notch, as this would promote arterial cell fate 237. The lower expression of 
Notch-1 in LECs (this study and 177,237,240,243,244) than in arterial ECs  supports this model and 
could also explain why incomplete Notch silencing sufficed to abrogate lymphatic but not 
arterial development. However, in the absence of more conclusive evidence that Notch 
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silencing abrogates Prox1 induction in PCV cells in the zebrafish model in vivo, a role for 
Notch in programming LEC fate remains unproven. Also, Notch may regulate other 
processes than LEC specification in lymphangiogenic sprouting. 
A recent study in mice further adds complexity to this model. Indeed, conditional 
inactivation of RbpJ, a mediator of canonical Notch signaling, in ECs did not alter the 
expression of lymphatic markers in venous ECs 235. While these data may suggest that 
Notch signaling is redundant for LEC specification in mammals in vivo, an alternative 
interpretation is that Notch regulates this process via non-canonical or even reverse 
signaling. This might also explain why we could not detect a robust signal in LECs or their 
precursors in the Tp1bglob:eGFPxFli1:DsRed line. Unfortunately, in zebrafish, knockdown of 
Su(H), the homologue of RpbJ, induced too severe developmental defects to analyze its 
involvement in lymphatic development. Also, species-specific differences between mammals 
and zebrafish could account for some of the observations. Overall, whether Notch signaling 
regulates lymphatic development in a cell-autonomous manner remains to be further 
elucidated in the future. 
Since Prox1 has been identified as the key regulator of lymphatic specification an 
important aspect of further research is to determine if Notch signaling is acting up- or 
downstream of or independent and in parallel with Prox1. In mice, Prox1 expression is 
induced at E9.5 in a subpopulation of venous ECs indicating lymphatic commitment of these 
cells 288. The factor inducing the polarized expression of Prox1 remains to be identified and 
also, the subsequent process of budding and migration of LECs is only partially understood. 
Our preliminary findings point to a possible synergistic inhibitory effect on lymphatic 
development upon knockdown of Prox1 and Dll4. Once the exact role of Prox1 during 
lymphangiogenesis in zebrafish has been confirmed (see higher), rescue experiments 
should clarify the order and hierarchy of the different lymphatic regulatory processes.  
Another important transcription factor that possibly links Notch signaling to lymphatic 
specification but for which the exact lymphangiogenic role remains to be further unraveled, is 
COUP-TFII. This transcriptional regulator is known to be essential for venous specification 
by blocking Notch-regulated arterial differentiation 179. Recent publications have pointed to 
an important role for COUP-TFII during lymphatic development as well 233-237. Expression 
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was shown in lymphatics and COUP-TFII was found to physically and functionally interact 
with the Prox1 transcription factor 233,234. Furthermore, deletion in mice impairs development 
of lymphatic vasculature 235,236. Considering the venous role of COUP-TFII to block Notch 
signaling, these findings suggest that Notch signaling needs to be inactivated for lymphatic 
specification as well. However, this contradicts our findings which document reduced 
lymphatic development upon Notch inhibition. Another proposed hypothesis is that COUP-
TFII indicates the prerequisite of a venous identity for lymphatic specification and that it 
differentially functions in venous and lymphatic ECs by interacting with other transcriptional 
regulators 289. In that regard, it is striking that COUP-TFII is able to negatively and positively 
regulate Prox1-induced VEGFR3 expression in blood and lymphatic ECs, respectively 234, 
whereas another study shows that Prox1 and COUP-TFII can either co- or counter-activate 
expression of different target genes 233. Altogether, these findings indicate that interaction of 
Prox1 and COUP-TFII can modulate each other’s function depending on the cellular context 
and other transcriptional regulators. Merely speculating, it is thus possible that COUP-TFII 
initially blocks Notch signaling in order to obtain a venous identity, after which, in a subset of 
venous ECs, interaction with Prox1 abolishes the inhibitory effect of COUP-TFII and re-
enables Notch signaling to induce lymphatic specification.  
 
 
3 ROLE OF NOTCH IN LYMPHATIC MIGRATION FROM THE PL 
Notch signaling also regulated the formation of LISVs, which arise from the PL cells. 
We have observed that LISV-PLs migrate exclusively along arterial ISVs, indicating that the 
PL cells must recognize a turning signal at the crossing with an aISV that instructs them to 
switch from tangential to radial migration. As indicated above, due to the shifted balance of 
angiogenic/lymphangiogenic secondary sprout formation Notch hypomorphants have a 
reduced availability of aISV templates, thus largely depriving PL cells from normal migration 
routes and thereby impairing normal TD formation. However, even though the arterial-
venous ISV shift was most prominent in hypomorphant embryos with the most severe 
lymphatic defects, not all aISVs underwent a venous shift (maximally 90%), possibly 
reflecting an incomplete knockdown or, perhaps, a fundamental physiological need to 
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establish at least some residual trunk circulation from aISVs to vISVs. When analyzing 
Notch hypomorphants with a partial or normal PL string, we observed that in the remaining 
fraction of aISV, most frequently, the LISV was absent and in other, rarer cases, migrating 
LISV-PLs stalled or became misrouted (Figure 26C-C’’’). Our findings suggest that 
lymphangiogenic EC migration per se (motility) was normal. Indeed, in embryos that formed 
a partial TD, cells of the lymphangiogenic secondary sprouts migrated dorsally without 
stalling and thereafter tangentially to establish the string of PL cells. Also, for PL cells that 
finished their ventral migration to the TD, Notch signaling was dispensable for their 
subsequent tangential outgrowth (not shown). Furthermore, in vitro migration or proliferation 
of LECs was also not affected by Notch signaling. Also, we did not detect signs of lymphatic 
regression or retraction (not shown). It is therefore tempting to speculate that LISV defects in 
Notch-silenced embryos reflect impaired lymphangiogenic cell pathfinding. LISV-PLs 
navigated in close association along aISV templates, raising the question whether aISVs act 
as guidance templates for LISV-PLs, reminiscent of how follower axons navigate along a 
pioneer axon’s pathway or how autonomic nerves use arterial tracks to reach their target 
290,291. Hence, it is tempting to speculate that, when fewer aISVs are present in Notch 
hypomorphants because of lymphangiogenic sprouting defects, PL cells are deprived of 
navigation templates and therefore cannot form LISVs normally (Figure 26C). The 
observations that LISV-PLs failed to switch from tangential to radial migration or, more 
rarely, stalled or selected incorrect paths (Figure 26C’-C’’’), are reminiscent of classic 
neuronal guidance defects. That arteries may act as navigation templates is evidenced by 
reports that autonomic nerves stall or become misrouted, when these arteries do not 
produce appropriate guidance cues 291. Su(H)-dependent Notch activity was detectable in 
aISVs, but not in vISVs, at the time when PL cells switch from tangential to radial migration 
alongside aISV, indicating that lymphatic navigation is regulated either non-cell 
autonomously or via non-canonical Notch signaling. Considering the close association of 
LISVs and aISVs, Notch signaling in the latter could indirectly signal to the former and 
thereby regulate lymphatic development.  
Whether and how Notch signaling regulates the production of turning and guidance 
cues for LISV-PL cells by aISVs or nearby (somitic) cells and how LECs recognize these 
signals remains to be determined. It would be interesting to analyze the specific behavior of 
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lymphatic tip cells during normal LISV pathfinding and to examine if inhibition of Notch 
signaling has similar effects in arterial and lymphatic sprouting. Notch has previously been 
implicated in similar processes of neuronal migration and axon guidance in Drosophila. In 
this context, Notch acts via a non-canonical CSL-independent manner by direct activation of 
the Abl tyrosine kinase by Notch receptors 292,293. This process involves a range of other 
proteins, such as Disabled, of which the mouse homolog Disabled1 was also shown to 
interact with the intracellular domain of Notch1 292-294. It has been speculated that a similar 
CSL-independent pathway might be involved in regulating EC migration downstream of 
Notch 245. Similarly, our observations of impaired LISV navigation upon Notch inhibition and 
absence of canonical Notch activation in the LISV, could be in agreement with such a 
regulatory process during lymphatic pathfinding. 
 
Notch1 and Notch4 have been shown to be expressed in normal and pathological 
lymphatics in mouse and human 230 and cultured LECs express some of the Notch receptors 
(Notch-1, -2 and -4), ligands (Dll1, Jagged1, Jagged2) and downstream targets (Hey1 or -2) 
231,232. However, no lymphatic abnormalities have been described in Notch mutant mice, 
possibly because these mutants die earlier than the onset of lymphatic vessel development 
due to vascular malformations 295. It therefore remains to be determined whether conditional 
inactivation of the other Notch pathway components at later stages, after critical vascular 
developmental steps and before lymphatic specification, unlike knockout of RbpJ 235, do 
reveal a role for Notch signaling during the different steps of mammalian 
lymphangiogenesis. 
 
 
4 GENERAL CONCLUSION AND PERSPECTIVES 
In conclusion, this study provides novel insight for a role of Notch signaling in 
lymphatic development, in part by regulating the initial steps of lymphangiogenic sprouting 
and PL formation. The findings raise the interesting perspective that Notch regulates, directly 
or indirectly, the potential of venous ECs to become lymphangiogenic / lymphatic. Moreover, 
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the navigation defects of LISV-PL cells along aISVs suggest that Notch also regulates lymph 
vessel pathfinding along arteries.  
Further study is required in order to unravel the exact molecular mechanisms in which 
Notch signaling is involved to regulate lymphatic development. As addressed during the 
discussion above, the key questions to further unravel include: 
-  Is the observed Prox1/Dll4 synergy in zebrafish embryos reflecting interaction 
between the Prox1 and the Notch pathway in lymphangiogenesis and how do they 
chronologically and hierarchically relate to one another? 
-  Is Notch signaling involved in the regulation of LEC competence/commitment, in 
LEC maintenance, LEC migration, or possibly in several of these steps? 
-  Does Notch signaling from the DA to the PCV occur directly or indirectly to 
regulate secondary lymphangiogenic sprouting? Or is the reduced number of 
lymphangiogenic sprouts an indirect result of vascular or other abnormalities?  
-  Does Notch signaling regulate PL cell migration along aISVs in zebrafish embryos 
in a cell-autonomous or cell non-autonomous manner? Which are the guidance 
cues and responsive molecules that instruct PL cells to switch from tangential 
migration at the horizontal myoseptum to radial migration along the aISVs? 
- Is Notch regulation of lymphangiogenesis different in zebrafish and mammals? Do 
conditional knockouts of specific Notch pathway components in mice (as opposed 
to the general knockout of canonical Notch signaling in RBPj knockouts 235) 
display lymphatic abnormalities? 
 
On a more general level, further characterization of the consecutive stages of 
lymphangiogenesis in zebrafish embryos is required as well:  
- What is the molecular mechanism underlying LEC specification? Are Sox18 and 
Prox1 involved in zebrafish lymphangiogenesis as in mammals?  
- Is there a genetic difference between the angiogenic and lymphangiogenic 
secondary sprouts of the PCV? etc.  
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Elucidation of these issues together with development of improved tools and methods 
to specifically stain lymphangiogenic/lymphatic structures at different stages of 
lymphangiogenesis, will greatly advance lymphangiogenesis research in the zebrafish model 
in general, as well as be instrumental to further unravel in-depth the precise involvements of 
the Notch signaling pathway.  
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1 SUMMARY 
Despite the importance of lymph vessels in both health and disease, very little is 
known about the genetic regulation of lymphangiogenesis, the formation of lymph vessels. 
The Notch signaling pathway is involved in many developmental processes. During 
angiogenesis, the formation of blood vessels, Notch regulates arterial versus venous 
differentiation of blood endothelial cells and controls the branching process of the blood 
vessel network. The molecular mechanisms determining the establishment of lymphatic 
endothelial cells, the third type of endothelial cells, and the outgrowth of an elaborate 
network of lymph vessels, are still poorly understood. Several indications suggest a role for 
Notch in all three EC types. Components of the Notch pathway are expressed in LECs and 
several Notch-related genes that are important for arterial differentiation are also required in 
lymphatic development. We therefore reasoned that Notch signaling itself might also be 
involved in lymphangiogenesis. In this study we investigated the role of the Notch signaling 
pathway in lymphangiogenesis using zebrafish embryos and tadpoles, two animal models 
that allow high-throughput screening for lymphatic genes. By adapting chemical and genetic 
silencing strategies to avoid vascular defects, we identified for the first time a dual role for 
Notch signaling in developmental lymphangiogenesis.  
We first showed that general inhibition of Notch signaling by a gamma-secretase 
inhibitor in zebrafish embryos and tadpoles or by knockdown in zebrafish of presenilin-1, 
involved in Notch activation, blocks lymphatic development.  
We next investigated further in the zebrafish model which of the known Notch 
receptors and ligands were the main actors and identified crucial roles of the Notch ligand 
Dll4 and the zNotch-1b/6 receptors, knockdown of which all arrest lymphatic development.  
In addition, we examined which developmental steps during lymphangiogenesis were 
affected, uncovering a dual action of Dll4/Notch signaling. During early stages, Dll4/Notch 
silencing reduces the number of sprouts that give rise to the parachordal lymphangioblasts 
(lymphangiogenic sprouts) from their venous precursor; instead, angiogenic sprouts are 
formed. This directly results in an increased formation of venous connected intersomitic 
vessels and impaired development of the parachordal lymphangioblast string due to a 
reduced delivery of parachordal lymphangioblasts at the horizontal myoseptum. At a later 
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phase, Notch silencing impairs navigation of lymphatic intersomitic vessels along their 
arterial templates. Together, the early and later defects result in impaired formation of the 
thoracic duct, the first functional lymph vessel in the zebrafish trunk. 
These findings imply critical roles for Notch signaling in the formation and wiring of the 
lymphatic network and raise the intriguing questions whether lymphatic and arterial 
endothelial cells coopted similar classes of signals from each other to acquire a non-venous 
EC identity and whether Notch signaling regulates their close physical association. The 
exact molecular mechanisms by which Notch signaling regulates both steps of the 
lymphangiogenic process remain to be defined. 
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2 SAMENVATTING 
Ondanks het belang van lymfevaten zowel voor het normaal functioneren van het 
lichaam als voor hun betrokkenheid in verschillende ziektebeelden, is er slechts weinig 
geweten over de genetische regulatie van lymfangiogenese, de ontwikkeling van 
lymfevaten. De Notch signaalweg is betrokken in vele ontwikkelingsprocessen. Tijdens 
angiogenese, de vorming van bloedvaten, zorgt Notch voor de differentiatie van arteriële 
versus veneuze bloedvat endotheelcellen, en controleert het de vertakking van het 
bloedvatennetwerk. De moleculaire mechanismen die het ontstaan regelen van lymfatische 
endotheelcellen, de derde soort endotheelcellen, en de vorming van een uitgebreid net van 
lymfevaten, zijn veel minder goed gekend. Er zijn meerdere indicaties dat Notch een rol zou 
kunnen spelen in alle drie de endotheelcel types. Componenten van de Notch signaalweg 
komen tot expressie in lymfatische endotheelcellen en verschillende Notch-gerelateerde 
genen zijn zowel belangrijk voor arteriële differentiatie als voor lymfatische ontwikkeling. Dit 
leidde ons tot de hypothese dat ook de Notch signaalweg zelf belangrijk zou kunnen zijn 
voor lymfatische ontwikkeling. Tijdens dit onderzoek hebben we de betrokkenheid van de 
Notch signaalweg bestudeerd tijdens lymfangiogenese door gebruik te maken van de 
zebravis en de kikkervis, twee diermodellen die kunnen gebruikt worden voor ‘high-
throughput’ identificatie van lymfatische genen. Door gebruik te maken van farmacologische 
en genetische inhibitie strategieën en de inhibite zo te doseren dat bloedvatdefecten worden 
vermeden, zijn we erin geslaagd om voor de eerste keer een dubbele rol aan te tonen voor 
Notch tijdens lymfangiogenese.  
In een eerste reeks experimenten, toonden we aan dat algemene inhibitie van Notch 
signalering met behulp van een gamma-secretase inhibitor in zebravis embryo’s en 
kikkervisjes, of specifieke inhibitie in zebravis embryo’s van preseniline-1 (via morpholino 
knockdown), lymfatische ontwikkeling blokkeert. 
Vervolgens onderzochten we in het zebravismodel welke van de gekende Notch 
liganden en receptors de  belangrijkste actoren zijn, en identificeerden een cruciale rol voor 
de Notch ligand Dll4 en de receptors Notch-1b en -6. Specifieke morpholino knockdown van 
deze signaalwegcomponenten resulteerde telkens in verstoorde lymfatische ontwikkeling.  
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Tenslotte gingen we na welke stappen tijdens lymfangiogenese getroffen waren, 
waarbij Dll4/Notch signalering een tweevoudige rol bleek te hebben. Tijdens vroege stadia 
leidt inhibitie van Dll4/Notch tot een kleiner aantal lymfangiogene vertakkingen die afsplitsen 
van de vene; in plaats daarvan wordt een groter aantal angiogene vertakkingen gevormd. 
Deze afwijking van de normale ~50:50 verhouding, resulteert rechtstreeks in een verhoogde 
vorming van veneus geconnecteerde intersomietische bloedvaten en een verstoorde 
ontwikkeling van de parachordale lymphangioblast koord door een verminderde aflevering 
van parchordale lymphangioblasten ter hoogte van het horizontaal myoseptum. Tijdens een 
latere fase verstoort inhibitie van Notch de navigatie van lymfatische intersomitische vaten 
langsheen hun arteriële migratieweg. Deze vroege en latere defecten resulteren in 
verstoorde vorming van de thoracale buis, het eerste functionele lymfevat in het lichaam van 
het zebravis embryo.  
Deze bevindingen tonen aan dat Notch signalering cruciaal is tijdens de vorming en 
uitgroei van het lymfatisch netwerk en roept de intrigerende vragen op of lymfatische en 
arteriële endotheelcellen gelijkaardige signalen gebruiken om een niet-veneuze identiteit te 
bekomen, en of Notch signalering het nauwe fysische contact dat waargenomen is tussen 
arteriële en lymfatische vaten, regelt. Verder onderzoek is vereist om de exacte moleculaire 
mechanismen te ontrafelen die Notch gebruikt om beide stappen van het  lymfangiogenese 
proces te reguleren. 
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